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ABSTRACT

SELF-ASSEMBLING BIOAFFINITY HYDROGELS FOR LOCALIZED ANTIBODY
DELIVERY

By
Wen Liu
August 2018

Dissertation supervised by Wilson S. Meng, Ph.D.
The scope of illnesses that are being treated using monoclonal antibodies (mAbs)
has been expanding from cancers to autoimmune diseases due to their high specificity to
their molecular target. Because many of the new mAbs are aimed to modulate the
immune system, an emerging concern is that patients with chronic illnesses are subjected
to immune-related Adverse Events (irAEs). Loss of immunological tolerance to selfantigens or increased susceptibility to infections have been documented in some mAb
treatments. Localized sustained release of mAb at disease sites might mitigate the risk of
such toxicities. Antibody drugs are formulated typically for parenteral delivery because
of degradative mechanisms in gastrointestinal tract. The assumption has been that
systemic administration via the vascular compartment is the best or only option in
achieving therapeutic drug concentrations at diseased tissues. This paradigm is being
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challenged as the benefit to risk ratio of exposing non-targeted tissues or organs is lower
in many of the new mAb drugs. Direct local mAb administration to target tissues is
enabled by biomaterials scaffolds in which drug retention at the intended sites can be
modulated. This dissertation is focused on two bioaffinity hydrogels designed for
administering mAbs locally. One was built on a fluorescent-based module: fluorogen
activating protein dL5 and its fluorogenic partner malachite green (MG) for immobilizing
IgG Fc binding molecule protein A/G into the hydrogel matrix. This design was shown
to render sustained release of mAbs and detectable binding sites in vivo through a built-in
imaging feature. The second design was built upon pG_EAK, a bifunctional polypeptide
in which the IgG-binding domain was genetically fused to the self-assembling sequence
(AEAEAKAK)3 (single amino acid code; hereafter “EAK”). The rationale was that
reducing the number of interactions would enhance the translational prospect of the
bioaffinity hydrogel. Sustained release and prolonged retention of IgG delivered in the
pG_EAK gel were observed in vitro and in vivo in skin allografts. In conclusion,
bioaffinity hydrogels built on dL5_EAK and pG_EAK are two injectable platforms on
which IgG mAbs of different specificities can be localized and sustained in diseased
tissues.
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Chapter 1
Introduction
Monoclonal antibody therapeutics
Antibodies (Abs), also known as immunoglobulins (Igs), are glycoproteins
produced by activated B lymphocytes in response to antigens (Ags). The Ags often
originate from bacteria, viruses and other microorganisms, but can also arise from
endogenous proteins. While the body generates Ab with diverse specificities, each Ab
binds to its cognate Ag in a specific way, with the paratope from Ab interacting with the
epitope from the Ag by spatial complementarity like lock and key. Electrostatic forces,
hydrogen bonding, hydrophobic interactions and van der Waal forces constitute the
reversible interaction between Ab and Ag. The basic structural unit of Ab is typically a
Y shaped molecule composed of two large heavy chains and two small light chains
(Figure 1-1). Light chains, comprising λ or κ peptide subunits, are connected to heavy
chains by disulfide bonds, giving rise to a symmetrical molecule with two identical
antigen-binding sites. The two heavy chains are also connected together through
disulfide bonds which constitute the hinge region providing various flexibility to each
antigen binding site in different subclasses of antibodies. The antigen-binding fragment
(Fab) is located on the tip of the “Y”. It is composed of heavy and light chains and is
made up of six hypervariable loops known as hypervariable region with each variable
region binding to the specific Ag. The hypervariable regions are also called
complementarity-determining regions (CDRs). The enormous diversity of Fab allows the
immune system to recognize a wide variety of Ags. On the other hand, crystallizable
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fragment (Fc) of the Ab is located at the base of "Y” composed of only heavy chains. Fc
is a constant region that can be used to distinguish between the five different subtypes of
Igs because the constant heavy chain can bind to its specific Fc receptor to communicate
with other components of the immune system, helping generate appropriate immune
response for different foreign objects the body may encounter. Thus, the general
structure of Ab is embedded with multiple functionalities [1].

Figure 1-1 the Y shaped structure of antibody.
There are five Ab classes in mammals: IgA, IgD, IgE, IgG and IgM, named
according to the type of their heavy chain types in α, γ, δ, ε, and μ respectively. They
differ in their biological properties, distribution and functions. IgA, usually present in
dimer, is mostly found in mucosal area, preventing colonization by pathogens [2]. IgE is
mainly involved in allergy by binding to allergens and triggers histamine release from
other immune cells. Both IgM (in the form of monomer) and IgD are expressed on the
surface of naive B cells, rendering the B cells ready to respond to Ag. IgM also exists as
a pentamer with very high avidity when in a secreted form and eliminates pathogens in
2

the early stages of humoral immunity before sufficient IgG is produced [3]. After
activation through the binding to Ag, B cells can divide and differentiate into Ab
producing cell (plasma cells). As the most abundant isotype of Ab (~75% of serum Ab),
IgG provides the majority of Ab based immunity protecting the body from infection. It is
also the only isotype that has receptors to facilitate passage through human placenta to
provide protection to the fetus in utero before its own immune system develops [1].

As the major component of humoral immunity, IgG plays its role by several
mechanisms including neutralizing binding to pathogens, immobilization and
agglutination of pathogens, coating of pathogen surfaces for the recognition and ingestion
by phagocytic immune cells (opsonization, phagocytosis and clearance), intracellular
antibody-mediated proteolysis, activation of classical pathway of complement system
(complement-dependent cytotoxicity, CDC) and antibody-dependent cell-mediated
cytotoxicity (ADCC) [4]. There are four subclasses of IgG in human: IgG1, IgG2, IgG3
and IgG4, named in order of their abundance in serum. IgG1 is the most abundant
subclass, comprising about two thirds of all IgG molecules. The four subclasses of IgG
differ mainly in the structure of hinge regions, leading to unique biological properties of
each class. They emerge at different stages of immune response and vary in segmental
flexibility, binding affinity to Fc receptor on phagocytic cells as well as the ability to
activate complement system [5].

Because of the high specificity of Ab to their cognate Ag, Ab has risen as the
leading molecular platform in the development of therapeutics for autoimmune diseases,
cancer, and inflammatory disease. While polyclonal antibodies (pAbs) are a collection of
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Ig molecules that react against different epitopes on a specific antigen, monoclonal
antibodies (mAbs) are produced by a unique parent cell, binding to the same epitope of
an antigen. Serum-pooled human pAb treatment provides wide population diversity of
Ab families against many possible targets, but suffers from the disadvantages including
nonspecific Ab components with possible side effects and no rational efficacy against
diseases, diluting effector functions specific to desired targets and effectors. Cost,
inconsistent efficacy and questionable reliability, toxicity and safety issues for a pooled
human blood-derived protein product hinders its clinical acceptance as an Ab therapy [6].
After mAb technique was first created in 1975 by using mouse x mouse hybridoma
(fusion of myeloma cell lines with B cells), the production of mAb at bulk quantity have
become possible [7]. Since FDA approved the first therapeutic mAb in 1986 to reduce
acute rejection after organ transplants [8], there has been over 70 therapeutic mAb
approved in the US as of March 29, 2018 (Table 1-1). The approval rate of mAb drugs is
historically high recently, with more than 10 therapeutic mAb products approved in 2017
alone. The global sales revenue for all mAb products constitutes approximately half of
the total sales of all biopharmaceutical products. The continuous growth in sales of the
approved mAb products, along with hundreds of mAb product candidates currently in
clinical trials, will lead to sustained growth in sales of mAb products and an expanding
market share of mAb in biopharmaceutical industry.

Table 1-1 FDA approved mAb. Information is up to date as of March 29, 2018.
Drug
Name
Ilumya
Trogarzo

Active Ingredients
TildrakizumabAsmn
IbalizumabUiyk

Initial U.S
Approval
3/20/2018
3/6/2018

Company

Target*

Merck Sharp
Dohme
Taimed
Biologics USA

IL-23

Therapeutic
indications*
Ps

CD4

HIV-1

4

Ixifi

Infliximab-Qbtx

12/13/2017

Pfizer Inc

TNFα

Ogivri

12/1/2017

Mylan Gmbh

HER2

Hemlibra

TrastuzumabDkst
Emicizumab

11/16/2017

Genentech Inc

bleeding episodes

Fasenra

Benralizumab

11/14/2017

Astrazeneca Ab

Factor Ixa& Factor X
IL5Rα

Mvasi

BevacizumabAwwb

9/14/2017

Amgen Inc

VEGF

Cyltezo

8/25/2017

Boehringer
Ingelheim
Wyeth Pharms
Inc
Janssen Biotech

TNFα
CD22

Tremfya

AdalimumabAdbm
Inotuzumab
Ozogamicin
Guselkumab

Metastatic
Colorectal Cancer
etc.
RA; JIA; PsA; AS;
CD; UC; Ps
ALL

IL-23

Ps

Rituxan
Hycela
Kevzara

Hyaluronidase; 6/22/2017
Rituximab
Sarilumab
5/22/2017

Genentech Inc

CD20

FL; DLBCL; CLL

IL-6R

RA

Imfinzi

Durvalumab

5/1/2017

PD-L1

Renflexis

4/21/2017

TNFα

urothelial
carcinoma
CD; UC; RA etc

Dupixent

InfliximabAbda
Dupilumab

Il-4Rα

atopic dermatitis

Ocrevus

Ocrelizumab

3/28/2017

Sanofi
Synthelabo
Astrazeneca Uk
Ltd
Samsung
Bioepsis Co Ltd
Regeneron
Pharmaceuticals
Genentech Inc

CD20

MS

Bavencio

Avelumab

3/23/2017

Emd Serono Inc

Pd-L1

MCC

Siliq

Brodalumab

2/15/2017

Il-17Ra

Ps

Zinplava

Bezlotoxumab

10/21/2016

Valeant
Luxembourg
Merck Sharp
Dohme

CDI

Lartruvo

Olaratumab

10/19/2016

Eli Lilly And Co

Clostridium
Difficile
Toxin B
PDGFR-α

Amjevita

9/23/2016

Amgen Inc

TNFα

RA etc.

Zinbryta

AdalimumabAtto
Daclizumab

5/27/2016

Biogen

MS

Tecentriq

Atezolizumab

5/18/2016

Genentech Inc

IL-2Rα
(CD25)
PD-L1

Inflectra

4/5/2016

Celltrion Inc

TNFα

Cinqair

InfliximabDyyb
Reslizumab

urothelial
carcinoma
CD; UC; RA etc

3/23/2016

IL-5

asthma

Taltz

Ixekizumab

3/22/2016

Teva Respiratory
LLC
Eli Lilly And Co

IL-17A

Ps

Anthim

Obiltoxaximab

3/18/2016

Elusys
Therapeutics Inc

Inhalational
Anthrax

Empliciti

Elotuzumab

11/30/2015

Portrazza

Necitumumab

11/24/2015

Bristol Myers
Squibb
Eli Lilly Co

PA
component
of B.
anthracis
toxin
SLAMF7
EGFR

lung cancer

Darzalex

Daratumumab

11/16/2015

Janssen Biotech

CD38

multiple myeloma

Besponsa

8/17/2017
7/13/2017

3/28/2017
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CD; UC; RA; AS
etc
breast cancer

asthma

STS

multiple myeloma

Nucala

Mepolizumab

11/4/2015

Praxbind

Idarucizumab

10/16/2015

Repatha

Evolocumab

8/27/2015

Praluent

Alirocumab

Unituxin

Glaxosmithkline
LLC
Boehringer
Ingelheim

IL-5

asthma
bleeding

Amgen Inc

direct
thrombin
inhibitor
dabigatran
PCSK9

7/24/2015

Sanofi Aventis

PCSK9

HeFH etc

Dinutuximab

3/10/2015

United Therap

neuroblastoma

Cosentyx

Secukinumab

1/21/2015

Opdivo

Nivolumab

12/22/2014

PD-1

Blincyto

Blinatumomab

12/3/2014

Novartis Pharms
Corp
Bristol Myers
Squibb
Amgen

glycolipid
GD2
IL-17A

Keytruda

Pembrolizumab

9/4/2014

Entyvio

Vedolizumab

5/20/2014

Sylvant

Siltuximab

Cyramza

HeFH; HoFH

Ps

CD19

melanoma; lung
cancer
ALL

PD-1

melanoma

integrin
receptor
IL-6

UC; CD

4/23/2014

Merck Sharp
Dohme
Takeda Pharms
USA
Janssen Biotech

Ramucirumab

4/21/2014

Eli Lilly And Co

VEGFR2

Gastric Cancer

Gazyva

Obinutuzumab

11/1/2013

Genentech

CD20

Kadcyla

2/22/2013

Genentech

HER2

Raxibacumab

AdoTrastuzumab
Emtansine
Raxibacumab

chronic
lymphocytic
leukemia
breast cancer

12/14/2012

Human Genome
Sciences Inc

inhalational
anthrax

Perjeta

Pertuzumab

6/8/2012

Genentech

PA
component
of B.
anthracis
toxin
HER2

Adcetris

8/19/2011

Seattle Genetics

CD30

Yervoy

Brentuximab
Vedotin
Ipilimumab

3/25/2011

CTLA-4

Benlysta

Belimumab

3/9/2011

Prolia

Denosumab

6/1/2010

Bristol Myers
Squibb
Human Genome
Sciences Inc.
Amgen

Hodgkin
Lymphoma
melanoma

Xgeva

Denosumab

6/1/2010

Amgen

Actemra

Tocilizumab

1/8/2010

Genentech

IL-6R

RA

Arzerra

Ofatumumab

10/26/2009

Glaxo Grp Ltd

CD20

CLL

Stelara

Ustekinumab

9/25/2009

Ustekinumab

9/25/2009

Ilaris

Canakinumab

6/17/2009

Novartis Pharms

IL-12 &
IL-23
IL-12 &
IL-23
IL-1β

Ps

Stelara

Centocor Ortho
Biotech Inc
Janssen Biotech

Simponi

Golimumab

4/24/2009

Centocor Ortho
Biotech Inc
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BLyS or
BAFF
RANK
ligand

TNFα

MCD

breast cancer

SLE
osteoporosis

Ps; PsA; CD
CAPS; FCAS;
MWS
RA; PsA; AS

Simponi Aria

Golimumab

4/24/2009

Janssen Biotech

TNFα

RA

Cimzia

4/22/2008

Ucb Inc

TNFα

CD

Soliris

Certolizumab
Pegol
Eculizumab

3/16/2007

Alexion Pharm

C5

PNH

Vectibix

Panitumumab

9/27/2006

Amgen

EGFR

colorectal carcinom

Lucentis

Ranibizumab

6/30/2006

Genentech

VEGF-A

Tysabri

Natalizumab

11/23/2004

Biogen Idec

α4-integrin

macular
degeneration
MS

Avastin

Bevacizumab

2/26/2004

Genentech

VEGF

Erbitux

Cetuximab

2/12/2004

Imclone

EGFR

Xolair

Omalizumab

6/20/2003

Genentech

human IgE

carcinoma of the
colon & rectum
colorectal
carcinoma
asthma

Humira

Adalimumab

12/31/2002

Abbvie Inc

TNF

RA

Zevalin

2/19/2002
5/7/2001

Spectrum
Pharms
Genzyme

CD20

Campath

Ibritumomab
Tiuxetan
Alemtuzumab

CD52

non-Hodgkin's
lymphoma
B-CLL

Lemtrada

Alemtuzumab

5/7/2001

Genzyme

CD52

B-CLL

Mylotarg

5/17/2000

myeloid leukemia

9/25/1998

Wyeth Pharms
Inc
Genentech

CD33

Herceptin

Gemtuzumab
Ozogamicin
Trastuzumab

HER2

Remicade

Infliximab

8/24/1998

Centocor Inc

TNFα

metastatic breast
cancer
CD

Synagis

Palivizumab

6/19/1998

Medimmune

Simulect

Basiliximab

5/12/1998

Novartis

Rituxan

Rituximab

11/26/1997

Genentech

RSV F
protein
IL-2Rα
(CD25)
CD20

lower respiratory
tract disease
acute organ
rejection
lymphoma.

Prostascint

Capromab
Pendetide
Imciromab
Pentetate
Abciximab

10/28/1996

Cytogen

PSMA

7/3/1996

Centocor Inc

12/22/1994

Centocor Inc

human
myosin
GP IIb/IIIa
receptor
of human 9
platelets

diagnostic imaging
agent.
cardiac imaging
agent
cardiac ischemic
complications

Myoscint
Reopro

Summarized from FDA website [9].
* Abbreviations: Interleukin: IL; Cluster of differentiation: CD; tumor necrosis factor
alpha: TNFα; human epidermal growth factor receptor 2: HER2; receptor: R; vascular
endothelial growth factor: VEGF; human programmed death receptor-1: PD-L1; plateletderived growth factor receptor alpha: PDGFR-α; Signaling Lymphocytic Activation
Molecule Family member 7: SLAMF7; epidermal growth factor receptor: EGFR;
proprotein convertase subtilisin kexin type 9: PCSK9; protective antigen: PA; human
vascular endothelial growth factor receptor 2: VEGFR2; soluble human B lymphocyte
stimulator protein: BLyS or BAFF; cytotoxic T lymphocyte antigen-4: CTLA-4;
complement protein C5: C5; respiratory syncytial virus: RSV; prostate specific
membrane antigen: PSMA; glycoprotein: GP; acute lymphoblastic leukemia: ALL;
Crohn’s Disease: CD; Ulcerative Colitis: UC; Rheumatoid Arthritis: RA; Merkel cell
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carcinoma: MCC; Follicular Lymphoma: FL; Clostridium difficile infection: CDI; soft
tissue sarcoma: STS; multiple sclerosis: MS; Juvenile Idiopathic Arthritis: JIA; Psoriatic
Arthritis: PsA; Ankylosing Spondylitis: AS; Plaque Psoriasis: Ps; Diffuse Large B-cell
Lymphoma: DLBCL; Chronic Lymphocytic Leukemia: CLL; multicentric Castleman’s
disease: MCD; systemic lupus erythematosus: SLE; heterozygous familial
hypercholesterolemia: HeFH; hypercholesterolemia: HoFH; active psoriatic arthritis:
PsA; CryopyrinAssociated Periodic Syndromes: CAPS; Familial Cold Autoinflammatory
Syndrome: FCAS; Muckle-Wells Syndrome: MWS; paroxysmal nocturnal
hemoglobinuria: PNH; B-cell chronic lymphocytic leukemia: B-CLL.
The first mAb drug OKT3 (Ortho Biotech) is murine-derived which brought acute
immunogenicity problems from patients responsive to murine-sourced Ab. Chimeric or
humanized mAb product emerged nearly a decade later to reduce the side effects
associated with the potential immunogenicity [10]. Most mAb products on market now
are humanized and their therapeutic effect is usually achieved through various
mechanisms including neutralization (bind to the ligand or receptor expressed on the cell
surface and block the target signaling pathway), ADCC, CDC or even antibody-mediated
toxin delivery [11]. When the body is in a diseased or dysfunctional condition, there is
typically an upregulation or downregulation of immune cell activation level and cytokine
secretion level. Exogenous therapeutic mAb could thus be administered to counteract
this irregular condition through immune response augmentation or suppression. In cancer
therapy, a need for cytotoxic T cell stimulation is usually favorable. For example, mAb
product Ipilimumab, which binds to the negative regulator of T cell activation CTLA-4,
could be used to block its interaction with its ligands CD80/CD86. The blockade of
CTLA-4 has been shown to augment T-cell activation and proliferation, thus enhancing
the treatment to melanoma. In a similar way, PD-L1, which blocks T-cell function and
activation through interaction with PD-1 and CD80, could serve as another anti-cancer
target. Delivering mAb binding to PD-L1 (e.g. Durvalumab) could release the inhibition
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of immune responses, increase T-cell activation in vitro and decrease tumor size in vivo.
In contrast, immune system sometimes needs to be suppressed through mAb intervention
in transplantation management to reduce the incidence of rejection or prolong the graft
survival time. For example, Basiliximab, which binds to IL-2Rα expressed on the surface
of activated T cells, competitively inhibits IL-2 mediated activation of lymphocytes, a
critical pathway in the cellular immune response involved in allograft rejection.
Therefore, Basiliximab is used to prevent rejection in organ transplantation, especially in
kidney transplant. In summary, the immune regulation exerted by mAb therapeutics
could be two-ways: either in cancer therapy to boost effector T cell function against
tumor cells or as immunosuppressive agent in transplantation scenario or autoimmune
diseases to aid in induction of tolerance.

Unmet needs in therapeutic antibody delivery
Most mAb products on market are formulated for intravenous infusion or
injection, usually at high doses because of their stoichiometric rather than catalytic
pharmacodynamics. More recently there have been products approved for subcutaneous
administration. These are often packaged in pre-filled syringes designed for selfadministration by patients, which can improve compliance. Because of incomplete
absorption of subcutaneous administered mAbs into the systemic circulation, very high
doses are required (up to 100 mg/kg), making the costs of mAb therapies for patients who
need regular repeated dosing comparatively unaffordable [4]. Another important aspect
associated with systemic delivery of immune modulatory mAbs is the induction of
potential immune-related adverse events (irAEs). These effects could be significant
because the impacts could remain after cessation of the therapy, due to loss of T cell
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tolerance. Such effects have been documented in checkpoint inhibitors in anti-CTLA-4
and anti-PD-1 mAbs in cancer patients, in some cases resulting in drug-induced
rheumatoid arthritis [12]. Based on these reasons, direct administration of therapeutic
mAbs into diseased tissues is justified. The technical challenge is that the mAb must be
retained at the site of intended action for extended durations. Therefore, localized
delivery vehicle for sustained release of mAbs at diseased site is essential to provide
opportunities to modulate the immune pathogenesis and at the same time reduce the risk
of irAEs.

Sustained-release strategies for therapeutic antibodies
Delivering active pharmaceutical ingredient (API) locally using matrix based
vehicles such as hydrogels or particles is a common strategy exploited to control the
release of the drug from delivery system. Drug loaded vehicle administered topically can
serve as a local drug depot to provide stable supply of the drug over a prolonged time
duration compared to drug delivered in aqueous formulation. The matrix geometry
including pore size, material architecture and interaction of the matrix with loaded drugs
would affect the release profile of the API from the vehicle [13].

Compared to conventional small molecular drugs, mAb drugs possess the
advantage of high intrinsic specificity and affinity to numerous targets and molecules of
various size and chemistry (binding constant at sub-nanomolar concentrations) [14].
However, due to its protein nature, it is easy to denature and aggregate under harsh
conditions. Their functions, which are linked to their 3D conformation, would be
compromised if they are subject to chemical and physical degradation including
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proteolytic and chemical degradation, physical unfolding and aggregation. Therefore,
mAb products are usually limited to parenteral formulations to avoid proteolytic
degradation in GI tract. While particle-based system does improve the injectability of
these formulations and achieve prolonged release, most of them suffer from low
encapsulation efficiency or incomplete release [15]. Also, organic solvent and high
mechanical energy introduced during the preparation of the polymer-based particles
could be detrimental to mAb stability. In addition, environmental changes such as pH
within the particle matrix throughout the release process could destabilize the
encapsulated protein molecule [16].

Alternatively, hydrogels, which are made of crosslinked polymers, can serve as
vehicles for mAb loading and release. The gel formation process usually proceeds at
ambient temperature and organic solvents are rarely required in the process due to the
hydrophilic nature of gel forming polymers [17]. The mild preparation condition of
hydrogels can help to preserve protein stability. The resulting porous structure of the
hydrogels, along with their high water content, are suitable properties to accommodate
high loads of water soluble molecules like mAbs. The nanostructure of the hydrogel
network, especially the mesh size, determines the mobility of encapsulated molecules and
controls their release rate from the network. Upon injection, hydrogels can also adapt to
the tissue contour in vivo. In addition, ‘smart’ hydrogels, or stimuli-responsive hydrogels
can be constructed. With varying chemical compositions and ionic moieties designed to
monomer comprising the polymer, the gelation of polymer solution can be triggered upon
environment changes such as temperature, pH or ionic strength. When the solution-gel
transition occurs at physiological conditions, in-situ forming hydrogels could be obtained,
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which is favorable in their biomedical applications including drug delivery. With the
exhibition of all the advantageous physicochemical properties, hydrogels can serve as an
excellent platform for local mAb delivery to preserve its stability while slow down its
release from the gel matrix [18].

Drug delivery hydrogel formed by β-sheet fibrillizing peptide
β-sheet fibrillizing peptide (βFP) is one type of self-assembling peptides (SAPs)
emerging as a novel material in the field of drug delivery and tissue engineering due to
their excellent biocompatibility and ease for manipulation [19-22]. The first discovered
βFP sequence EAK16-II (AEAEAKAKAEAEAKAK with A as alanine, E as glutamic
acid and K as lysine) self-assembles into cross-linking fibrils upon exposure to electrolyte
solutions [23]. EAK16-II can be used to formulate depots of small molecule drugs,
proteins, and even cells [24-27]. The in-situ gel forming feature of EAK16-II allows it to
be administered through conventional needled syringes. In gels made with the FP
sequence RADA, the molecular size of the encapsulated protein governs release kinetics;
IgG, the largest molecule tested, reaches maximum release by 24 hours [28].
Koutsopoulos et al. subsequently demonstrated that burst release can be suppressed by
encapsulating IgG in double-layer nanofibers using two amphiphilic building blocks,
RADA and KLDL [29]. These studies demonstrate the versatility of FP in controlling
the release of protein drugs.

The release rate of loaded protein from FP hydrogel is mainly controlled by the
relative size of the protein and the pore size of the hydrogel matrix because simple
diffusion is the only mechanism controlling the release and the diffusion coefficient is
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affected by mesh size and protein size according to obstruction-based theories [17]. In
general, the smaller the drug molecule and the larger the pore size of the hydrogel matrix,
the faster the drug would release from the hydrogel. Therefore, large protein like IgG
would have the slowest release rate compared to other smaller molecules when the mesh
size of the gel, temperature and viscosity of the fluid are fixed and the protein gel nonspecific interaction is the key factor determining the release rate. Although Ab is
released slower in hydrogel than in simple aqueous solution, a burst release effect still
takes place within the first few hours [30]. Therefore, an improvement on the design of
the βFP based hydrogel is required to achieve the desired sustained release of Ab from
the gel.

Bioaffinity hydrogel for sustained release of antibodies
To further extend the release duration, an affinity mechanism controlling the
drug release from hydrogel could be introduced to the hydrogel design. This mechanism
is chemically-controlled release where the release of loaded protein drug is determined by
reactions that occurs within the hydrogel matrix. Reversible binding occurring between
the polymer network and protein falls into this category of reaction where the binding
equilibrium reflected by binding constant (Kd) and association rate (kon) or dissociation
rate (koff) would determine the drug release rate [17]. Biomolecules can provide affinity
interactions for tuning protein release from hydrogel matrices. The Sakiyama-Elbert
group has engineered heparin-embedded hydrogels as protein delivery systems. As
highly sulfated glycosaminoglycans, heparins bind growth factors through ionic
reversible interactions. These systems mimic reservoirs of endogenous growth factors in
extracellular matrix [31-36] in which secreted proteins are protected from denaturation
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and aggregation. Hydrogels functionalized with aptamers have been used to control
protein release [37-40]. The Shoichet group has used Src homology domain 3 (SH3) to
tune the release of growth factors fused with SH3 ligands [41-44]. In these designs, rapid
diffusion is suppressed; instead, drug release is a function of the affinity of the binding
interactions (Kd), the relative ratio of binding sites (ligands) to proteins, and the
dissociation rate constant (koff) of the protein-binding site complexes [43]. Thus affinitybased hydrogels afford the ability to tune release kinetics by adjusting classical
biochemical parameters. Based on this mechanism theory, through appropriate
functionalization of βFP, the retention or release of drug cargo could be extended by
introducing an affinity module onto the βFP sequence, allowing elongated therapeutic
effect. Hydrogels formed by the coassembly of EAK16-II and its functionalized analog
provide affinity mechanisms for tuning Ab release from hydrogel matrix.

The design of EAK16-II based bioaffinity hydrogel in our lab hinges on the
design of bifunctional constructs where IgG binding module is linked to gel forming
sequence EAK directly through recombinant technology or indirectly through a
functional domain attached to EAK to provide additional imaging advantage.

The IgG binding modules we employed in our design are essentially based on
protein A, protein G, or the recombinant protein A/G (pA/G). Protein A and protein G
are Ig-binding proteins found on the surface of cell wall of bacteria staphylococcus
aureus and streptococcal respectively [45, 46]. They are extensively used as antibody
purification tools because of their specific affinity to the Fc domain of Ab. Protein A
consists of five IgG binding domains and protein G consists of three IgG binding
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domains [46, 47]. The interaction of protein A with Igs is pH dependent with the binding
capacity for protein A optimal at pH 8-9 whereas the binding capacity of protein G is
high over a broader pH range [48]. Protein G also has a wider reactivity profile than
protein A and it binds to all human IgG subclasses as well as rabbit, mouse and goat IgGs
but does not binds to IgM, IgA, and IgD [45]. Its binding to Igs is often stronger than
protein A [49]. pA/G is a recombinant protein comprising of four Ig binding sites from
protein A and two Ig binding sites from protein G and is ideal for binding the broadest
range of IgG subclasses from different species.

pA/G was used as the antibody binding moiety in the first generation of the
bioaffinity hydrogel design in my dissertation. In this design, protein A/G was
immobilized to the hydrogel matrix through a fluorescence-based module: a fluorogenactivating protein (FAP) dL5 and its fluorogenic partner malachite green (MG). FAP
dL5 is a single chain variable antibody fragment light chain homodimer that has a
specific affinity for MG. The fluorescence of MG (λex = 653 nm, λem = 684 nm) is
enhanced 20,000-fold upon binding to dL5 due to the constraint of single bond rotation
within MG molecule. Functional dL5 was recombinantly attached to EAK to generate a
bifunctional construct dL5_EAK. dL5 can thus be embedded in the hydrogel by
coassembly of dL5_EAK with excess EAK16-II [50]. Both the immobilization and
detection of pA/G in the hydrogel could be achieved by conjugating MG to pA/G. With
the help of the conjugation, the resulting conjugate pAGMG helps to link the binding sites
pA/G to the hydrogel matrix through the binding between MG and embedded dL5. The
generated fluorescence upon binding provides signal for antibody binding sites detection
(Figure 1-2).
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Figure 1-2 schematic representation of the FAP dL5 embedded bioaffinity hydrogel
design
The benefits of this design are three-fold: first, it provides affinity driven capture
and release; second, specific binding of IgG molecules to pA/G facilitates oriented IgG,
rendering reduced denaturation; third, the intrinsic fluorescence generated within the
fluorescence based module (dL5 and MG) allows easy monitoring of the IgG binding
sites.

The second generation of the bioaffinity hydrogel design (Figure 1-3) is based on
a novel bifunctional construct pG_EAK where a truncated Fc-binding domain pG was
directly attached to gel forming βFP in order to simplify the first generation design and
promote the translational prospect. With less components involved in the design,
therapeutic antibodies could be directly anchored to the bioaffinity hydrogel formed by
pG_EAK and EAK16-II coassemblies and the release rate of antibodies from the
hydrogel is directly controlled by their binding affinity with pG.
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Figure 1-3 schematic representation of pG embedded bioaffinity hydrogel

Projects overview
My dissertation work centers on the design of biomaterials for therapeutic Ab
delivery. The biomaterial delivery platform is based on self-assembling βFP EAK16-II.
EAK 16-II and its functionalized analogs (dL5_EAK or pG_EAK) are formulated into
injectables to establish hydrogels in which antibodies could be stably localized. The
central hypothesis of this project is that the release of subcutaneously injected antibodies
could be extended using bioaffinity hydrogels made of βFP EAK16-II and its
functionalized analogs. To test this hypothesis, two designs of the bioaffinity hydrogel
were proposed and characterized.

In the first generation design (chapter 3), fluorogen activating protein dL5 was
attached to EAK sequence to form the functional analog dL5_EAK. The coassembly of
EAK16-II and dL5_EAK was optimized in molar ratio. The colocalization of dye labeled
IgG molecules with MG fluorescence after loading of the conjugate pAGMG and model
IgG within the bioaffinity hydrogels, have been experimentally verified. Prolonged
release and delivery of IgG were demonstrated in vitro and in vivo. A sustained release
profile was observed for our pAGMG-decorated dL5 hydrogels for at least two months.
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For in vivo study, after subcutaneous foot pad injection of IgG loaded bioaffinity
hydrogels, local retention of the antibody showed higher signal intensity for 3 days
compared with hydrogels without pAGMG.

In the second generation design (chapter 4), Fc binding domain protein G (pG)
was directly attached to EAK sequence to form the functional construct pG_EAK. The
coassembly of pG_EAK with EAK16-II was verified using gel electrophoresis and
Congo Red absorbance change after binding. A superior IgG loading on pG hydrogel
and a sustained release profile of IgG from the gel for at least three months were
observed. The prolonged retention of IgG loaded on the bioaffinity pG hydrogels was
monitored in normal subcutaneous tissue for 2 days and murine skin allo-transplantation
model for 6 days after local injection compared to control system with free IgG or IgG
loaded in nonspecific EAK gel. Less systemic exposure of IgG displayed by pG
bioaffinity gel was reflected in the constrained organ distribution compared to the control
groups.

The continuous miniaturization of the Fc binding domain attached to EAK was
pursued to reduce the potential immunogenicity of the bioaffinity hydrogel. Z34c, a B
domain mimetic of native protein A, is a disulfide-linked cyclic peptide has a much
smaller molecular weight (4.18 kDa). It was fused to EAK to construct the bioaffinity
hydrogel with fewer potential MHC-II ligands in the Fc binding domain which indicates
a lower predicted immunogenicity compared to other Fc binding domains. Preliminary
studies have been performed to study the anti-neutrophil IgGs (anti-Ly6G and antiCD11b IgGs) loaded Z34c gel in inhibiting neutrophil trafficking in skin transplant model
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(Appendix I). The infiltration of neutrophils at the graft site were verified both ex vivo
and in situ by detecting neutrophil elastase activity as the indicator. Reduced neutrophil
accumulation at transplantation site was observed in treated mouse by tracking the
neutrophils after tail vein injection of neutrophil specific, NIR fluorescent imaging agent.

The concept of combinational use of bioaffinity hydrogel and gel trapped particles
was proposed. Anti-neutrophil IgGs loaded bioaffinity hydrogel, coupled with antineutrophil elastase particles (load with elastase inhibitor), could potentially work
synergistically to effectively impede continuous neutrophil infiltration as well as counter
tissue-destructive mechanism elicited by neutrophil elastase.

Another valuable application for bioaffinity hydrogel is cellular therapeutics
which is exemplified in the construction of mini thymic unit by 3D aggregation of TECs
with anti-EpCAM antibody displayed bioaffinity hydrogels (Appendix II). The formation
of 3D clusters of TECs facilitated by the bioaffinity hydrogel was observed in in vitro
culture and the cell viability was verified. The artificial mini thymus units were
transplanted into athymic nude mice and their support to T-lymphopoiesis in vivo was
confirmed [51].

Significance
Each year more than 1.1 million patients suffer from thermal and chemical burns
(Center for Disease Control and Prevention), with close to 30,000 hospitalizations in
specialized burn centers. Patients with extensive partial and full-thickness burns benefit
from intact epidermis and dermis which together serve as a protective barrier to minimize
desiccation of the underlying tissues, limit water evaporation, reduce bacterial
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contamination, relieve pain, and promote wound healing by accelerating reepithelialization [52]. Despite the use of immunosuppressants, a significant fraction of
organ allografts undergoes acute rejection, resulting in substantial parenchyma loss
within weeks [53]. While multiple leukocytes are involved in the rejection mechanisms,
neutrophils are one of the early cell types infiltrating graft tissues and induce necrosis
[54]. Neutrophils rapidly infiltrate into wounds, constituting for more than 50% of all
cells on day one. These early arriving neutrophils can shape subsequent adaptive
immune responses [55, 56]. Currently there are no therapies approved for selective
suppression of neutrophil infiltration in transplant settings. Survival of skin allografts
can be prolonged by systemic depletion of neutrophils [57]. Wound healing is
accelerated in neutrophil-depleted mice [58].

One potential application of our bioaffinity hydrogel platform is to create a local
anti-neutrophil Ab depot at the transplant site to reduce graft damage by arresting local
neutrophil infiltration in the first 48 hours. Blunting the intensity of this early event is
expected to bend the overall trajectory of the rejection by limiting the production of
proteases, the flow of alloantigens to draining lymph nodes [59, 60], suppressing T cell
proliferation [61, 62], and subverting the migration of T cells to inflamed tissues [63].
Localized delivery of immunomodulatory mAb can increase drug concentration at the
inflamed graft while reducing non-specific toxicities in off-target tissues.

Another target for mAb therapeutics is tumor. mAbs could be locally
administered to the tumor site to reprogram the immune system more efficiently [64, 65].
The tumor site delivery can serve as a vaccination site to locally amplify the immune
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system by redirecting the lymphocytes to the activated form instead of tolerant form,
thereby impeding the metastasis of the tumor. Delivery of Ab against the checkpoint
proteins such as PD-1 and CTLA-4 is an effective way to unleash T cell suppression in
cancer immunity [66]. Local delivery of Ab therapeutics by our bioaffinity hydrogels
could concentrate the IgGs to their antigen rich region, thus augmenting the immune
response toward tumor in a more efficient way.

The broader Impact of the research is that the bioaffinity hydrogels may lead to
development of new strategies in formulating mAb for subcutaneous (SC) administration
in attaining systemic absorption. While the majority of marketed mAbs are formulated
for intravenous (IV) administration, SC administration of mAb has the advantage of
allowing patients to self-administer in ambulatory settings. However, a key challenge in
SC administration of recombinant proteins is incomplete bioavailability, in particular at
high doses [67]. For macromolecules such as IgG (Mr >145 kDa), lymphatic uptake is
the main route of absorption from the SC space into the systemic circulation. Preclinical
studies indicate that movement of IgG through the extracellular matrix (ECM) is the ratelimiting step. The slow diffusion of IgG through the ECM exposes the drug to presystemic, intracellular catabolism [68]. The reduction of bioavailability via this
elimination pathway is compensated in part by binding of IgG to local tissue neonatal Fc
receptors (FcRn) and endosomal recycling, in which a fraction of the administered mAb
is protected from proteolytic degradation in cells. High doses of IgG (e.g. 40 mg/kg),
however, can saturate FcRn in local tissues, thereby increasing the fraction vulnerable to
proteolysis [69]. Reducing the rate of mAb release from SC depot constructed by our
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bioaffinity hydrogels has the opportunity to increase bioavailability by keeping drug
concentrations in ECM below FcRn saturation.

Summary
In summary, embedding bioaffinity domain into fibrillar hydrogels can help
extend the retention of incorporated IgGs at injection sites and prolong the release of IgG
from local depot.

The first generation of EAK based functionalized gel described in this dissertation
incorporated a fluorescence based module to introduce an imaging feature in the design.
The fluorescence generated upon the binding of embedded functional domain dL5 to its
fluorogenic partner MG provide a convenient way to detect the IgG binding sites after
conjugating MG to protein A/G. The loading of IgG to the hydrogel was found to be
colocalized with MG fluorescence where protein A/G is located which indicates the
specific binding of IgG to protein A/G. The near to 700nm fluorescence peak wavelength
allows the imaging of binding sites in superficial tissue after subcutaneous injection of
the system locally. This facilitates the in vivo optimization of the antibody delivery
vehicle.

The second generation of EAK based bioaffinity hydrogel entails a simplified
design where the IgG binding domain protein G was directly attached to the selfassembling domain EAK. With a wider and stronger reactivity profile towards Ab
compared to protein A, protein G embedded hydrogel provide a valid affinity mechanism
for efficient IgG loading and sustained release for IgGs of all human subtypes. The
improvement of IgG retention enabled by the bioaffinity hydrogels and restrained
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systemic exposure was both verified in normal and inflamed tissues after subcutaneous
injection.

For both dL5 and pG gel designs, the ratio of the IgG dose and IgG binding sites
embedded in the hydrogel will determine the release profile for a specific formulation.
Higher dose of the IgG will render higher portion of IgG to be release through simple
diffusion with less percentage of IgG being sustained by the bioaffinity mechanism.
Therefore, by modulating the comparative amount of the two, locally administered IgG
aimed for systemic exposure and local effect could be manipulated to achieve the optimal
therapeutic outcome for a specific disease condition.

In addition, the bioaffinity hydrogel system could be exploited for cell
therapeutics in tissue engineering by enabling 3D organization and proper cell to cell
interaction in the cell culture. The formation of mini thymus unit by generation of 3D
aggregation of thymus epithelial cells (TECs) could be realized by mixing the cells with
anti-EpCAM (TECs surface marker) antibodies loaded bioaffnity hydrogels. The
successful support of T cell development by these mini thymus unit after transplanted to
athymic mouse suggests this bioaffinity gel platform could serve as a promising tool in
modulating immunity through cell therapeutics.
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Chapter 2
Literature Review: Self-assembling Peptides as Hydrogel Forming
Materials
Self-assembly amphiphilic peptides have gained substantial interests among
biomaterials scientists in the past twenty years. The reasons being that peptides are
generally biodegradable and that novel peptides can be generated through amino acid
substitutions. They can form noninvasive and injectable supramolecular scaffolds upon
exposure to environmental stimuli such as temperature, pH, ionic strength. Although
initially present as soluble solutions, the self-assembled three-dimensional structures can
serve as a versatile platform for tissue regeneration and drug delivery. They are also
capable of displaying bioactive epitopes and/or proteins, as well as resembling
hierarchical structures of extracellular matrix (ECM) component. Extensive research has
been conducted on various self-assembly systems in recent years, from synthetic
molecules to naturally occurring biomaterials. This chapter will focus on the three most
widely studied self-assembling peptide amphiphiles: ionic-complementary selfassembling peptides, self-assembling β-hairpins and alkylated peptide amphiphiles. The
first category is the design basis for our bioaffinity hydrogel. Common analytical
techniques used to characterize the micro- or macro-structure of the assemblies or to
investigate the self-assembling mechanisms will be summarized. The characteristics of
assemblies and their corresponding biomedical applications will be elaborated. The
limitations and challenges facing the development of peptide-based self-assembly
systems and the future directions will be discussed in this chapter as well.

24

Introduction
Molecular self-assembly is a very prevalent phenomenon in nature. For example,
phospholipid molecules can self-assemble into a bilayer and is the basis of cell membrane
composition. Detergent surfactant molecules can self-assemble into micelles when its
concentration exceeds critical micelle concentration (CMC) and help to clean poorly
soluble lipophilic species. Silk fibroin proteins can be fabricated into silk materials over
2km in length and have sufficient stiffness and toughness to be used in textile
manufacture [70]. By definition, molecular self-assembly is considered as the process by
which molecules spontaneously organize themselves into well-defined and stable
structures through non-covalent interactions under near thermodynamic equilibrium
conditions [71]. Essentially, it is a reversible formation of large molecular aggregates.
The effects of self-assembly can be both beneficial and deleterious. For instance, it can
serve as an essential mechanism for organism composition formation, such as cell
membranes. However, it can also be the cause of harmful diseases such as Alzheimer’s,
Parkinson’s, Huntington’s diseases as well as type II diabetes. For example, amyloid
fibril formation resulting from protein assembly is extensively considered as the cause for
the listed neurodegenerative diseases [72]. Amyloid β-protein (Aβ), a well-known selfassembling biomolecule, has been considered as an important factor in the cause of
Alzheimer’s disease [73]. These protein assemblies are rich in cross β-sheet structures.
The macroscopic membranes or plaques formed by these assemblies are speculated to
interfere with and/or prevent cell-to-cell communications, thus leading to neurological
disorders [74].

25

There are numerous molecular systems that can self-assemble, such as collagen
mimetic peptides, peptide amphiphiles, protein polymer hybrids and DNA-based
materials. Among these different types of materials, self-assembling peptide amphiphiles
have been extensively designed to form well-ordered structures for biomedical
applications since 1990s. They were brought to the attention of scientists mainly because
of their noticeable advantages in biodegradability and low toxicity to the biological
entities. The self-assembly process can lead to the formation of different nanostructural
architectures such as nanotubes and ribbons. It can also further develop into fibers or
hydrogels [75]. The unique properties of the formed structure can provide different
applications in diverse fields especially in tissue engineering and drug delivery.
Meanwhile, due to their similarity in the resulting self-assembly structures to amyloid
proteins, some of them were studied as a simpler substitute for amyloid protein (40-42
amino acids) as a way to find inhibitors to prevent fibrillogenesis in neurological
disorders [76, 77].

These self-assembling peptide amphiphiles can serve as novel materials for tissue
engineering mostly due to the hierarchical supra-molecular structures they generate can
resemble biological ECM and interact with cells at the molecular level. They are
exploited to create scaffolds for drug delivery basically owing to the unique
characteristics of the matrix geometry formed after self-assembly and their non-covalent
interactions with the drug payload. In addition, the triggered self-assembly feature of
these peptide amphiphiles can provide a ‘switch’ function which means the formation of
insoluble structures (typically fibrous networks) can be induced by the changes in their
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external environment. This makes it possible for self-assembly to take place in response
to physiologically relevant changes through rational design of the peptide composition.

Considerable studies have been done on three types of self-assembling peptide
amphiphiles, namely, ionic-complementary self-assembling peptides, self-assembling βhairpins and alkylated peptide amphiphiles. Each type possesses distinct peptide
sequence composition and/or structural organization. The ionic-complementary selfassembling peptide consists of regular repeats of alternating hydrophobic and hydrophilic
amino acid residues. The hydrophilic residues contain both positively charged and
negatively charged amino acids. These charged residues exhibit a self-complementary
pattern of charge when the peptides are aligned in a β-sheet conformation. By
comparison, self-assembling β-hairpins are peptide amphiphiles comprising a central
tetrapeptide flanked by two extended strands. The central tetrapeptide has high β-turn
propensity, while the two strands are composed of alternating hydrophilic and
hydrophobic residues, primarily lysine and valine respectively. In contrast, alkylated
peptide amphiphiles are made of a long linear hydrophobic alkyl tail attached to a
polypeptide block that includes β-sheet-forming segments, charged residues, and
biological epitopes, etc. Although displaying distinct molecular organization and
adopting slightly different mechanisms during self-assembly, these peptide materials do
share common features in terms of self-assembled macrostructures and functional
applications. To facilitate a comprehensive understanding of peptide amphiphiles and
meanwhile identify their similarities and differences, the characteristics, self-assembling
mechanisms and applications for each peptide amphiphile will be summarized and
compared in this chapter.
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Analytical techniques in characterizing the assemblies
In order to prepare a detailed discussion about the properties of each peptide
amphiphile, it is necessary to summarize the analytical methods commonly used to
characterize structures and properties of peptide-based materials. These techniques
usually offer insight into the secondary structures of the peptide in the self-assembled
state, the nanoscale morphology of the assembled structures and the bulk mechanical
properties of the resulting biomaterials.

Fluorescent spectroscopy
Fluorescence is the property of some substances to emit light at a longer
wavelength shortly after they absorb light at a certain wavelength [78]. Fluorescent
spectroscopy has been one of the most powerful methods to study protein folding,
dynamics, assembly and interactions due to its high signal-to-noise ratio and small
sample amount required for analysis. Extrinsic fluorescent dyes such as Thioflavin T,
ANS, Bis-ANS, and Nile Red are widely used as tools for protein characterization
because of their versatility, sensitivity and suitability for high-throughput screening [79].
The fluorescence emission of these dyes will change after interacting with protein
structures. This interaction will induce a change on the preferred relaxation pathway of
the dye molecule, therefore exhibiting a distinct fluorescent spectroscopy profile as
compared to the unbound dye molecule. This detected change in fluorescent
spectroscopy profile can be indicative of the presence of certain protein structures.

Among those dyes, Thioflavin T is commonly used in the field of fibrillation and
amyloid fibril characterization [80]. For Thioflavin T, its fluorescence properties can be
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affected by the solvent viscosity and the rigidity of its microenvironment. In solvent of
low viscosity, Thioflavin T has low fluorescence. In the presence of amyloid aggregates,
Thioflavin T exhibits an additional absorption peak at 450 nm and a highly fluorescent
emission maximum at 480 nm [72]. The mechanism for the change in emission spectra
of Thioflavin T is still not very clear. Some propose that Thioflavin T interacts with βsheet structures [81] while others attribute the fluorescence increase to the formation of
Thioflavin T micelles which bind to the grooves of the twisted protofibrils or fibrils [82].
Researchers have been using the unique feature of thioflavin T to semi-quantify the
formed β-sheet fibril structures [83]. Given that peptide amphiphiles have been expected
to form similar fibrillar structures to amyloids, thioflavin T could be utilized to
characterize and quantify the self-assembled structures formed by these peptide
amphiphiles.

It is worth mentioning that Congo red is a dye frequently used in combination
with Thioflavin T for fibril analysis. When Congo red interacts with fibrils, the changes
lie in the shifts of UV absorbance (from 490 nm to 540 nm) and other optical effects such
as birefringence under plane polarized light, instead of the increase in fluorescent
intensity. Moreover, with the help of Congo Red, the invisible and insoluble fibrillar
structures could be visualized under bright field microscopy, which facilitates the
recognition of amyloid proteins and study of the macrostructure formed by selfassembling peptides [84].

Atomic force microscopy (AFM)
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AFM is a type of scanning probe microscopy with relatively high resolution. It
can serve as an important tool to study the local nanostructure or morphology of the selfassembled materials because it can gather information by probing the surface of the
sample with a mechanical cantilever. In contrast to other popular microscopic
techniques, the outstanding signal-to-noise ratio of the AFM topograph and 3D AFM
images allows the observation of structural details of these assemblies [85-89].
Compared to scanning electron microscope (SEM), AFM provides superior topographic
contrast as well as the direct measurement of surface features such as quantitative height
information [90]. In addition, the AFM samples could be imaged in their hydrated state
and no dehydration of the sample is necessary. This renders it a non-destructive
technique. However, its capability to accurately measure the XY dimension which
defines the width of the fiber is limited [75].

Circular dichroism (CD)
Circular dichroism (CD) is defined as the phenomenon of the unequal absorption
of left-handed and right-handed circularly polarized light by some materials [91]. It is
known that any linearly polarized light wave can be obtained as a superposition of a left
circularly polarized and a right circularly polarized light waves (with electric fields
rotating clockwise ER and counterclockwise EL respectively) when their amplitude is
identical. Therefore, if linearly polarized light traverses a substance exhibiting circular
dichroism, its properties will change since the substance could absorb the two circularly
polarized components to different extents. CD is either reported in units of ∆E (the
difference in absorbance of ER and EL by an asymmetric molecule) or in degree ellipticity
(the angle whose tangent is the ratio of the minor to the major axis of the ellipse). CD is
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considered as an excellent tool to rapidly determine the secondary structure or folding
properties of proteins or peptides [92-94]. Different structures of proteins or peptides
possess characteristic CD signature spectra due to the varying aligned patterns of the
chromophores from the amides of the polypeptide backbone of the proteins. For
instance, α-helix has negative bands at 222 nm and 208 nm and a positive peak at 193
nm. Well-defined β sheet has a negative band at 218 nm and positive peak at 195 nm.
Disordered proteins have very negative bands near 195 nm and very low ellipticity above
210 nm. Figure 2-1 shows the CD spectra for some representative secondary structures
in polypeptides and proteins. One of the biggest advantages of CD is that the data can be
collected and analyzed within a few hours. Samples containing only 20 ug or less of
protein in aqueous buffers under physiological conditions can be analyzed. This makes
CD the most frequently used method for studying secondary structures of peptides and
proteins.
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Figure 2-1 CD spectra for polypeptides and proteins with representative secondary
structures (reprinted from reference [91]).

Fourier transform infrared (FTIR) spectroscopy
FTIR spectroscopy is another commonly used technique to study the secondary
structure of peptides in the self-assembled state. IR is a vibrational spectroscopy with
spectra observed in the wavelength range between 1 and 100 µm (102-104 cm-1).
Infrared absorption comes from a changing dipole moment in the molecules during the
vibration of interest. Therefore, it is sensitive to the changes in inter-nuclear distances
and bond angles which are decided by the conformations and configurations adopted by
the particular molecular groupings [95]. Fourier transform is a mathematical process
required to convert the raw absorption data into the actual spectrum. A major advantage
of FTIR spectroscopy is that its structural characterization does not rely on the physical
state of the sample. Samples could be easily examined in the form of aqueous or organic
solutions, hydrated gels, in homogeneous dispersions or solids. Also, it is not limited by
protein size (can be very big) or the nature of the environment. It is especially valuable
when a peptide or protein is existing in a rapidly inter-converting dynamic equilibrium
[96]. There is an empirical correlation between the frequency on FTIR spectroscopy of
the amide I and amide II absorptions of a protein and the predominant secondary
structural motif within the protein. The amide I absorption contains mainly the
contributions from the C=O stretching vibration of the amide group while amide II arises
from N-H bending and C-N stretching vibrations. Comparatively, amide I absorption is
considered to be more useful since it is purer in its composition. This empirical
correlation in amide I frequencies and various secondary structure can be explained by
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dihedral angles, hydrogen bond strengths and C=O group electron density. Briefly, the
dihedral angles of a polypeptide chain determine the chain geometry, thereby dictating
the length and direction of the hydrogen bonds. Different resulting hydrogen bond
strengths further contribute to the different characteristic electron densities in the amide
C=O groups. The stronger the hydrogen bond, the lower the electron density in the C=O
group thus the lower the amide I absorption appears. As a result, while CD is sensitive to
the backbone information, FTIR is more sensitive to the degree and strength of hydrogen
bonding to the amide C=O groups. The following table (Table 2-1) provides the most
common correlations between protein secondary structure and the amide I frequency.

Table 2-1 The correlations between common protein structures and amide I frequencies
(adapted with permission from reference [97]. Copyright (1992) American Chemical
Society)
Structure

Amide I frequency (cm-1)

Antiparallel β-sheet

1675-1695

α-helix

1648-1660

Unordered

1640-1648

β-sheet

1625-1640

Aggregated strands

1610-1628

Oscillatory rheology
Oscillatory rheology is a technique used to measure the viscoelastic behavior of
soft materials such as emulsions, foams, colloidal suspensions or polymer systems which
have mechanical properties that lie between a purely elastic solid and a viscous liquid
[98]. Many researchers use it to study the mechanical properties of hydrogels made of
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self-assembling peptides [87, 93, 99]. An oscillatory rheometer is the instrument
designed to make measurement of these viscoelastic properties. The principle of the
instrument is to measure the resultant stress response of the material after a sinusoidal
shear deformation is applied to the sample. The viscoelastic behavior of the sample at
certain frequency of oscillation (ω) is characterized by the storage modulus G’(ω), and
the loss modulus G’’(ω). These two moduli characterize the solid-like and fluid-like
contribution to the measured stress response respectively [98]. Knowledge of the
mechanical properties of these self-assembled peptide materials through oscillatory
rheology measurement allows rational design of the peptides with appropriate mechanical
strength for specific applications in biomedical engineering or nanotechnology.

Surface tension measurement
Surface tension measurement is commonly employed to study the solution
properties of molecules with an amphiphilic structure. Axisymmetric drop shape
analysis-profile (ADSA-P) is a powerful and reliable technique to acquire surface tension
at the interface between water and air [100]. Technically, in order to get surface tension
information for a peptide amphiphile solution, a pendant drop of the solution can be
formed at the tip of a vertical Teflon needle which is connected to a motor-driven
microsyringe. The sample should be placed in a temperature-controlled environmental
chamber which is saturated with water vapor. The image of the pendant drop can be
acquired by an optical microscope and a CCD camera and then transferred to a computer
for software analysis. The surface tension value is finally generated by fitting a
theoretical curve governed by the Laplace equation of capillarity to the profile of the
pendant drop [76]. Hydrophobicity, surface activity of the peptide and kinetics of peptide
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adsorption can be quantified by applying ADSA-P measurement. The conformation of
the peptide assemblies or the aggregation status can be related accordingly [101]. By
monitoring the surface tension change under various conditions or over time, we can get
a better understanding about the self-assembly process and thus speculating the selfassembly mechanism.

Other analytical techniques
In addition to the frequently employed methods listed above, there are still a lot of
other techniques which are less commonly used due to inconvenient sample preparation,
high cost or inaccurate information. These techniques include solid-state nuclear
magnetic resonance (ssNMR) [102-104], X-ray diffraction (XRD) [104], molecular
dynamics (MD) simulations [92], scanning electron microscopy (SEM)[87] and
transmission electron microscopy (TEM) [99, 105] et al. Some of them, especially
ssNMR and XRD, can provide us with even higher resolution and more precise
information down to molecular or atomic level. They are increasingly recognized as
more useful and accurate tools to study fibril structure although high cost and limited
availability may constrain their wide application. It should be noted that, when studying
these peptide amphiphiles, multi-technique approach is required to generate a more
comprehensive and accurate picture of the self-assembly structure.

Self-assembling peptide amphiphiles and their corresponding properties
I. Ionic-complementary self-assembling peptide
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Zhang et al. from Massachusetts Institute of Technology discovered the ioniccomplementary self-assembling oligopeptides [106]. These peptides are composed of
alternating hydrophilic and hydrophobic amino acid residues and tend to adopt β-sheet
conformation in solution. The hydrophilic amino acids contain both positively charged
and negatively charged residues. They are able to form complementary ionic pairs in
secondary or higher order of structures. This class of self-complementary oligopeptides
can spontaneously assemble to form large macroscopic structures/matrices when exposed
to environmental stimuli such as temperature, pH, and monovalent inorganic salts.

The first discovered self-assembling peptide of this type is EAK16-II (sequence:
Ala-Glu-Ala-Glu-Ala-Lys-Ala-Lys-Ala-Glu-Ala-Glu-Ala-Lys-Ala-Lys) (structure see
Figure 2-2). It was originally found in a region of zuotin, a putative left-handed Z-DNA
binding protein in yeast [107]. Because of the adoption of β-sheet conformation in
solution, this oligopeptide molecule can present hydrophobic alanine side chains on one
side while orienting self-complementary pairs of positively charged lysine and negatively
charged glutamic acid side chains on the other surface. It can form membrane-like
structures upon addition of monovalent metal ions. The assembly is considered to be
facilitated by side chain ionic bond interactions between glutamic acids and lysines as
well as the hydrophobic interactions among alanines in addition to the conventional βsheet backbone hydrogen bonding (Figure 2-3). The formed membrane has high
stability. It is resistant to protease digestion, high temperature and a wide range of pH
values (1.5-11). It is also mechanically stable and can be stained by Congo red, a dye
that preferentially stains β-pleated sheet structures. SEM observation revealed that the
membrane was composed of a fibrous structure consisting of interwoven individual
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filaments (Figure 2-4) [23]. It was later found that those interwoven filaments have
diameters of 10-20nm and porous enclosures of about 50-100nm in diameter [24].

Figure 2-2 Schematic three-dimensional molecular model of EAK16-II (carbon atoms are
cyan, oxygen atoms are red, nitrogen atoms are blue and hydrogen atoms are white, A, E
and K are single letter codes for amino acids alanine, glutamic acid and lysine
respectively, reprinted from reference [108])
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Figure 2-3 Initially proposed model of the membrane by Zhang et al. (a) view
perpendicular to the β-sheet; (b) stacking of β-sheets (reprinted from reference [23],
Copyright (1993) National Academy of Sciences, U.S.A.)
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Figure 2-4 SEM images of membranes formed by EAK16-II with serial magnification.
The diameter of the filaments are about 10-20 nm and the distance between fibers are
about 50-80 nm. (a, 300X, b, 1200X, c, 4500X, d, 15,000X, arrows mark the same
location. Reprinted from reference [23], Copyright (1993) National Academy of
Sciences, U.S.A.)
Later, EAK16-II was systematically altered to generate other ionic
complementary peptides, such as RAD16, EFK16, KLD12 and EAR8 etc, which could
also self-assemble through similar mechanisms. Presumably, any hydrophobic amino
acid residue, such as valine (V), leucine (L), isoleucine (I) and phenylalanine (F) can be
used to substitute alanine (A). Likewise, on the hydrophilic side, arginine (R), histidine
(H) as well as lysine (K) can be included as positively charged residues while aspartic
acid (D) and glutamic acid (E) are commonly used negatively charged residues in the
alternating sequence. There are usually 8-32 amino acids in the short peptides. For
easier reference, the hydrophilic sides have been classified into several moduli according
to their varied charge distribution patterns: modulus I (-+-+-+-+); modulus II (--++--++);
modulus III (---+++); modulus IV (----++++) [109]. Here, the roman numerals indicate
the number of the same kind of charges grouped together. The total number of amino
acid residues in the peptide is indicated in the name as well. For example, EAK16-II has
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16 amino acid residues and a charge distribution pattern of modulus II (--++--++).
Notably, these oligopeptides all consist of L-amino acids. Therefore, their degradation
will only yield normal amino acids which will not arouse any biocompatibility problem
in vivo [110].

This class of ionic-complementary self-assembling peptides has also attracted
significant interest from P. Chen group from Waterloo University in Canada. His group
set forth to investigate various factors that influence the self-assembling process of these
oligopeptides. Those factors include peptide concentration, pH, salt concentration,
charge distribution, etc. Their findings, together with data collected by Zhang’s group,
accelerated our knowledge about these peptides and provided us with critical information
to speculate the self-assembling mechanisms.

Self-assembling mechanisms and factors affecting the self-assembling
It was initially postulated by Zhang et al. that the β-sheet system formed by
EAK16-II may exist in two possible forms [111]. One is a single β-pleated sheet
containing many EAK16 molecules. In the middle of the single sheet, each amino acid
residue is held to its neighboring peptides by two hydrogen bonds. Meanwhile, on one
side of the sheet there is a collection of alanine side chains forming a hydrophobic
domain while on the other side of the sheet there are a number of ionic bonds between
lysine side chains on one peptide strand and glutamic acid side chains on another. The
other existing form could be two or more sheets assembled together. Specifically, there
would be layered structure in which the sheets are held together alternatively by
hydrophobic interactions and ionic interactions between the sheets (Figure 2-3b).
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Without doubt, the hydrogen bonds, hydrophobic interactions and ionic interactions
stabilizing the single sheet still exist in this form.

It was experimentally proven that different conditions such as amino acid
sequence, peptide concentration, salt concentration, pH, etc. can influence the peptide
aggregation process and further development of macrostructures. Therefore, it is of
importance to investigate the influential factors in order to understand the self-assembling
mechanisms for the amphiphilic oligopeptides.

The amino acid sequence of these peptides is critical to the self-assembling
mechanism. Various sequences of the EAK family repeats such as KFE12, KIE12,
KVE12, KFE8/16 KFQ12 were designed by Caplan et al. to study the sequence influence
[112] (sequences see Table 2-2). Three aspects were taken into consideration: 1) the
hydrophobic side chains; 2) the number of repeats; and 3) the charged side chains. The
results of this study showed that increasing the hydrophobicity of the nonpolar resides
would facilitate the self-assembling which is reflected in the decrease of the critical
coagulation concentration (CCC) after increasing the hydrophobicity of the nonpolar
residues. CCC is defined as the salt concentration below which the oligopeptide does not
form a gel and above which it does form a gel. Therefore, lower salt concentration is
required to drive the gel formation if the nonpolar residues are more hydrophobic. The
phenomenon that increasing the hydrophobicity of the nonpolar residues contributes to
matrix formation was also supported by another study. It has been reported that alaninecontaining amphiphilic peptides (such as EAK) require at least sixteen-mer peptides for
salt-induced stable matrix formation. By contrast, leucine-containing amphiphilic
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peptides (such as ELK) form salt-induced stable matrices from eight-mer peptides [113].
Wang et al. found that, for aliphatic residues, not only the hydrophobicity, but also the
size of these residues could introduce different steric topologies to the non-polar side of
the β-strand, thus affecting the matrix morphology of self-assembled structure [114].
Specifically, if different non-polar residues are incorporated into one peptide sequence,
diverse topologies of the β-strand non-polar side can be formed by modulating the
hydrophobic residue combinations of glycine, alanine, valine, leucine, isoleucine, and
phenylalanine. It was proven that steric size differences of non-polar residues can cause
variations in peptide secondary structures and complementary non-polar topologies
encourage cooperative binding between amphiphilic peptides which would further
facilitate matrix formation.

Table 2-2 amino acid sequences studies by Caplan et al. (reprinted from [112])

As to the number of repeats, it was found that increasing the length of the
oligopeptide will increase the intermolecular attraction as well as the entropy of the
backbone. Since self-assembly is a process facilitating intermolecular attraction while
also decreasing peptide backbone entropy, the competition of these two opposite effects
to the thermodynamic process would make the final CCC have a biphasic trend (i.e.
minimum CCC exists at intermediate length).
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In addition, the charged residues in the sequence can decide the charge
distribution and overall charge carrying in the peptide molecules. Charge distribution can
make a difference to the self-assembling process even when the same amino acid
composition is concerned. In particular, different types of EAK16 (EAK16-I, EAK16-II
and EAK16-IV) with the same amino acid composition but varying charge distributions
were studied [108]. The difference in charge distributions can lead to distinct favored
conformations for each molecule. This will further affect the final self-assembly
structure observed by AFM. It was demonstrated that EAK16-I and -II favors relatively
stretched conformation and forms a fibrillar self-assembly structure while EAK16-IV
favors a β-turn conformation and forms globular self-assembly structure. On the other
hand, the overall charge carried by the peptide can be manipulated by substituting the
charged residues with other uncharged residues. This allows the control of the conditions
(especially pH) under which the oligopeptides can gel. Peptides have a higher propensity
to self-assemble when there are no repulsive charge forces between peptide molecules.
Therefore, pH can take effect by changing the charge distribution/status of the peptide
sequence [115]. For peptides having a positive overall charge at neutral pH, increasing
the environmental pH can initiate the self-assembling whereas for negatively charged
peptides at neutral pH, decreasing pH helps to protonate the negative charge, bringing the
overall charge to zero. Hence, different sequences may display totally opposite trends in
conformational change and self-assembly process when exposed to a pH change in the
solution as evidenced by M. Altman et al. [116].

Concentration is also a key factor controlling the self-assembling process. It was
proposed by Fung et al. [101] that oligopeptides like EAK16-II aggregate into
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protofibrils through seeding and/or a nucleation process depending on its critical
aggregation concentration (CAC). Below CAC (~0.1 mg/ml), two forms of nanostructure
of protofibrils can be adopted, i.e. the thin filament and globular aggregates which were
postulated to consist of monolayers of β-sheets and at least 2 layers of β-sheets
respectively. Over time these protofibrils can further aggregate into fibrils at
concentration above CAC and these fibrils are composed of many globular aggregates
lining up and stacking together. It is worth noting that incubation time is another
important factor to consider in order to understand the kinetics of aggregation.
Oligopeptides at low concentration may start to aggregate at prolonged incubation time
under the condition in which it will not normally self-assemble.

The effect of salt is of particular importance because salt concentration is
physiologically relevant and is a most frequently utilized trigger to initiate the selfassembling. They can affect the aggregation process and resulting aggregation
morphologies by electronically screening ionic interactions during the molecular selfassembling. However, it was also found by Hong et al. [117] that the self-assembling
process of EAK16-II to form nanostructures does not strongly depend on the presence of
NaCl (i.e. electrostatic interactions) when the peptide concentration is high (>0.3 mg/ml).
On the other hand, the dimensions of the resulting self-assembled nanofibers at low
peptide concentrations (<0.1 mg/ml) appear to be dependent on NaCl concentration. The
size of the nanofibers increases until the NaCl concentration reaches about 20 mM. The
radius of the peptide fibrils decreases with further increase in salt concentration. Besides,
globular assemblies were observed in the absence of NaCl at low peptide concentration
but not observed when the electrolyte is present. This indicates that NaCl promotes
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formation of fibril at low peptide concentration. It was thus speculated that the charge
screening effect of the salt promotes non-electrostatic interactions between the peptide
molecules.

In summary, consensus has been reached on the theory that these peptides
assemble in water due to the hydrophobic effect and the charged polar side chains also
play important roles in determining what conditions promote assembly and what
conformation the aggregates will preferentially adopt [118]. Specifically, the
hydrophobic effect facilitates self-assembling through the entropy increase of water
molecules in the system. On the other hand, like-charge repulsion from the charged
residuals prevent self-assembling from happening. The superposition of hydrophobic
interactions and electrostatic repulsion decide the existence state of the peptide in a
certain media. However, most of current mechanism studies are still limited to these
qualitative conclusions summarized from phenomenon observed under varying
conditions. Few publications look deep into the assembled structures down to the
molecular level and explain the process from the physicochemical or thermodynamic
perspective. Systematic research is still lacking for the big ionic self-complimentary
peptide family since most studies are concentrated on EAK16 and RAD16. More efforts
need to be invested to obtain a broad understanding about this type of peptide, thereby
generating more reliable self-assembling mechanisms.
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Characteristics and applications
Having explored the self-assembling mechanisms for ionic complementary
oligopeptides, the features of the resulting self-assembly structures and their potential
applications will be discussed.

Mechanical strength of the hydrogel scaffolds is a critical property in deciding
their potential to have a satisfactory manner within the biological environment in which
they are applied [119]. It was found that higher concentration of peptide usually leads to
higher density of the fiber network which further contributes to the increase in gel
stiffness. Also, crosslinking can be an effective strategy to increase the stiffness of selfassembling oligopeptide gels. It can be achieved, for example, by introducing cysteine
into the sequence to allow disulfide bond formation or adding glutaraldehyde to crosslink
amine groups in the residue side chains [120]. With a thorough understanding of
fundamental mechanisms governing the mechanical properties of these gels, we can
custom-design a gel scaffold with desirable stiffness for a specific biomedical
application.

It is worth noting that the well-defined nanofiber scaffold formed by ionic selfcomplementary peptides could reassemble after undergoing certain types of mechanical
breakage. This is evidenced by the dynamic reassembly of RAD16-I [(RADARADA)2]
after disrupted by sonication. The smaller fragments resulting from sonication are able to
quickly reassemble into nanofibers which were indistinguishable from the original selfassembly [120, 121]. This feature is of great value because the self-assembly scaffold
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will be subject to certain mechanical strength when applied to an in vitro or in vivo
environment.

Chirality of the amino acids could also play some role for the final properties of
the self-assembly structure. It is already known that natural proteins are made of only Lamino acids. Using the chiral counterpart –D-amino acids to generate a chiral mirror
image peptide (such as d-EAK16-II) can make the self-assembled structure more stable
and better resistant to natural enzyme degradation since the chiral peptide cannot be
recognized by natural proteases and is thus more durable [84, 122].

With so many superior features being displayed, these self-assembling
oligopeptides have been demonstrated to have the potential for diverse biomedical
applications including scaffolds for tissue repair, tissue regeneration, instant stopping of
bleeding, wound healing, drug delivery and biological surface engineering, etc. These
applications arise from their capability to self-assemble into a three-dimensional matrix
scaffold in situ under physiological conditions as well as their potential to resorb into
biocompatible degradation products.

With regard to tissue engineering, self-assembling peptide scaffolds have been
proven to support cell attachment and differentiation of plenty of mammalian primary
and transformed cells [24, 123-125]. For example, it was noted that scaffold generated
by RAD16-II peptides provided cells with a soft three-dimensional support which can
facilitate angiogenesis and allow them to form capillary-like structures [126]. This
capillary morphogenesis and endothelial cell adhesion can be affected by primary
sequence of the self-assembling peptide considering the fact that KFE8 and KLD12
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cannot produce this effect while RAD16-I and RAD16-II can [127]. Moreover, the selfassembled structure can serve as substrates for extensive neurite outgrowth and active
synapse formation in addition to supporting neuronal cell attachment and differentiation.
It did not elicit any measurable immune response or tissue inflammation when introduced
to animals [128]. It was also reported that hydrogel scaffold made from RAD16-I could
be used for instant stopping of bleeding when applied on top of multiple tissues and a
variety of wounds [115]. The results showed that the complete hemostasis can be
achieved in less than 20 seconds. The hemostatic process is directly proportional to the
length of the self-assembled nanofibers: the longer the nanofiber, the shorter the duration
of bleeding [129]. Furthermore, the nanofiber scaffolds with favorable designed
properties could be used in in-vitro 3-dimensional cell culture which mimics the
extracellular matrix (ECM) in providing support and allowing the natural flow of oxygen,
nutrients and growth factors.

In addition, functional motifs such as RGD (Arg-Gly-Asp, for cell adhesion),
BMHP (bone marrow homing peptide) [130], YIGSR and RYVVLPR (two sequences
present in laminin-1 to promote cell adhesion, migration and endothelial cell tubular
formation), and TAGSCLRKFSTM (sequence from collagen IV to bind to heparin and
promote adhesion and spreading of bovine aortic endothelial cells) [131], can be
incorporated in the peptide sequence by direct solid phase synthesis extension at peptide
termini in order to be displayed in the gel matrix for biologically active applications. In
fact, sequences with desired biological functions can be incorporated into the selfassembling peptide with varied insertion patterns, not necessarily on the two termini. For
example, a metalloproteinase (MMP-2)-sensitive substrate can be inserted centrically
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within RADA blocks with 3 RADA units flanking on each side. The hydrogel matrix
formed by this novel peptide has comparable mechanical properties and nanofiber
morphology to material built with RAD16-I alone. Exposure of the new gel to MMP-2
can lead to peptide cleavage, mimicking the remolding of natural ECM during tissue
engineering [132]. Notably, both regular and D-form (chiral counterpart) self-assembling
peptide systems could be employed to form the matrix and promote cell viability and
functionality through rational design [133]. It is encouraging that the oligopeptide
RAD16-I has already been developed as a product under the brand name PuraMatrixTM
for multiple biomedical applications [134, 135], mainly as 3D cell culture matrix.

Ionic-complementary self-assembling peptides have also drawn a lot of attention
in controlled drug delivery field due to their desirable properties. For example, they can
be easily engineered to form a variety of stable nanostructures such as fibers, rods, tubes,
nanovesicles and globules and these structures have great potential to be used as delivery
vehicles [136]. Since there are two sides on the β-sheets formed through backbone
hydrogen bonding: hydrophobic side and hydrophilic side, this class of peptide
amphiphile possesses a superior capability to incorporate both polar and nonpolar drugs
in the matrix as a drug delivery platform. A wealth of successful examples especially for
hydrogels made of EAK16-II or RAD16-I have been found for the delivery of
hydrophobic drugs [26, 136] as well as functional proteins [30], cytokines [137], growth
factors [138] and antibodies [139]. The release profiles of these molecules are usually
controlled by the self-assembling peptide concentration (nanofiber density) as well as the
electrostatic interaction between the fiber surface and diffusant molecules [140]. The
release will decrease with increasing peptide concentration (physical hindrances) and
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stronger charge-induced interactions. Thus, the release kinetics can be tailored
accordingly by changing the peptide composition and concentration. It was also
demonstrated that the conformation and functionality of the proteins or antibodies will
not be affected by the peptide matrix encapsulation and the loading efficiency can reach
as high as 100% since the peptide hydrogel consists of water up to 99.5% [139].
Moreover, the self-assembling peptides may have the potential to form complexations
with some hydrophobic drugs in aqueous solution (e.g. EAR8-II with anticancer drug
pirarubicin) [141] or allow the drugs to present as different molecular states in the carrier:
protonated and crystalline (such as EAK16-II with drug ellipticine), resulting in different
therapeutic activities [27, 136]. It is also worth noting that hydrogels composed of more
than one species of peptide have been designed for programmable sustained release of
cargo. For example, RAD16-I and KLD12-I were paired to make a two-layered hydrogel
structure for human IgG release with a concentric sphere of RAD16-I as the core and
KLD12-I as the shell [139]. Controlled release of the antibody can be fine-tuned by this
system.

In the Meng lab, we have been working on EAK16-II and EAK16-II with
appended functional groups such as EAKIIH6 [19, 20] (with six consecutive histidines at
the C-terminus) and dL5_EAK (with a fluorogen activating protein dL5 attached to the
N-terminus) [50]. All of them can co-assemble with EAK16-II to form an insoluble
bioaffinity hydrogel, thus presenting the functional groups at local site of injection for an
extended period of time. For EAKIIH6, with the help of intermediate protein adaptors
(anti-H6 antibody and protein A/G), any antibody of interest could be displayed locally
by the co-assembly structure for immune modulation purposes. Its effectiveness has been
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proven in vivo using two epithelial tumor cells. As to dL5_EAK, due to the fluorescence
enhancement function of the dL5 domain upon specific binding to the dye malachite
green (MG), it has a potential to be used as an in situ forming local biosensor. In both
cases, EAK16-II functions to immobilize and concentrate the functional group in situ.

Other than applications in tissue engineering and drug delivery scaffold, the selfassembling peptides have also been used in electronics field as template for metallic
nanowire and electronic device fabrication. For example, functional Cu2+ binding group
GGH (G, glycine; H, histidine) was attached to the C-terminus of EAK16-II by H. Yang
et al. to create a bi-functional material which can form stable nanofibers and at the same
time incorporate copper into the structure via a metal binding site in the self-assembling
peptide [142].

Additionally, these peptides may serve as a good model system for studying the
mechanism of many neurodegenerative diseases such as Alzheimer’s and Parkinson’s
diseases considering that the fibrillar nanostructures resulting from these peptide
assemblies are similar to the amyloid fibrils found in those diseases. Therefore, the
mechanism or theoretical studies for this self-assembling system will give us insight into
the driving forces for the assembly of more complex endogenous proteins such as βamyloid and prion proteins, thereby facilitating the research trying to find the treatment
that will prevent plaque formation in vivo.
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II. Self-assembling β-hairpins
Pochan, Schneider and coworkers in Delaware developed a type of peptide that
can have an intramolecular folding event before undergoing intermolecular self-assembly
into hydrogel scaffolds. This intramolecular folding can be triggered by different kinds
of stimuli such as changes in pH [143], temperature [144], ionic strength [145], light
[146] or the introduction of cell culture media [147]. This class of peptide amphiphile is
composed of a central tetrapeptide (VDPPT) which has high β-turn propensity flanked by
two extended strands containing high β-sheet propensity residues. The first peptide
designed by this group is named MAX1 (structure see Figure 2-5). The strands contain
alternating hydrophilic and hydrophobic residues, mainly lysine (K) and valine (V)
respectively. Interestingly, these strands have a similar pattern to the ioniccomplementary self-assembling peptides discussed above in terms of amino acid
organization. The biggest difference lies in the charge state of the sequence. Here,
mainly positively charged lysine is incorporated as the hydrophilic residue while
positively charged and negatively charged amino acids were alternated in the previous
case. Therefore, the overall net charge for β-hairpins at neutral pH is positive compared
to zero for the ionic-complementary peptides. This difference can affect their
corresponding self-assembling trigger conditions. Later, derivatives of MAX1 containing
other amino acid substitutes at different positions and/or with different numbers were also
created to achieve tunable stimuli functions.
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Figure 2-5 proposed β-hairpin structure and amino acid sequence of MAX 1, a typical
peptide of this category (20 residues). (reprinted with permission from reference [145].
Copyright (2004) American Chemical Society)

Self-assembling mechanisms
It is not surprising that the self-assembling of β-hairpins can also be initiated by
the previously mentioned environmental cues (temperature, salt, pH, etc.) to form the
hydrogel scaffold. Many researchers have shown interest in studying the underlying
mechanisms as well. Work on different stimuli will be discussed separately.

For pH responsive hydrogels, the charge state of the hydrophilic residues plays an
important role in intramolecular folding. Since lysine is basically the hydrophilic amino
acid incorporated in the sequence of β-hairpins, increasing the pH above the intrinsic pKa
(10.8) of the lysine side chains can reduce the intrastrand charge repulsion from
neighboring lysines, thus initiating the intramolecular folding and subsequent selfassembly to hydrogel structure. The final self-assembled structure is supported both
laterally through hydrogen bonds between adjacent hairpins and facially by hydrophobic
association of the valine-rich faces [143].

For ionic strength responsive hydrogels, the addition of salts is able to trigger the
intramolecular folding due to the formation of salt-bridge physical cross-links or charge
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screening effects for the electrostatic interactions between the charged amino acids [145].
In the folded state, the single peptide molecule is facially amphiphilic, displaying all
hydrophobic residues on one face of the hairpin and hydrophilic residues on the other.
Once it is folded into a β-hairpin conformation, self-assembly can be driven by both
intra- and inter-molecular hydrogen bonding laterally and hydrophobic interactions
facially. Well-defined, bilayered fibrils can thus be formed and further developed into a
β-sheet rich hydrogel network. The final elastic property of the hydrogel can be tuned by
salt concentration. The higher the salt concentration added, the more rigid the hydrogel
formed. The network of the hydrogel is composed of dense fibrillar assemblies that are
cross-linked to each other by physical junction points. The proposed self-assembling
pathway and fibril structure for MAX1 β-hairpin molecule are shown in Figure 2-6.

Figure 2-6 (a) proposed self-assembly pathway for MAX1, (b) the structure of selfassembled MAX1 β-hairpin molecules in a fibril and (c) TEM micrographs of MAX1
hydrogels showing the nanostructure of 0.5% wt% network, scale bar: 100 nm; insets:
magnification of MAX1 fibrils that are ≈ 3 nm in width, scale bar: 20 nm. (adapted with
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permission from reference [145] and [148]. Copyright (2004) American Chemical
Society and Copyright (2007) National Academy of Sciences, U.S.A.)
For thermally responsive hydrogels, the hydrogel forms upon temperature
increase. The increase in temperature serves to dehydrate the nonpolar residues of the
unfolded peptide and the folding is hence triggered via hydrophobic collapse [144].

As to light-activated hydrogel formation, it is achieved through covalently
incorporating a photocleavable moiety into the peptide sequence. The photocleavable
moiety possesses an electrostatic feature which inhibits peptide folding. Therefore, after
exposed to light at a certain wavelength, the photocage can be released to initiate
intramolecular folding, self-assembly and finally the formation of a mechanically rigid
hydrogel [146].

It was proposed by Yucel et al. [149] that after the bilayered β-sheets are formed
through folding, the possible cross-linking mechanisms for the final hydrogelation
include (1) self-assembly defect-induced branching (i.e. kinetically trapped, imperfect
hydrophobic face collapse may lead to nucleation of a branch, see Figure 2-7) and (2)
entanglement of self-assembled fibrils. Both can lead to permanent physical cross-links.
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Figure 2-7 Schematic representations for two different self-assembled cross-links: (a) a
defect-induced branch and (b) an entanglement (adapted with permission from reference
[149]. Copyright (2008) American Chemical Society)
It is worth mentioning that more than one environmental stimuli can take place
simultaneously. For example, the folding and self-assembly of the parent MAX1 peptide
can be induced by changing the solution pH to reduce the point charge of the lysine
residues, increasing the ionic strength to screen the electrostatic repulsions, or increasing
the temperature to enhance the attraction between hydrophobic residues. These changes
can work collectively to facilitate the hydrogelation process.

Since most peptides developed by this research group possess a high β-turn
propensity tetrapeptide flanked with two extended strands, predominantly an alternating
sequence of valine and lysine residues or some point substitutions with other amino acids,
the charge state of the whole strands was proven to affect the gelation kinetics of the
peptides because the electrostatic repulsion between positively charged lysine is an
important force preventing the folding and self-assembly. Therefore, the rate of the gel
formation becomes faster for point substitutions with less total charge. As a result, the
careful design of the peptide sequence can be employed to modulate the charge state and
finally the gelation kinetics of the peptides to obtain a desired profile under certain
environmental condition [150].

Characteristics and applications
Stimuli-responsive hydrogels generated from β-hairpin peptides have the potential
to be used as biomaterials due to their superior morphological and physicochemical
features. At early-time hydrogelation, peptides undergo intramolecular folding into β56

hairpins and concurrently self-assemble into branched clusters of well-defined, β-sheet
rich nanofibrils. These fibers are very uniform with monodisperse dimensions (3nm
cross section). It was postulated that the hydrogel network rigidity is boosted by the
finite interpenetration of percolating cluster with smaller clusters as well as permanent
intercluster entanglements [149].

One of the most distinguished advantages of β-hairpin hydrogels is that they can
be injected as pre-formed solids. The pre-formed solid gel can shear-thin under a proper
shear stress and consequently flow during injection; but upon removal of the stress, it
recovers back into a solid immediately. This feature allows the hydrogel system, together
with the payloads that are encapsulated during the original hydrogelation, to be delivered
via simple syringe to a targeted in vivo site and stay localized at the site of injection to
achieve the required therapeutic effect. The unwanted leakage and flow of the injected
liquid to neighboring tissue or the blood stream can be minimized by the design of higher
viscosity precursors or fast in situ gelation kinetics. The duration of shear, the shear rate
as well as the pre-shear gel rigidity all affect the gel stiffness immediately recovered after
flow and the ultimate stiffness after complete rehealing of the gel [151]. It was also
demonstrated that the shear-thin delivery process of syringe injection had little or no
effect on cell viability and three dimensional cell distribution which indicates that these
peptidic hydrogels can serve as excellent candidates for injectable therapeutic delivery
vehicles for cells [147, 151, 152].

Interestingly, the chirality of the β-hairpin peptides (MAX 1) was found to affect
the mechanical rigidity of the self-assembled hydrogels. Specifically, hydrogels
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generated from enantiomeric mixtures of self-assembling β-hairpins exhibit non-additive,
synergistic enhancement in mechanical rigidity compared to gels made from either pure
enantiomer. The racemic hydrogel shows the greatest mechanical rigidity [105]. The
underlying molecular mechanism for this phenomenon is still not clear, but spectroscopy,
rheology and microscopy data suggest that it might be due to energetically favorable
interactions between the enantiomers either occurring at molecular level or hydrogel
network level or both. Therefore, biomolecular chirality has a potential to be utilized as a
tool for material design and controllably modulating the mechanical properties to the
desired level by adjusting the molar ratio of β-hairpin enantiomers.

When it comes to applications, β-hairpin self-assembling peptides are mainly used
to prepare hydrogels as injectable therapeutic delivery vehicles. Similarly to ionic
complementary peptides, a large range of drug molecules, from hydrophobic small
molecules such as curcumin [153] to hydrophilic macromolecules such as proteins [154],
could be encapsulated into the self-assembling peptide hydrogels to make an injectable
localized drug delivery system for sustained and controlled release. This is achieved by
initiating the self-assembly in the presence of drug of interest. The drug molecule
mobility within and release out of the hydrogels can be adjusted by the mesh size of the
gel, which can be modulated by altering the peptide sequence or simply varying the
concentration of the peptide. Furthermore, the electrostatic interactions between the drug
molecules and the peptides constructing the gel can affect the mobility and release of the
drug. For example, for electropositive fibrillar hydrogels, release of positively charged
and neutral molecules is controlled by the steric effect imposed by the gel network. In
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contrast, negatively charged drugs interact strongly with the positively charged network,
leading to significantly slower release [155].

β-hairpin peptides self-assembly and hydrogelation can also be employed to
deliver cells through triggering the self-assembly in cell culture medium containing cells
of interest. The resulting well-controlled, homogeneous, three-dimensional encapsulation
of desired cells and the maintenance of high cell viability after the shear-thinning process
render these gels promising tools to deliver cells at target biological sites for tissue
engineering or other purposes [148].

Moreover, the electrostatic character of the gels can affect cell behavior
incorporated within. Although hydrogel networks can afford similar rheological behavior
and local network morphologies, different network electrostatic status can influence the
cell viability after encapsulation and delivery, extracellular matrix deposition, and gene
expression. For example, by comparing hydrogels made of different charge state
monomers MAX8 and HLT2 (+7 and +5 per monomer, respectively), less electropositive
HLT2 gel was found to provide a microenvironment more favorable to chondrocyte
encapsulation, delivery and phenotype maintenance. Besides, a higher cell viability was
observed for HLT2 gels compared to MAX8 gel [156].

III. Alkylated peptide amphiphiles
The Stupp research group from Northwestern University in Chicago has
developed a type of peptide amphiphile (PAs) which consist of a long linear hydrophobic
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alkyl tail coupled to a polypeptide block [157]. This polypeptide block usually includes
β-sheet-forming segments, charged residues for solubility and biological epitopes, etc.
There are a large variety of possible combinations for the peptide block components.
Some only contain a β-sheet-forming segment and a charged head group while others
also include different kinds of sequences for biological signaling and functionality. In
addition, consecutive cysteine residues can be incorporated to introduce intermolecular
cross-linking for higher robustness of the supramolecular fibers and photo-cleavable
group can be employed to introduce photo-responsive property. This type of alkylated
peptide amphiphile has the potential to self-assemble into cylindrical nanofibers with
diameters on the order of a few nanometers and lengths in the micrometer scale [158].
The hydrophobic alkyl tails pack on the inside of the fiber while the peptide portions are
displayed on the surface of the fiber which makes a cylindrical micelle with an overall
conical shape from intersection [159] (see Figure 2-8). The amino acid selection and
alkyl tail modification confer nanofibers with varying morphology, surface chemistry,
and potential bioactivity [157]. The alkyl tail is usually attached to the N-terminus of the
peptide and the epitope segment is placed at the C-terminus which will be displayed on
the periphery for cell interaction after self-assembly. There are also PAs with reverse
polarity which means the alkyl tail is attached to the C-terminus and free N-terminus is
exposed to the periphery. They co-assemble with PAs with free C-terminus leading to
assemblies with unusual thermal stability when compared to assemblies composed of
only one type of PA molecules [160]. There are three main modes of induction for the
alkylated peptide amphiphiles to self-assemble into nanofibers: pH control, divalent ion
induction, and concentration induction [161].
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Figure 2-8 (a) Chemical structure of one alkylated peptide amphiphile with 5 key
structure regions. Region 1: alkyl tail; region 2: four consecutive cysteine residues;
region 3: three glycine residues serving as a flexible linker; region 4: phosphorylated
charged residue; region 5: cell adhesion ligand RGD (b) Molecular model of the PA
showing the overall conical shape of the molecule going from the narrow hydrophobic
tail to the bulkier peptide region; (c) Schematic showing the self-assembly of peptide
amphiphile molecules into a cylindrical micelle; (d) Vitreous ice cryo-TEM image of the
fibers reveals the diameter of the fibers to be 7.6 ± 1 nm (adapted from reference [159])

Self-assembling mechanisms
Since there are usually more than three distinct components in one PA molecule
(such as alkyl tail, β-sheet-forming segment, tetra-cysteine region, charged residues and
biological epitopes), studying the effect of each portion to the self-assembling
phenomenon is essential for the comprehensive understanding of the self-assembling
mechanism. In order to know what components of the peptide amphiphile are
responsible for their self-assembly, different derivatives of the PAs were designed by
Hartgerink et al. [157] and three main regions of the molecules were modified: the length
of the alkyl tail (from 22 carbons to no carbon), the tetra-cysteine region (cross-linking
effect of thiol groups) and the head group region (the C-terminal end which can interact
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with the environment and incorporate different cell adhesion ligands or crystal nucleation
centers). It was found that hydrophobic interactions between the alkyl tails play a key
role in self-assembly in water given the fact that the PAs without an alkyl tail cannot selfassemble and PAs with sufficiently long alkyl tails can self-assemble more easily.
Moreover, the presence of cysteine residues is not required for self-assembly although it
can provide covalent capture of the fibers by the formation of intermolecular disulfide
bonds upon oxidation. Also, the head group of PAs, which would be exposed on the
surface of self-assembled fibers, allows a large flexibility on the sequence. In other
words, different bioactive motifs or even sequences without bioactivity can be
incorporated in this region without hurting the self-assembling propensity of the general
design. Paramonov et al. demonstrated that hydrogen bonding close to the hydrophobic
core was necessary for the nanofiber formation and had the biggest impact on the gel
properties [162].

The mechanism of peptide amphiphile self-assembly was also studied by
molecular simulation technique with a model that incorporated molecular structure and
inter- and intra-molecular interactions [163, 164]. Different morphology could be formed
due to different molecular structures or at different phases of self-assembly. These
morphologies include single β-sheet connected laterally by hydrogen bonds, stacks of
parallel β-sheets, spherical micelles, micelles with β-sheets in the corona and long
cylindrical fibers (Figure 2-9). It was found that the self-assembly of PA molecules is
driven mostly by the interplay of hydrophobic interactions between alkyl tails and
hydrogen bonds between peptide blocks. Molecular length and thermodynamic
parameters such as temperature and concentration all play important roles in self-
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assembly. However, this study did not consider electrostatic interactions between epitope
head groups or with salt ions as well as the effect of the solvent which may hydrogen
bond with the peptide units. The thorough consideration of all influencing factors
requires significant computational resources and efforts.

Figure 2-9 The simulated morphologies that could exist during PA molecule selfassembly process. A) free molecules, b) spherical micelles, c) micelles with β-sheets on
the outside forming the corona, d) long cylindrical fibers, e) stacks of parallel β-sheets,
and f) single β-sheet. (Adapted with permission from reference [163]. Copyright (2008)
American Chemical Society)
In regard to different modes of alkylated PA self-assembly, pH is one of the major
triggers. When the pH is neutral, peptides containing acidic amino acids have a net
negative charge which keeps the PAs from self-assembly due to electrostatic repulsion.
This negative charge can be eliminated upon acidification so that hydrophobic tails can
start to aggregate after pH is reduced. In addition to pH, polyvalent metal ions such as
Ca2+, Mg2+, and Cu2+ can also induce self-assembly which could be explained by the
ionic interactions between the acidic groups in PAs and positively charged counterions
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(could be the formation of ion-peptide complex). However, monovalent ions are not able
to induce the formation of self-supporting gels for most PAs. Thus, it appears that
polyvalent ions are significantly more effective initiators of self-assembly than
monovalent species. Gels produced by addition of polyvalent metal ions to PA solutions
are very stable under a broad pH range (from 4-11 for some PAs) and high temperature
up to 100 °C. In contrast, gels formed by pH-triggered mechanism are only stable at pH
below 3.5. The high stability of cation-mediated PA gels is postulated to be determined
by the diversity of intermolecular interactions including hydrophobic, ionic and hydrogen
bonds [165]. In addition, concentration is important simply because sufficient fibers are
needed to form the three-dimensional networks which will further allow the gelation to
occur.

Characteristics and applications
This type of alkylated PA molecules consists of a fatty acid chain containing 1022 carbon atoms in length connected via an amide bond to a peptide block which includes
6-12 amino acid residues for different functions. They can self-assemble into selfsupporting gels at concentration as low as 0.25% by weight [165]. The gels are
composed of a network of cylindrical nanofibers, and these fibers formed by alkylated
PAs all possess a diameter between 5-10 nm and a length on the order of microns. As we
already discussed, the hydrophobic alkyl tails are located at the core of the fiber while the
hydrophilic peptide segments comprise the outer surface. Although all the PAs form
fibers with comparable diameter, the length and stiffness of the fibers vary significantly
depending on the sequence of these PAs [166]. It was demonstrated by FTIR studies that
the hydrogen bonding of β-sheets tends to be aligned along the long axis of fibers but
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with some amount of twisting or disruptions [167] (see Figure 2-10). Since the alkyl tails
are attached to the same terminus of the peptide segment for a certain kind of PA
molecule, every peptide would have the same C-N direction in the formed nanofibers.
Therefore, it is very likely that the fibers contain only parallel β-sheets.

Figure 2-10 Schematic representation of a single β-sheet in (a) linear and (b) twisted
geometry in a peptide amphiphile nanofiber; (c) schematic of two β-sheets in the fiber
with arrows indicating the hydrogen bonds. (adapted with permission from reference
[167]. Copyright (2010) American Chemical Society)
Aside from the cylindrical shaped fibers, giant flat nanobelts could also be formed
by certain alkylated peptide amphiphiles which contain an alternating sequence with
hydrophobic and hydrophilic side chains in its peptide block [158]. The nanobelts
possess fairly mono-disperse widths on the order of 150nm and lengths of up to 0.1mm,
eliminating all curvature from the nanostructure. With variations in monomer
concentration, these PAs can generate morphology with twisted ribbons. After
appropriate functionalization, these nanostructures could offer a novel architecture to
display epitopes to cells for therapeutic applications.
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It was also demonstrated that oppositely charged PA molecules with different
bioactive sequences can co-assemble into nanofibers with the simultaneous display of all
epitopes on the surface [160]. The electrostatic attractions between the oppositely
charged head groups can facilitate self-assembly by forming salt-bridged pairs at neutral
pH [168]. In this case, pH serves as a trigger to introduce the opposite charge state to the
PA molecules, thus promoting the self-assembly. In addition, since different PA
molecules are capable of co-assembly, optimized cell signaling can be achieved by
mixing a specific bioactive molecule with a different bioactive molecule or a nonbioactive diluents molecule to vary the epitope density on the assembled nanostructure.

The stiffness of the gels formed by PAs is an important feature when the matrix is
used for regenerative medicine scaffold since cells respond to the mechanical properties
of their environment and the mechanical properties could influence cell behavior [169171]. The matrix stiffness can be affected by the amino acid sequence in the PAs. A
study was performed to investigate the number and position of valines and alanines in the
peptide sequence to the mechanical properties of the nanofiber gels that the PAs form
[167]. It turned out that increasing both the number and fraction of valine, which has the
highest propensity to from β-sheets, is especially effective at raising mechanical stiffness
of the gels. Moreover, the high gel stiffness is also facilitated by alignment of hydrogen
bonds along the fiber axis as well as the placement of β-sheet-forming residues near the
hydrophobic core of nanofibers.

The alkylated self-assembling PA molecules studied by the Stupp’s group were
initially designed for tissue engineering purposes and have been used for a host of
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biological applications. For example, a phosphorylated residue was introduced into the
peptide segment to induce the mineralization of hydroxyapatite in order to recreate the
nanoscale structure of bone [159]. Also, with proper functionalization in the peptide
terminus, the self-assembled nanostructures offer architecture to present epitopes to cells
for varying therapeutic applications. Commonly incorporated epitopes include RGD
[172], IKVAV [173] and YIGSR[174], etc. Some bioactive epitopes can promote rapid
and selective differentiation of neural progenitor cells into neurons [175]. A heparinbinding peptide amphiphile (HBPA) was designed by Ghanaati et al. with a heparinbinding domain to specifically bind and self-assemble at the presence of heparin sulfatelike glycosaminoglycans (HSGAG), allowing for the capture of angiogenic growth
factors such as VEGF and EGF-2 in a biomimetic fashion. The formed gels were
demonstrated to have good biocompatibility and be able to promote angiogenesis in vivo
which was reflected by extensive blood vessel formation in a rat cornea [176]. It can also
improve cell viability and function in the interior islets as an artificial ECM after
delivered to pancreatic islet at a very low concentration together with angiogenic growth
factor. This contributes to the treatment of type 1 diabetes through islet transplantation
[177]. Moreover, the heparin-presenting nanofiber networks were demonstrated to
capture and deliver paracrine factors therapeutically for cardiovascular diseases to elicit a
paracrine effect [178]. Another example includes bioactive, cylindrical nanofibers
bearing a cationic α-helical cytotoxic peptide (KLAKLAK)2. This novel amphiphilic
molecule is generated by attaching the peptide to a PA molecule. These (KLAKLAK)2
nanostructures formed after self-assembly, but not the peptide alone, could be readily
internalized by breast cancer cells and induce cancer cell death by membrane disruption
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[179]. The cytotoxic peptide amphiphiles bearing (KLAKLAK)2 have been applied for
cancer therapy since it can self-assemble into supramolecular membranes acting either as
reservoirs for sustained release of cytotoxicity upon enzymatic degradation or just as
membranes with surface-bound cytotoxicity [180].

As we already know, the nanostructure matrix formed in the presence of
suspended cells before self-assembly can entrap cells in the matrix. This entrapment
should not arrest cell proliferation and motility and is presumably expected to improve
cell viability and promote retention after targeted application if we use PA-based
nanostructure scaffold for cell delivery. This has been demonstrated with bone-marrow
mononuclear cells (BMNCs) for ischemic tissue therapies [181]. In addition, the
entrapped cells were proven to be able to internalize the nanofibers and probably utilize
PA molecules for metabolic pathways which solves the toxicity problem and at the same
time provide nutrients for the cells [165].

Since the cylindrical nanofibers formed by these PAs containing hydrophobic
cores, hydrophobic small molecules or drug moieties have the potential to be
encapsulated within the core for desirable delivery. The encapsulation has been tested in
multiple substances such as pyrene [182], prodan [183] etc.

In addition to therapeutic applications, magnetic resonance imaging (MRI)
contrast agents could also be designed into some PA molecules to combine highresolution three-dimensional MR fate mapping of the scaffolds with targeting of specific
cellular receptors [184, 185].
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Common features of these self-assembling peptide amphiphiles
Although the self-assembling mechanisms and peptide orientations in the fibers
are slightly different for each type of peptide amphiphiles discussed in this chapter, the
intrinsic forces contributing to the self-assembly are the same in nature. They include
hydrogen bonding, hydrophobic forces, electrostatic interactions, repulsive steric forces,
nonspecific van der Waals interactions, π-π stacking and chiral dipole-dipole interactions
[157]. All systems involve a combination of these forces which could counterbalance the
entropic cost caused by peptide aggregation.

These self-assembling peptide amphiphiles are all designed to go through sol-gel
transition after exposure to external environmental changes and they share a lot of
common features in regard to the physical structure of resultant material after selfassembly. The interwoven fibrillar networks formed by all of these peptide amphiphiles
possess diameter and length on the same order of magnitude although their specific
values may vary due to their different lengths, compositions and external cues
(comparison see Table 2-3). These peptide-based networks can serve as novel materials
for tissue engineering simply because the hierarchical supramolecular structures and
mechanical strength those peptides generate resemble biological ECM and they can
interact with cells at the molecular level [165]. Their applications as drug delivery
scaffolds can be attributed to the restriction effect of gel matrix to the drug molecules
incorporated. The release of the drug payload is dependent on the mesh size of the
matrix as well as the electrostatic interaction between the drug molecule and peptide
scaffold. In addition, these peptide-based structures are biologically benign toward
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various cell lines and will not incite immune responses in macrophages since they could
be eventually degraded to naturally occurring amino acid residues.

Table 2-3 Comparison for properties of representative peptide amphiphiles from each
category
Peptide
category

Representative
sequence

Concentration
threshold

Hydrogel
geometry

Reassembly
property

Mechanical
rigidity

Ioniccomplementary
self-assembling
peptide

EAK16-II

CAC: 0.1
mg/ml (6*10-5
M)
[101]

Fiber
diameter:
10-80 nm;
pore size:
20-500 nm
[24, 84, 101]

N/A

G’< 20 Pa
even at 10
mg/ml
[133]

RAD16-I
(PuraMatrixTM)

N/A

Fibers
width: 10-20
nm;
length:1001000 nm
[115];
pore size: 5200 nm
[130, 131]

Dynamic
reassembly
completes
within time
scale for
hours [120,
121]

G’= 36.81
Pa [130] /
1541.7 Pa
[132] / 4.7
kPa [120] for
10 mg/ml
RAD16-I
(not
consistent)

β-hairpins

(VK)4VDPPT(VK)4
(MAX 1)

N/A

Fiber width:
3 nm
Fiber height:
2 nm [145]
Fiber length:
10-200 nm
[148]
Pore size
18-50
nm[155]

Gel
recovers
immediately
after
cessation of
shear [151]

mechanically
rigid gel
G’>2500Pa
(2 hours
after
initiating
selfassembly for
2% MAX1)
[147]

Alkylated
peptide
amphiphiles

C16H31O-NHCCCCGGGS(P)RGD
(Generally: 10-22
carbon chain
attached to 6-12
amino acids)

Gelation
threshold:
0.25% (wt%)
[157]

Fiber
diameter:
7.6nm
(5-10nm in
general)
Fiber length:
several
micrometers
[157, 167]

N/A

stiffness
varies
considerably
depending
on sequence
(G’: from
<100 Pa to >
10 kPa)
[165, 167]

CAC: critical aggregation concentration; N/A: not available
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Moreover, most of the peptides can be easily chemically synthesized through
solid-state phase peptide synthesis technology and this technology can produce peptide
amphiphiles in relatively large quantities within short time. One exception is alkylated
PAs which need an additional manual coupling reaction to attach the peptide portion
generated from solid phase synthesis to long-chain aliphatic acid via the formation of an
amide bond. Alternatively, with the help of genetic engineering, epitopes with different
functionalities can be incorporated into the peptide sequence to introduce adhesion,
differentiation or other specific biological effects [186]. Supramolecular self-assembling
biomaterials could thus be easily controlled in terms of architecture, shape and
dimensions as well as density of bioactive signals.

Owing to the easy manipulation of both peptide composition as well as external
conditions, the properties (including gelation kinetics, gel stiffness, network mesh size) of
the self-assembled structure (usually cross-linked fibrils) can be readily controlled and
modified by the adjustment of amino acid sequence, peptide concentration or external
environmental conditions such as solution ionic strength, pH or temperature etc. in order
to achieve desired cell encapsulation or controlled release of therapeutics [152].

Altogether, common features shared by these peptide amphiphiles such as low
toxicity and high biocompatibility, easy production and manipulation, and wide
biomedical applications have made the study of these self-assembling peptides the focus
interest of multiple research groups. So far, great strides have been made in the study of
multifaceted aspects of these peptides, from underlying self-assembly mechanism to
macrostructure characteristics favoring their practical use in diverse fields. Continuing
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effort is still needed to design novel materials and explore their applications in different
aspects.

Conclusions and future prospects
Extensive research has been done on the self-assembling peptides in the last three
decades due to their favorable features and extensive potential applications in biomedical
engineering and nanotechnology. These peptide-based molecules are present in different
forms as single molecules as discussed above, however, they all tend to form similar
fibrillar-entangled macrostructures after self-assembly. This self-assembling process
usually needs to be initiated by exterior environmental stimuli and the final resulting
structure has a semi-solid gel-like behavior with a certain mechanical strength. Those
unique characteristics of the materials make them ideal material candidates as tissue
engineering scaffolds or drug delivery vehicles. Despite high levels of similarity in
macrostructures, the differences in self-assembling mechanisms and material
microstructures still exist. Therefore, it is challenging but beneficial to distinguish the
differences among them and find the optimal application for each category.

Comparison and property predictions
Although considerable effort has been invested in the study for each type of selfassembling peptide amphiphile as well as their corresponding biomedical applications,
little comparison has been made to find their relative suitability at a given condition. For
example, if three-dimensional culture for a particular cell line is desired, little information
is available for us to target the best fit material for this situation. Therefore, a systematic
prediction system for the performance of each peptide amphiphile under certain condition
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is expected to be created to take the most advantage of the existing resources. In order to
accomplish this, a structure-property correlation for these self-assembling peptides needs
to be established. With the knowledge of this relationship, more rational molecular
design for these peptides is made possible by simply modifying their
sequences/compositions or stimulus conditions. Hence, not only comparison within each
type of peptide is valuable, inter-category comparison would further facilitate the
selection of the best possible material for each specific situation. A more thorough
understanding of relationship between peptide molecular structure and network
biomedical properties can ultimately lead to a better bio-molecular network behavior in
general. This could be one of the most compelling directions for future research.

Standardization of analytical techniques
To get a better comprehension of the self-assembling systems, the analytical
techniques employed to determine their structures and speculate their self-assembling
mechanisms are of critical importance. So far, CD and FTIR are the most frequently
used methods to determine the secondary structures of these peptides in self-assembling
process while AFM and SEM are the most popular microscopic methods to observe the
dimensions and morphologies for the self-assembled structure. However, most
researchers use only two or three techniques for each peptide studied. This may lead us
to less accurate conclusion since each technique has its own limitations. Another
drawback is that the results obtained by one group lack consistency to the results
observed from other groups who use different techniques [187]. For example, the fiber
diameter measured by one group was 10-20nm [23] but 40-80nm [117] by another group
for the same peptide. Therefore, the speculation for its organization in the self-assembled
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structure could be significantly different. That explains why controversy still exists in
terms of peptide molecules orientation in the self-assembled fiber structures for ioncomplementary self-assembly peptides. Some proposed that these oliogopeptides are
either staggered or organized in registry to form intermolecular interactions (i.e.
hydrophobic and ionic interaction between the polar and nonpolar side chains) and fiber
is formed by the extension of these interactions where the direction of these
intermolecular interactions is parallel to the fiber axis [23]. Others speculated that fibers
are developed in length through the extension of intermolecular backbone hydrogen
bonding where hydrophobic interactions only help to form the β-sheet bi-layer which
determines the height of the filament [112]. Since the fiber dimensions are usually used
to speculate molecular organization in the structure and the self-assembling mechanisms
are derived accordingly, different values obtained from different groups may lead to
contradictory conclusions with regard to self-assembling mechanisms. Therefore,
multiple other technologies with higher resolutions such as X-ray crystallography, solid
state nucleic magnetic resonance (ssNMR) and even computer simulation could be
employed together with CD, FTIR, and microscopy to generate a more comprehensive
picture. More detailed information on the molecular level of these peptides can be
provided by X-ray fiber diffraction [188] and ssNMR [189] to confirm those speculations
and facilitate the development of more accurate mechanisms. For example, ssNMR
studies (together with 13C isotopic labeling) performed on RAD16-I recently [189]
confirmed that the nanofibers are composed of two stacked β-sheets stabilized by a
hydrophobic core formed by alanine side chains. More detailed studies should be
conducted in future work to derive more convincing and precise mechanisms/theories for
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peptide self-assemblies. This will promote the fundamental understanding of selfassembling principles and practically avoid unnecessary contradictory conclusions drawn
by different groups, thereby facilitating rational design of peptide-based self-assembling
materials for specific applications.
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Chapter 3
Genetic Engineering of a Fluorogenic Module in Bioaffinity
Hydrogels for Antibody Delivery
A biomaterial design in which a fluorogen-activating protein (FAP) is used to
mediate loading and release of antibodies is described in this chapter. The system
consists of the FAP dL5, a dimerized single-chain variable fragment (scFv), appended
with three repeats of the amphiphilic sequence AEAEAKAK via a glycine-serine peptide
linker. This fusion generates a polypeptide called dL5_EAK. Intermixing dL5_EAK
with the -fibrillizing peptide AEAEAKAKAEAEAKAK (commonly known as EAK16II) results in a functionalized composite referred herein as dL5 hydrogel. The bioaffinity
hydrogel illuminates fluorescence upon addition of malachite green (MG), the
fluorogenic partner of dL5. MG was conjugated with protein A/G (pAGMG) as an adaptor
that can capture IgG to the dL5. Using confocal microscopy and dose-response titration,
we demonstrate that loading of IgG into the hydrogel was mediated by binding of pAGMG
to dL5. In in vitro experiments, it was observed that only 26% of the IgG were released
from hydrogel embedded with pAGMG after five days, compared to close to 90% in
hydrogel without pAGMG. Close to 60 % of the antibody recovered over time remained
bioactive. Denaturation may be further reduced by modulating the ratio of IgG to the
multivalent pAGMG, identified in the computational simulations as a principal parameter.
In mouse footpads, dL5 hydrogel delivered IgG were retained locally, with distribution
through the lymphatics impeded. The ability to monitor bioaffinity sites in vitro and in
vivo, orthogonal to IgG release, will aid the development and optimization of local
antibody delivery systems.
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Background and Rationale
Drug discovery efforts are increasingly turning toward immunomodulatory
monoclonal antibodies aimed for chronic ailments [190]. While most antibodies are
formulated for systemic infusion, opportunities exist in developing delivery systems to
concentrate drugs in affected tissues and to target regional lymph nodes in order to affect
local immune milieu [191]. Outcomes of inflammation are governed in part by the
phenotypes of granulocytes, myeloid cells, and lymphocytes trafficking between injured
tissues and draining lymph nodes. As such, there are opportunities for developing novel
systems for local delivery of biologics. In situ-forming hydrogels can create depots of
antibody drugs in subcutaneous space. Local administration of immune modulators can
enhance efficacy and reduce adverse events. In situ-forming hydrogels or coacervates
formed by cross-linked polymer chains that remain physically intact with high water
intake are particularly attractive because of their ability to adapt to tissue space [192].
Drug loading can be accomplished by introducing the biologic during polymer crosslinking. The pore sizes (5-100 nm) and the resulting high permeability of such depots
[193], however, preclude the ability to concentrate antibodies at injection sites and
accumulate in draining lymph nodes. Rapid diffusion of drugs out of the network (“burst
release”) can be limited by increasing cross-linking density [194] or through bioaffinity
retardation [17]. A less explored challenge is that the location of the depot cannot be
ascertained in vivo, making it difficult to determine the rate-limiting mechanism of drug
localization.

The EAK16 series of low molecular weight, -sheet fibrillizing peptides (FP)
can be formulated into hydrogels for delivering small molecule drugs, proteins, and cells
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[195-197]. The FP EAK16-II, comprised of AEAEAKAKAEAEAKAK (with A as
alanine, E as glutamic acid, and K as lysine), self-assembles into cross-linking fibrils in
high ionic strength aqueous environment [195]. When administered through
conventional needled syringes, EAK16-II forms stable networks in vivo, adapting and
adhering to the local tissue contours [198]. Due to the high water content (~99.5% w/v)
[195], IgG can be loaded into the gel matrices with high efficiency. The amphiphilic
EAK16-II, carrying no net charge at pH 7.4, presumably interacts with IgG via weak
non-specific interactions, resulting in a large fraction of the protein molecules remained
unbound [199].

We have used a coassembly strategy to engineer biochemical functionalities into
EAK16-II fibrillar matrices [198, 200-203]. Using the analogue EAKIIH6, His-tags are
incorporated into EAK16-II fibrils, driven by the FP domain for -sheets. The two
peptides co-assemble efficiently, with greater than 90% of EAKIIH6 incorporated into
the composite [198] generated from excess EAK16-II. By embedding recombinant
protein A/G (pA/G) via anti-His-tag antibodies, IgG can be loaded and release over time
[201-203]. Because Protein A and Protein G bind to IgG with relative high affinities
(with apparent binding constants reported at 2.9 x 107 and 1.13 x 108 M-1 [204],
respectively), pA/G provides a stable and extended affinity mechanism [205]. In vivo,
diffusion of IgG from the material is driven by concentration gradient between the depot
and the surrounding tissues, including the lymphatics. The system renders retention of
IgG molecules in subcutaneous injection sites for up to ten days [201]. The EAK16II/EAKIIH6 system, when adapted with pAG and anti-His-tag antibodies, was designed
as antibody-functionalized scaffolds for cytokines and cells [201, 202]. The ability to
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monitor binding sites in vivo would enhance correlation with in vitro or in vivo
optimization.

In this chapter, we describe an in situ-forming hydrogel platform on which the
binding sites for IgG, pA/G, can be monitored using an activation-dependent fluorescent
module. The hydrogel are generated by intermixing EAK16-II with its analogue
dL5_EAK, a polypeptide consisting of a FAP with two light chains, called dL5, fused to
three repeats of AEAEAKAK via a glycine-serine spacer, (GGGGS)3 [200] (Figure 3-1a).
In high ionic strength environment, EAK16-II and dL5_EAK undergo solution-gel phase
transition and coassembly, apparently simultaneously. The resultant materials are
illuminated in the presence of malachite green (MG), the fluorogen that can be activated
by dL5 [206]. Relative to free MG, the fluorescence of dL5-bound MG is enhanced by
up to 20,000 folds, due to constraining of the rotatable bonds in MG by two L5 proteins.
Crystallographic studies have shown that MG mediates dimerization of two L5 proteins
to form a fluorescent ternary complex [207]. We hypothesized that the system of MGconjugated pAG (pAGMG), dL5_EAK and EAK16-II, when deployed together (called
dL5 hydrogel, see Figure 3-1b), serves as a self-illuminating, injectable formulation for
local deposition of IgG. The tight binding of dL5 to MG ensures a stable intermediate
[207]. The exceptionally low fluorescence background renders the fluorogenic module
an efficient reporter of binding sites, independent of model IgG drugs [206]. We
characterized and modeled the release kinetics in vitro, and found that the dL5 hydrogel
retained IgG at the injection site and draining lymph node in vivo.
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Figure 3-1 Diagrams showing (a): the construct of dL5_EAK and (b) pAGMG embedded
dL5 gel displaying IgG molecules.

Materials and Methods
EAK16-II and expression of dL5_EAK
EAK16-II was custom synthesized by American Peptide Company (Sunnyvale,
CA) at greater than 95% purity with the N-terminus acetylated and C-terminus amidated.
The sequence was confirmed by mass spectrometry. The peptide, received lyophilized,
was reconstituted in sterile deionized water (18.2 M at 25C) as needed and stored at 80°C until use. Construction of plasmids encoding dL5_EAK was described previously
[200]. Specifically, the plasmid pET21 GST HRV dL5 was constructed by PCR
amplification of L5 (E52D L91S, referred to as L5 in this work) monomer and ligation
into the bacterial expression vector pET21 GST HRV. An annealed DNA insert
encoding the amino acid repeat (G4S)4 was ligated downstream from the L5 subunit,
followed by the ligation of PCR amplified DNA encoding an additional L5 subunit. The
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plasmid pET21 GST HRV dL5_EAK was constructed by ligation of double stranded
DNA encoding 3 additional repeats of (G4S) followed by 3 repeats of the amino acids
AEAEAKAK downstream of the dL5 sequence of pET21 GST HRV dL5. Plasmid
sequences were verified by DNA sequencing. Expression and purification of dL5_EAK
was carried out by transforming pET21 GST-HRV-dL5_EAK into calcium competent
Rosetta-Gami 2(DE3) E. coli. (Novagen, Madison, WI). The transformed bacteria were
grown in 500 ml volumes and induced using 500 µM IPTG and 0.4% glucose overnight
at 20ºC. Proteins in cell lysates were captured using Ni-NTA agarose columns (Qiagen,
Valencia, CA) and eluted by HRV3C protease. Fractions containing the protein were
combined and dialyzed against PBS, with the resultant concentrate quantified using UVVis ( = 280 nm). Details of plasmid construction, protein expression and purification,
can be found in Saunders et al. [200].

Conjugation of protein A/G
Protein A/G (pA/G) and malachite green isothiocyanate (MG-ITC) were
purchased from Life Technologies (Carlsbad, CA). Conjugation of pA/G to MG-ITC
was carried out in alkaline aqueous buffers (pH = 8.5 to 9.5), with the resultant conjugate
separated from unreacted MG-ITC using PD-10 columns (Sephadex G-25 M, GE
Healthcare, Aurora, OH). The degree of labeling of the eluent was calculated based on
the molar ratio of dye concentration to protein concentration. Each mole of pA/G was
conjugated with 0.67 mole of MG, as determined by bicinchoninic acid assay for the
former and UV-Vis absorbance at 633 nm of the latter.
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Gel electrophoresis
Different amounts of EAK16-II (10 L, 20 L, 40 L, 80 L or 160 L, at 5
mg/ml) were added to 8.3 L of dL5_EAK (72 M) to prepare mixtures containing
EAK16_II to dL5_EAK at 50:1, 100:1, 200:1, 400:1, and 800:1 molar ratios. Each
sample was suspended in a total volume of 500 l, followed by incubation at 37°C
overnight. The samples were centrifuged at 16,000 RFC for 6 minutes with the
supernatants analyzed using denaturing Novex NuPAGE 4-12% Bis-Tris gels. To each
sample, the supernatant (5 µL) was added with 5 µL of NuPAGE SDS buffer and 10 µL
of PBS, with the resulting solution heated at 70 °C for 10 minutes before loading. All
samples were run at 200 V for 35 min in NuPAGE MES SDS running buffer. Proteins
were visualized using the SilverQuestTM staining kit for which a detection limit of 0.3 ng
has been reported. All electrophoretic reagents were purchased from Life Technologies
(Carlsbad, CA). Images were captured using the Kodak 440 Image Station (Kodak,
Rochester, NY), and band intensities were quantified using the NIH Image J software.
Percent dL5_EAK incorporated into the insoluble fraction was quantified by subtracting
the intensity of the protein band in samples containing EAK16-II from the intensity of the
samples without EAK16-II.

Viscosity measurement
Stock solutions of EAK16-II and dL5_EAK were prepared in distilled water at the
level of 10 mg/mL and 12.2 M respectively. Samples of EAK16-II with or without
dL5_EAK were prepared in PBS (pH = 7.4) and drew into positive displacement pipettes
(RheoSense Inc., San Ramon, CA). EAK16-II was prepared in different concentrations
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(0.01–2 mg/ml) in two solvents (PBS and distilled water). The EAK16-II with dL5_EAK
in PBS was prepared at the ratio 400:1 and the final concentrations were 1.5 mg/ml and
2.3 µM, respectively. Measurements were performed using the VISC unit (RheoSense
Inc.) equipped with a temperature control module, which was set at 25C. Samples were
subjected to different shear rates by changing the flow rate through the capillaries (depth
= 50 m) in the sensor cartridge (HA01-01). The instrument is capable of measuring
viscosity between 0.2 to 100 mPa·s from shear rates 6.5 to 5,850 s-1 at within 2%
accuracy according to the manufacturer.

Titration of pAGMG to dL5_EAK gel
Hydrogels composed of EAK16-II and dL5_EAK (400:1) were established in
Corning FluoroBlok 96-well plate (Thermo Scientific, Inc.). Different amounts of
pAGMG were added to the hydrogel to generate samples containing dL5_EAK to pAGMG
molar ratios of 1:8, 1:4, 1:2, 1:1, 2:1, 4:1, 8:1, or 16:1. Sufficient PBS was added to each
well to attain a final total volume of 200 l. The solvated hydrogels were incubated
overnight at 37 °C before measuring MG/dL5 fluorescence using a Tecan Infinite M1000
microplate reader, with excitation set at 635 nm and emission at 670 nm. EAK16-II
with pAGMG, or EAK with a PEGylated form of MG [206] were used as the controls
(n=3).

Laser-scanning confocal microscopy
Samples were prepared for confocal imaging as described below. To 20 L of 5
mg/ml EAK16-II, 40 L of 10 M dL5_EAK were added and mixed to produce a gel
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with a molar ratio of 150:1. To this mixture, 12.2 µL of 11 M pAGMG, 4 µL of 0.05
mg/mL FITC-labeled rat anti-mouse CD23 IgG antibody were added in a confocal dish
(MatTek Corp., Ashland, MA). The sample was brought up to 100 µL with PBS and
incubated overnight. The hydrogel was collected by centrifugation and washed with 200
µL of fresh PBS five times before transferring to a glass bottom microwell dish. Imaging
was performed using a Zeiss Axioplan 2 imaging microscope equipped with a mercury
lamp. Fluorescein fluorescence was collected a 470/530 nm filter, and Cy5 fluorescence
was obtained using a 710/75 nm filter (Chroma, Lititz, PA). Control samples without
dL5_EAK, without pAGMG, or containing only EAK16-II and fluorescein-labeled IgG,
were also imaged.

In vitro IgG release
The kinetics of release of a fluorescein-labeled antibody (Pierce goat anti-human
IgG) from pAGMG-embedded dL5 hydrogel were determined by monitoring fluorescence
over time. The IgG-loaded materials were established in MicroSert (inner diameter =
4.15 mm, maximum volume = 500 µL) by instilling a mixture of EAK16-II (60 nmol),
dL5_EAK (150 pmol), pAGMG (150 pmol), and IgGFITC (75 pmol). The 50 l mixture
was incubated overnight at 37°C before adding 400 l of PBS (0.1% BSA, 0.025%
NaN3) as the release medium. The insert was placed in its receptacle vial and capped
before incubation at 37°C at the start of the release. At various time points, 200 l of the
release medium was collected for measurement (excitation = 485 nm; emission = 535
nm) using the Tecan Infinite M1000. Aliquots of fresh release medium were added to
restore the system to its initial volume.
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Modeling Methodology
To delineate the parameters driving IgG release, a mathematical model is
described and implemented here. The data for this comparison is taken directly from the
in vitro case described in Figure 3-10, in which diffusion of the antibody IgG from a
tailored hydrogel with and without pAGMG binding sites is compared. Six components in
the system with four possible interactions were considered:

k1
pAGMG + dL5 ⇌ pAGMG·dL5
k2
k3
IgG + pAGMG·dL5 ⇌ IgG·pAGMG·dL5
k4
MG

IgG + pAG

MG

IgG. pAG

(1)

k5
⇌ IgG·pAGMG
k6

k7
+ dL5 ⇌ IgG·pAGMG·dL5
k8

To understand the affinity interactions on the overall release dynamics, we
considered the systems of equations previously described for other affinity systems
designed for sustained release of proteins and drugs [17, 32, 42, 208]. These models
contain parameters analogous to those describe the current system in which two sets of
reversible interactions operate: binding of pAGMG to dL5_EAK, and binding of IgG to
pAGMG. Free pAGMG would bind IgG, generating IgG-pAGMG complexes that bind to
dL5 associated with EAK16-II fibrils. All dL5_EAK are assumed remained in the main
EAK16-II fibrils throughout. The relative fractions of these components are governed by
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the rate constants associated with identifiable processes: with k1 > k2, and k7 > k8.
Because pAGMG was found to be relatively immobile compared to the IgG (Figure 3-8b),
the concentration of pAGMG in the sample was held constant. This allows for the isolated
study of IgG diffusion for describing the behavior of the system, focusing on the third
reaction in Equation set (1).

The diffusion of unbound IgG from the hydrogel is first modeled through Fick’s
law in a heterogeneous medium as shown in Equation (2), where  IgG is the molar
concentration of unbound IgG, and D is the variable diffusion coefficient. Diffusion is
assumed to be one-dimensional, and the hydrogel and aqueous regions are assumed to be
divided neatly into two cylindrical volumes as depicted in Figure 3-10a.

  IgG 
t

D
diff

 2  IgG 

(2)

x 2

The diffusion equation is solved using central-order finite-difference methods.
The hydrogel and release medium are discretized with respect to x with even grid spacing
(100 points evenly distributed across the length of the vial). The change in IgG
concentration at each node is then estimated and integrated through finite difference
approximations (Equation (3)) [209]. Zero-flux boundary conditions are enforced at
either end of the vial. Since the diffusion coefficient is assumed to vary with location, the
averaged value between the neighboring nodes is used.
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The binding-release behavior of IgG from the pAGMG sites is assumed to follow
Hill’s law [210], commonly used for ligand binding with multiple sites. This equation
was selected due to uncertainty of the exact nature of the binding sites, by combining
them into a single association constant with a variable describing their interactions. Each
pAGMG possesses six binding sites for IgG (4 on protein A, 2 on protein G), which may
exhibit cooperative or competitive effects between the sites as binding progresses. Here
n is Hill’s coefficient, where n > 1 corresponds to positive cooperativity and n < 1
corresponds to negative cooperativity. Y is the ratio of bound sites to total sites, and K is
the association constant.

K  IgG 

n

Y

(4)

1  K  IgG 

n

As the unbound IgG diffuses away from the hydrogel and into the surrounding
medium, the equilibrium value for the bound pAGMG complexed with IgG shifts as well,
releasing a portion of the IgG to replace some of the diffused components. Therefore, the
total change in IgG concentration may be modeled as a combination of diffusion and
release. The diffusion component is captured through Equations (2, 3), and the release
component may be calculated by taking the derivative of Equation (4) with respect to the
concentration of unbound IgG and multiplying by the total change in concentration [211,
212]. This produces the final system of equations summarized as Equation (5).
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  IgG 

   pAG MG  IgG  dl 5 

1  
  IgG 



Zero-flux boundary conditions are enforced, and the total concentration of IgG within the
vial is integrated and tracked throughout the simulation to estimate and control the error.
The resulting model calculates the concentrations of both bound and unbound IgG with
respect to time for various conditions and association constants and cooperativities. The
apparent association constant K is estimated by assuming that the concentration of bound
and unbound IgG within the hydrogel at t = ∞ are equal, and K is recalculated for each
value of the Hill coefficient n from Equation (6).

K

 IgG  dl5
  pAGMG    IgG  dl5   IgGnfinal

(6)

Mice and in vivo studies
Six to eight week old female (certified-virus-free) BALB/c mice were purchased
from Charles River Laboratories (Wilmington, MA) and housed in the Duquesne
University Animal Care Facility certified by the USDA. Animals were handled in
accordance with protocols approved by Institutional Animal Care and Use Committee.
The injection mixtures contained 60 nmol (in 20 µL) of EAK16-II together with 0.15
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nmol of dL5_EAK, 0.15 nmol of pAGMG, and 75 pmol of Dylight-800 4X PEG
conjugated IgG (Thermo Scientific). Mixtures, some without pAGMG, were drawn into
25 G’ needled syringes and injected subcutaneously into the footpads of mice while
anesthetized with isoflurane (induction 5%, maintenance 3%). For retention studies
(Figure 3-11), each mouse was injected with the system and control, but on different
footpads. Four replicates were performed. For distribution studies (Figure 3-12), each
mouse received either solutions containing the intact system or control, in both footpads.
Three replicates were performed for these experiments. In both studies, footpads and/or
lymphatic organs were excised 72 hours after injection and imaged using an Odyssey
imager (Li-Cor, Inc., Lincoln, Nebraska). All images were captured at low intensity (2.0)
and the same focus offset (3.2 mm), and quantified using the software Image Studio (LiCor, Inc.). Table 3-1 shows the formulations used in the in vivo experiments.

Table 3-1 Formulations used in in vivo experiments

Intact systema

Control: retentionb
(g)

Control:
distributionc

EAK16-II (µg)

100

100

-

dL5_EAK (µg)

4.3

4.3

-

pAGMG (µg)

7.7

-

-

IgG (µg)

11.3

11.3

11.3

Fluorescein
Fluorescein
Fluorescein
Total volume
49.4
49.4
49.4
a
(

l)
“System” formulation used in experiments shown in Figure 3-11 and Figure 3-12.
b
c

“Control” formulation used in experiments shown in Figure 3-11.

“Control” formulation used in experiments shown in Figure 3-12.
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Results
In this chapter, we aimed to develop a bioaffinity-driven system in which the
release of IgG from a fibrillar matrix was retarded in order to concentrate therapeutic
antibodies locally at injection sites and in regional lymph nodes. By concentrating
antibodies in lymph nodes to which inflamed tissues drained toward, dosage of the
injection can be reduced. Techniques of parenteral injections targeting selected lymph
nodes are established [213]. The design hinges on engineering a fluorogenic module into
the network of FP within which binding sites for IgG can be monitored optically. Two
dye-labeled IgG molecules, IgGFITC and IgG800, were used as model payloads in in vitro
and in vivo studies, respectively. Expression and purification of dL5_EAK were
enhanced by that the polypeptide does not self-assemble. The identity of dL5_EAK was
verified using SDS-PAGE and mass spectrometry [200]. Building upon the prototype
described in Saunders et al. where the coassembly of dL5_EAK and EAK16-II were
visualized by the dye Congo red and probed with SEM (Figure 3-2), we determined here
that intermixing EAK16-II with dL5_EAK at 400:1 molar ratio resulted in 94% of the
latter being incorporated into the final composite (Figure 3-3b). Unless noted otherwise,
the experiments described herein were conducted at the same molar ratio.
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Figure 3-2 Morphological features of EAK16-II and dL5_EAK/EAK16-II hydrogels as
revealed in (a) Optical images (40X; scale bar=50 µm) captured using a cooled CCD
camera immediately after solutions containing 5 µL of EAK16-II (left panel), 5 µL of a
1:100 ratio of dL5_EAK to EAK16-II (middle panel) and 5 µL of 58 µM dL5_EAK
alone (right panel) were pipetted into an equal volume of PBS with 0.01% Congo red and
spotted on glass slides. β sheet structures formed by self-assembly of EAK16-II domains
are visible by Congo red incorporation. (b) SEM images (5000X magnification) of fixed
and lyophilized membrane samples. The particles (circles and pointed by a red arrow in
the image) formed on the membrane is indicative of dL5 domain.
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Figure 3-3 Co-assembly and association of dL5 gel system components. (a) Schematic
depiction of the affinity hydrogel for release of IgG. (b) Analysis of incorporation of
dL5_EAK into EAK16-II fibrils using SDS-PAGE. Increasing amounts of EAK16_II
were added to the same amount of dL5_EAK to make the ratio of the two from 50:1800:1. The bands represent unincorporated, soluble fraction in the mixture after
centrifugation. (c) Viscosity of EAK16-II mixed with dL5_EAK at different shear rates
(n = 3). Measurements were made at 25°C using a µVISC unit equipped with a
temperature control module.
To characterize the mixing effect of adding dL5_EAK to EAK16-II fibrillar
networks, viscosity of solutions containing both was measured using capillary rheometry
by which pressure gradient of the sample is measured across microfluidic channels [214].
Consistent with results reported by the Chen group [215], viscosity of diluted EAK16-II
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peaked at approximately 25% of PBS (Figure 3-4), indicating that the method is sensitive
to the same material behavior of the FP. Mixtures containing EAK16-II and dL5_EAK
were tested in a range of shear rates at 25C in PBS. Solutions dissolved with only
dL5_EAK exhibited baseline viscosity, at near 1 mPa·s (Figure 3-3c), confirming our
previous observation that the polypeptide does not self-assemble at the concentrations
tested. At shear rate 4,000 s-1, the viscosity values of EAK16-II and EAK16-II mixed
with dL5_EAK both fell between 1 to 1.5 mPa·s, indicating that the materials lack shear
resistance. Scanning EAK16-II in PBS at lower shear rates (1,000-3,000 s-1) revealed a
sharp transition at 1,800 s-1 for EAK16-II (Figure 3-3c); the downward trend from 2.1
mPa·s to 1.5 mPa·s suggests a pseudo-elastic material. The transition was attenuated in
the presence of dL5_EAK, with viscosity measured between 1.3 to 1.5 mPa·s within the
range of shear rates tested. Intermixing the two peptides does not diminish staining by
Congo red [200]. These results show that the microscopic organization in EAK16-II
appeared sensitive to perturbation by dL5_EAK, but the macroscopic structure appeared
intact. The lack of mechanical strength of the materials is not unexpected because the
low-molecular weight and the low concentration of the FP used. The mixture can be
injected without clogging, for the shear rate applied in 25 gauged syringe needles is
estimated approximately 8000 s-1. The deformable hydrogels can adapt to tissue space
when injected subcutaneously.
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Figure 3-4 Viscosity of EAK16-II at different salt concentrations. Measurements were
made using VISC with shear rate set at 1,600 s-1 at 25°C. Symbols represent
independent experiments conducted.

pAGMG conjugate
Malachite green (MG) was conjugated to pA/G by using an amine reactive form
of MG –MG isothiocyanate (ITC). Under slightly alkaline pH, the lone pair electron on
the amine group of amino acid residues of pA/G is attacking the electron deficient carbon
in the ITC group and forms the thiourea product pAGMG. SDS-PAGE verified the slight
increase in molecular weight of pA/G after the conjugation (Figure 3-5).
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Figure 3-5 Electrophoretic analysis of native pAG and pAGMG using SDS-PAGE.

Localization of IgG in pAGMG-embedded dL5 hydrogel
The conjugate pAGMG was tested for binding to composites of dL5_EAK mixed
with molar excess of EAK16-II (referred to as “dL5 hydrogel” hereafter) pre-formed on
plastic surface. KD between pAGMG and dL5 gel was determined to be 90.9 nM,
calculated based on titration experiments using MG fluorescence as the readout (Figure
3-6a). Saturation was observed at molar ratio of 1:1 between pAGMG and dL5. No
fluorescence was observed in PBS containing pAGMG, or in water dissolved with
EAK16-II without dL5_EAK (Figure 3-7a), all indicating specific binding of pAGMG to
dL5.
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(a)

(b)

Top view

IgG-FITC

(c)

MG

Merged

Side view

Figure 3-6 Binding and localization of pAGMG in dL5 hydrogel. (a) Titration of pAGMG
to established hydrogel (n = 3). KD was determined using the one site-specific binding
model (y axis title: FI, fluorescent intensity; a.u., arbitrary unit). No washing steps were
needed because no background fluorescence was generated from unbound MG. (b) Top
view of IgGFITC-loaded pAGMG-dL5 gels, the intact system, showing fluorescence
associated with IgG (green), MG-dL5 (red), and the two combined. Scale bar represents
20 μm. (c) Side view of the intact systems, showing fluorescent components along the
vertical axis of the gel. Gels were deposited into glass bottom microwells immediately
prior to imaging. Controls examined included gels made with components used for
making the intact system without pAGMG or dL5_EAK (Figure 3-7b).

We next determined if pAGMG can indeed mediate IgG loading in dL5 hydrogel.
As the EAK16-II fibrillar network contains large aqueous void volume (99.5% w/v), we
did not attempt to saturate the system, but determined that at least 70 g of IgG could be
loaded per mg of the peptides. Even this sub-saturating dose may suffice for delivering
96

antibodies for local effects, for example with an anti-tumor necrosis factor antibody
[216]. Using laser scanning confocal microscopy, we observed scattered non-specific
IgG adsorption (green) on the surface, but the extensive co-localization (yellow)
underneath suggests dL5-bound pAGMG captured the majority of the antibodies in the
matrix (Figure 3-6). Without pAGMG, IgGFITC in the matrix was significantly reduced, as
evidenced by the relatively low fluorescence (Figure 3-7b). These data support the
fluorescence-generating loading mechanism.

(a)

(b)

Figure 3-7 Loading and co-localization of IgGFITC in dL5 hydrogels. Images were
obtained from the same experiment described in Figure 3-6 (b and c). (a) MG
fluorescence in solutions containing different components. (b) Images obtained using
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confocal microscopy of control samples, including the intact system (EAK16-II,
d_5_EAK, pAGMG, and IgGFITC) without dL5_EAK (top panel), without pAGMG (second
panel) and without IgGFITC (third panel). The last panel shows image of a sample made
with EAK16-II and IgGFITC without the other components.

In vitro IgG release from pAGMG-embedded dL5 hydrogel
Release of IgGFITC from pAGMG-embedded dL5 hydrogel was monitored in vitro
over two months. The experiment was initiated by mixing the antibody with the hydrogel
components in a small cylindrical vessel with defined dimensions. In the control
experiment in which hydrogel were made without pAGMG, almost 90% (mean value,
n=3) of the antibody loaded were released in the first five days (Figure 3-8a). In contrast,
a biphasic pattern was seen with hydrogel embedded with pAGMG; a slow initial phase,
during which only 26% were released by day 5, was followed by a second phase during
which approximately 50% were released over 2 months. At the end of the eight-week
period, 22.7% of the IgG still remained, suggesting that the release would continue. The
cumulative amount released might suffice the dosage needed for local antibody drug
delivery [216]. The IgGFITC, an anti-human IgG antibody, released from the hydrogel at
the end of the 2-month period were shown to bind its cognate antigen (human IgG) at
58% capacity: 1.7 g/ml of the 2.9 g/ml anti-human IgG released recognized plasticadsorbed human IgG (Figure 3-9). Dissociation of pAGMG from dL5 appeared slow, as
evidenced by that more than 60% of the initial MG fluorescence remained in the gels at
the end (Figure 3-8b). These results demonstrate that the affinity binding delayed the
release of IgG from the matrix, and that pAGMG-bound dL5 is a relatively stable
component.
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Figure 3-8 Monitoring in vitro IgG release and pAGMG – dL5 interaction. (a) Cumulative
release of IgGFITC from dL5 gels with (n = 3) or without pAGMG (n = 3). Each time point
represents measurement from triplicate samples in gels setup in parallel. (b) Images and
quantification showing MG fluorescence in release vessels at the start and the amount
remained at the end of the period (n = 3 for all groups). “Start” refers to day 0, “End”
refers to day 60, “Control” was the same in (a), and “Blank medium” refers to vials
containing PBS with no other components added.
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(a)

(b)

(c)

Figure 3-9 Biological activity of released anti-human IgGFITC tested by binding to
immobilized human IgG (y axis title: FI, fluorescent intensity; a.u. arbitrary unit). (a)
Standard curve established for quantifying the anti-human IgGFITC (b) Titration of the
anti-human IgGFITC to plate-bound human IgG as target antigen with concentrations
determined using the standard curve. (c) Fluorescence measurements of fresh anti-human
IgGFITC and the same antibody incubated at 37°C for 60 days to validate the stability of
FITC fluorescence as the readout for IgG release amount quantification.

Modeling and simulation of release
We sought to understand the parameters governing the kinetics of IgG release
from the hydrogel. The initial phase of the in vitro release was fit to the non-steady state
Fickian model (Figure 3-10a and Table 3-2). Apparent diffusion coefficients (Dapp) were
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determined by relating Mt/M as a function of t0.5. Dapp of IgG in hydrogel without
pAGMG was an order of magnitude higher than Dapp of IgG in hydrogel embedded with
pAGMG. Release of IgG was impeded in both systems, as Dapp of IgG in aqueous solution
is estimated much higher [29]. While the analysis does not encapsulate the entire release
profile, the results show that without pAGMG, a large fraction of loaded IgG would escape
by rapid diffusion shortly after the components coalesce.

Figure 3-10 Modeling and simulation of IgG release in vitro. (a) Short time
approximation of release of IgGFITC in vitro (see Figure 3-8) using Fick’s second law.
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Because the small vial diameter relative to the vial length, the release is assumed 1-D
along the vial length into the saline medium. No IgG escapes the sides and bottom of
from the gel placed in the cylindrical glass vials. The volume of the gels was assumed
constant, as FP matrices do not swell. IgG was assumed distributed in the matrices
homogenously and released in one-dimensionally, with IgG concentration at boundary
assumed zero at the start. The height of the gel is 3.7 mm, with the base inner diameter
equals to 4.15 mm (per manufacturer specification). (b) The evolution of unbound IgG
with respect to time for non-cooperative binding (n = 1.0). Initially the IgG is contained
exclusively within the fibrillar matrix. Upon exposure to the release media, the IgG
begins to diffuse into the simulated vial, accompanied by a gradual release of the bound
IgG from the gel. (c) The percentage of IgG released into the vial is plotted with respect
to time with varied binding characteristics through the Hill equation. The release profiles
show the effect of the binding characteristics, and an increase in sustained release
achievable through cooperative hexavalent binding.

Table 3-2 Apparent diffusivities (Dapp) determined using approximation of early releasea
Dapp (10-10 m2s-1)

R2

IgG remained in gel (%)

Control

0.075

0.92

1.4

System

0.0086

0.82

22.7

IgG in aq.

0.40b

N/A

N/A

a

Fick’s second law was used in the approximation, with Dapp being apparent diffusion
coefficient, t as time in hours, H is one-dimensional height of matrix (3.7 mm), Mt being
the amount of IgG released at time = t, and M∞ being the theoretical maximal amount
released at time infinity. Dapp were determined by regression of the data to the question:
𝑀𝑡
𝑀∞
b

16 𝐷𝑎𝑝𝑝. 𝑡 0.5

=(

𝜋 𝐻2

)

Calculated based on the Stokes-Einstein approximation of IgG in water at 37°C [29].
The numerical model outlined in modeling methodology section was used to

further examine the experimental results, expanding on this observed decrease in
apparent diffusion with the bioaffinity hydrogel. Figure 3-10b shows the predicted
evolution of the unbound IgG along the length of the vial, assuming 1-D diffusion.
Initially all IgG is assumed to exist only in the gel, and the concentration along the length
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of the vial is approximated through a sharp sigmoidal function at the boundary of the
fibrillar matrix. The diffusion coefficient is assumed to vary in a similar fashion between
the Control value and the IgG in aqueous values in Table 3-2, and the difference between
the measured Control and system values is accounted for by the binding behavior within
the model. The concentration is calculated by dividing the initial IgG concentration by
the volume of the matrix, assuming an even distribution. Equation (4) is then used to
divide the concentration into bound and unbound concentrations. As the model IgG
diffuses out of the hydrogel into the release media, additional IgG is dissociated from
pAGMG, thereby replenishing in the matrix the IgG lost to diffusion.

The concentration of unbound IgG outside of the matrix region was integrated
with respect to time and divided by the saturation concentration. This is calculated as the
original number of moles of IgG within the vial divided by the total volume of the vial (
n
 IgG final ), and remains constant between each case. Four cases are recreated; one

without pAGMG, and three with varying levels of cooperativity between the binding sites
on pAGMG, n=0.5 (negative cooperative binding), 1.0, and 2.0 (positive cooperative
binding) as defined in Equation (4) and (6). The apparent association constant K is
estimated by assuming that the concentration of bound and unbound IgG within the gel at
t =  are equivalent, and K is recalculated for each value of the Hill coefficient n from
Equation (4). The values for the association constant K are calculated as 1.08, 62.54, and
2.08 * 105 for n = 0.5, 1.0, and 2.0 respectively.

The molar concentration of IgG outside of the gel is integrated across the length
of the vial and divided by the equilibrium concentration, where the moles of IgG are
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evenly distributed across the vial volume. The total fluid volume considered is 250 L to
better approximate the original fluid left in the vial between measurements. This
methodology does not take into account the experimental removal and replenishment of
the buffer solution, as this removal of IgG concentrations introduced undesirable
instability in the finite difference method. Consequently, the model under predicts the
diffusion rate for the Control case, likely due to a combination of the
removal/replenishment behavior combined with the potential convective flow introduced
as a result. However, the complete system simulations in which IgG is bound to the
fibrillar matrix provides a favorable result, indicating that the binding between IgG and
pAGMG is responsible for the controlled rate of diffusion, and suggesting that the nature
of the binding is cooperative. If the diffusion for the complete system is enhanced
experimentally by the removal/replenishment of the buffer solution, then the binding is
likely to further favor the cooperative case.

Simulated cases containing a positive cooperativity show a more sustained
release. Comparing the results to Figure 3-8a, it is demonstrated that the improved and
controlled release offered by the bioaffinity gel may be predicted through a numerical
model, and this model predicts that the IgG-pAGMG binding is cooperative. The profile
of the release is intrinsically tied to the hexavalent binding between IgG and pAGMG, and
this binding is crucial for the controlled and sustained release observed in experiments.
From the plots given, the estimated values for the pAGMG-IgG binding are an association
constant of K  2.08 * 105, and a Hill coefficient of n  2.0.
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Deposition of dL5 gel formulated IgG in vivo
To test the notion that dL5 hydrogel serves to retain IgG in vivo, dL5_EAK and
EAK16-II mixed with pAGMG and IgG800 were injected subcutaneously into footpads of
mice and imaged ex vivo (Figure 3-11a). The results indicate that gelation occurred
beneath the skin (Figure 3-11b). Compared to IgG800 formulated without pAGMG, the
intact hydrogel system rendered superior retention at the injection site, as reflected by the
relatively strong fluorescence emitted in the 800 nm channel (green). The concentrated
fluorescence sustained for at least 72 h, after which the signals in both sets of mice
dissipated to background level. Movement of animals would no doubt perturb the
materials located in the subcutaneous space. To this end, we probed the localization of
the pAGMG-dL5 hydrogels in footpads of living mice. In a separate experiment, it was
detected at the injection site (after 48 h) that IgG800 (green) co-localized with pAGMGbound dL5 (red; 700 nm) (Figure 3-11c). No MG fluorescence was detected in the
control footpad administered with free IgG800. Note that in footpads injected with the
intact system, IgG was also detected in the draining lymph node (indicated by arrow).
No MG fluorescence was detected in the same lymph node, consistent with the in vitro
observation that the pAGMG/dL5 complex is a stable component in the matrix. These
results demonstrate the consistent coalescence of IgG800, pAGMG, dL5_EAK, and
EAK16-II in vivo.
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(a)

(b) mouse #1

control

mouse #2

control
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(c)

mouse #4

control

system

NIR800

control

system

system

MG

system

control
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Figure 3-11 Retention of IgG and binding sites in footpad. Retention of IgG delivered
with dL5 gel at injection site. (a) Diagram depicting the in vivo experiments. Each
mouse was injected subcutaneously with solutions containing all hydrogel components
(system) in one footpad and the same except without pAGMG (control) in the other. The
mixture was drawn into a 25’ G needled syringe as a low viscosity liquid by keeping in
low ionic strength buffer. The mice were sacrified at 72 hours after the injection. (b)
Images of four replicates showing fluorescence associated with IgG800 in footpads of each
mouse three days after injection. (c) Images taken from a separate experiment 48 hours
after injection, showing fluorescence in mouse injected with IgG800 injected in saline (left
panel) and the same antibody injected in the same mouse with all components in the
system (right panel).
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In a separate set of mice, distribution of IgG800 was traced by fluorescence in
regional and distant lymphoid organs (Figure 3-12). Mice injected with the antibody in
plain PBS (into both footpads) resulted in detectable fluorescence in sciatic, inguinal,
brachial lymph nodes, and to a lesser extent, the spleen. Distribution of IgG800 delivered
with the system (i.e. pAGMG, dL5_EAK and EAK16-II) was mostly sequestered to sciatic
lymph nodes, draining from the footpads; inguinal and brachial nodes showed lower
fluorescence, with spleen at near background level of intensity. In mice receiving the
intact system, the low fluorescence in distant lymph nodes is congruent with the strong
fluorescence remained at the injection site. These results indicate the dL5 hydrogel
impeded the distribution of IgG deposited at the injection site.
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3

spleen

2’

2
1

3’

footpads

system mouse #1

control mouse #1

system mouse #2

control mouse #2

system mouse #3

control mouse #3

1’

same injection (system or
control) in both footpads

Figure 3-12 Distribution of IgG800 injected in footpads 72 h after injection. (a) Mice were
injected with either control or system mixtures in both footpads. Unlike the experiments
described in Figure 3-11, here each mouse was injected with the same formulation. (b)
The images show fluorescence associated with IgG800 in (1 and 1’) sciatic, (2 and 2’)
inguinal, (3 and 3’) brachial lymph nodes, the spleen, and footpads from mice
administered with the intact gel system mixed with IgG800, or IgG800 in PBS (control).
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Discussion
This bioaffinity hydrogel design was motivated by the need for a tractable
injectable system by which antibodies could be concentrated and monitored in vivo.
Potential applications include intratumoral antibody injection [20], and topical delivery of
anti-cytokine antibodies [217]. The inflammatory mediator TNF driving non-healing
cutaneous wound is a case in point. In addition to releasing soluble TNF, macrophages
infiltrated into the wound tissues express transmembrane TNF [218]. Together with
neutrophils and adipocytes, macrophages impose local inflammation via autocrine and
paracrine actions of both forms of TNF. To maximize effectiveness, topically delivered
anti-TNF antibody must penetrate into tissues underneath the wound bed. Macrophages
and neutrophils transverse on and below the wound surface, trafficking through the
dermis and draining lymph nodes, and cluster around adipocytes underneath. Thus,
design of topical formulations should aim at rendering sustained anti-cytokine antibodies
releasing into local-regional tissues, yet without excessive drug partitioning into the
blood circulation.

The results presented herein demonstrate that the dL5 hydrogel system can
accumulate IgG at the site of injection and in draining lymph nodes. The study is a step
towards modular engineering of local antibody delivery. The binding of pAGMG to dL5
serves two purposes, in rendering IgG binding sites, and generating fluorescence that can
be detected in subcutaneous tissues. We presented data demonstrating that the system
delayed release of IgG. In vitro, approximately 50% of IgGFITC were released in the last
55 days of the two-month period with dL5 hydrogel embedded with pAGMG, without
which near 90% of the antibody were released in the first five days (Figure 3-8). The
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adaptor pAGMG mediated IgG loading (Figure 3-6) and was found to be a relatively
immobile component in the system (Figure 3-8b). In vivo, distribution of IgG was
impeded by the dL5 hydrogel, restricting a large fraction of the dose at the injection site
and in the immediate draining lymph node (Figure 3-11 and Figure 3-12). The prototype
delivered a limited dose over 24 hours, but such formulation may be suffice for local
immune modulation [216]. The computational simulations suggest cooperative binding
of IgG to pAGMG (Figure 3-10).

The hydrogel is generated through coassembly for functionalized FP [210, 219222]. We have shown that the EAK16-II/EAKIIH6 composite prolongs in vivo retention
of IgG in inflammatory tissues, in mammary tumors implanted in syngeneic mice [201],
and in tissues underneath skin allografts [202]. By separating affinity binding and
gelation, the former can be adjusted independently of the latter. The ability to vary the
density of dL5 through intermixing the polypeptides allows mutual optimization of bulk
physical properties and IgG loading and release kinetics. Because the pore size and
tortuosity of the hydrogel matrix can be tuned by changing EAK16-II concentration,
other agents, including small molecule drugs, or clusters of cells [223], may be
encapsulated without impeding the ability to regulate IgG loading and release. In the
presence of excess EAK16-II, dL5_EAK incorporates efficiently into the network,
without disrupting the integrity of the fibrils [200]. But excess dL5_EAK in vivo may
self-aggregate (similar to EAKH6 [198]), creating ectopic clusters of pAGMG outside the
hydrogel matrix, diverting IgG from the main depot. This can be mitigated by
formulating the molar fractions of the two polypeptides such that greater than 90% of
dL5_EAK is incorporated (Figure 3-3). Thus the ratio of the two polypeptides is an
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important parameter in engineering functionalities within the EAK16-II fibrillar matrix
[21].

After incubation for two months in vitro, IgG released from dL5 gels retained
58% of antigen-binding capacity (Figure 3-9). The high water content of EAK16-II
hydrogels should preserve protein native conformations [224], but the long incubation
period in vitro (Figure 3-8) may have promoted denaturation of the IgG. Through Fc
binding to pAGMG, IgG in dL5 hydrogel are oriented [225-227] and patterned such that
random adsorption and denaturation can be reduced. This is supported by scanning
electronic microscopic images of EAK16-II/EAKIIH6, which show what appear as
individual islands of IgG/pAG complexes [201]. The templated antibodies are active
against soluble [201] and cell-bound antigens [203]. Denaturation can be minimized by
optimizing key parameters; the simulations (Figure 3-10) show cooperativity of IgG
binding in the system driven by the hexavalent pAGMG on which two or more IgG may
be captured. Altering the density of pAGMG in the hydrogel, guided by MG fluorescence,
could minimize the loss of protein activity.

Potential systemic toxicities are mitigated by the fact that the gel is largely
retained locally at the injection site. Because pAGMG remained largely with the hydrogel,
the amount released into the systemic lymphatic and blood circulation should be low.
Phagocytes will likely opsonize the fluorogen-protein conjugate. We have evidences
showing that EAK16-II appears non-inflammatory; neither EAK16-II nor pAGMG elicited
IL-6 production from freshly isolated splenocytes cultured in vitro (data not shown). As
with other synthetic biomaterials, the hydrogel is likely be degraded by the foreign body
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reaction (FBR) [228]. The process is triggered by adsorption of endogenous proteins,
followed by adhesion of macrophages, which may fuse into foreign body giant cells
(FBGC). This pathway, which may take weeks to consummate, serves to sequestrate
foreign substances.

The system described herein is unique in that the bioaffinity module has a built-in
imaging feature. In dL5-pAGMG, the hydrogel can be imaged in superficial tissues.
Compared to conventional fluorescent reporters, MG-dL5 has enhanced photo-stability.
The FAP protects the fluorogen from oxidative damage as crystallographic studies show
that a single MG molecule is flanked by two L5 domains [207]. This feature was
exploited here to monitor the stability of the IgG binding sites, as pAGMG would escape
from the gel matrix to become non-fluorescent. Degradation of dL5, either through
extracellular or intracellular means, would diminish the signal, as unbound MG has low
intrinsic fluorescence. The fluorescence generated by MG and dL5 interaction could
serve as a surrogate for the extent of in vivo degradation, such as phagocytosis by
macrophages [229].

While the present study used dL5-MG as the fluorogenic module, other FAPs
have been synthesized for additional fluorogens. FAP-fluorogen pairs can be selected
based on binding affinities and fluorescent spectra suited for specific applications.
Fluorescence generated from dL5-MG can be detected optically in superficial tissues, but
other FAP systems, such as far-red fluorogenic dyes currently being explored, may be
used for internal imaging [230]. There are also promiscuous FAPs that can bind more
than one fluorogen [231], with alternate excitation and emission wavelengths and varying
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affinity constants for fluorogen binding. There may be biological scenarios in which
higher or lower binding affinities are called for, such as using a low affinity FAPfluorogen combination as a more rapid but controlled release mechanism, through
disassociation of the pA/G-dye conjugate from the FAP itself. Additionally, other dyes
which generate higher quantum yields and signal such as cyanine-tagged MG [232] could
be used to improve signal-to-noise ratio for hydrogel with low FAP incorporation
efficiency. These other FAPs can be genetically fused with FP domains such as
AEAEAKAK as functional modules in excess EAK16-II, as demonstrated here.

Conclusions
We demonstrated herein that biochemical and imaging functionalizing of a βFPbased injectable platform. This depot platform can be used to deliver IgG locally of a
variety of specificities. The delayed release demonstrated in vitro may be translated into
in vivo prototypes through iterative optimization, guided by in situ detection of MG-dL5
fluorescence. This design could be used to deliver antibodies for suppressing cutaneous
inflammation and targeted immune modulation in draining lymph nodes.
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Chapter 4
A Facile Fc-binding Composite in Bioaffinity Hydrogel for Antibody
Delivery
The ability to congregate high concentrations of multiple antibodies in diseased
tissues for prolong durations renders a method to engage diverse molecular targets in a
sustained manner. In this chapter we sought to determine the extent to which IgG
molecules could be concentrated in subcutaneous tissues and allogeneic skin transplants
while limiting systemic exposure using a facile Fc-binding composite. This biomaterial
design centers on the novel polypeptide pG_EAK, consisting of a truncated protein G
fused with repeats of the amphiphilic sequence AEAEAKAK (“EAK”). The direct
attachment of Fc binding domain protein G to EAK reduced the number of noncovalent
interactions involved in the bioaffinity hydrogel compared to the pAGMG-dL5 gel
described in the previous chapter, rendering a design with a better translational prospect.
Intermixing pG_EAK with molar excess of EAK generated fibrillar gels with multivalent
Fc-binding sites. Capture of IgG was verified in gels prepared from admixing pG_EAK
and EAK16-II (pG gel). Injection of a dye-conjugated IgG formulated with pG gel into
skin allografts resulted in detectable fluorescence at the site in mice for at least six days,
at which time only background signal was observed in grafts injected with the same
antibody delivered in saline or non-Fc binding EAK gels. The advantage coincided with
weaker fluorescence in the liver, spleen and lymph nodes, relative to those in graftbearing mice injected with the antibody formulated in saline or non-Fc binding EAK gels.
In conclusion, pG gel was shown to display IgG locally, thus a potential platform for
modulating the cellular and molecular mechanisms in target tissues.
114

Background and rationale
Described in the preceding chapter was a system in which IgG capture was made
possible by two non-covalent interactions and one conjugation reaction. The complexity
of the design complicates the effort to optimize performance of such system. To reduce
the complexity and improve the translational prospect, a second generation bioaffinity
hydrogel was constructed by incorporating the IgG capture domain directly in the EAK
gel matrix, without the need for conjugating pA/G with MG [233]. This simplified
system consists of only one interaction between IgG and Fc-binding domain, in this case
a truncated Streptococcal protein G appended with EAK repeats, hereafter referred as
“pG_EAK”. Functionalized gels can be prepared by intermixing excess EAK with
pG_EAK, thereby encasing the latter.

Protein G (along with protein A) is widely used in lab-scale and commercial
purification of antibodies. Staphylococcal Protein A (SpA) has been developed into a
systemic therapeutic agent (PRTX-100) approved for use in humans [234]. Native
protein G variants are cell wall components isolated from Streptococcal strains (e.g.
G148) [45]. The optimal binding of protein G spans over a broad pH range, from 4 to 9
for human IgG [48]. Compared with SpA, protein G reacts with IgG from broader range
of species, and in particular binds to all four subclasses of human IgG [47, 235]. The
equilibrium binding and kinetic constants of protein G for IgG have been determined
(Table 4-1), and the binding was found to be more stable than protein A-IgG [48]. Since
the affinity interaction between protein G and IgG is not as pH and salt-dependent as it
between protein A and IgG and protein G has a wider and stronger reactivity profile
compared to protein A [236], protein G was selected to be directly attached to
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amphiphilic self-assembling peptide EAK for the bioaffinity gel construction. Through
coassembly of the novel construct pG_EAK with excess parent polypeptide EAK16-II,
protein G could be directly embedded in the hydrogel for IgG loading, thereby
independently replacing dL5 bound pAGMG in the gel design described in the previous
chapter.

Table 4-1 Equilibrium constants comparison between protein G and protein A with IgG
from various species (Determined by Scatchard plots using immobilized IgG and
radioiodinated protein G or protein A. Republished with permission from reference [48],
permission conveyed through Copyright Clearance Center, Inc.)
IgG

Protein G

Protein A

M-1 (X 10-9)
Human

67.4

44.1

Rabbit

69.8

52.3

Goat

14.3

Not detected

Mouse

41.5

25.7

Rat

1.4

0.018

Human IgG1

2.0

1.3

Human IgG2

3.1

2.1

Human IgG3

6.1

Not detected

Human IgG4

4.7

3.4

Native protein G contains multiple domains, including three homologous regions
to the amino-terminus that have affinity for albumin [237, 238]. Toward the C-terminal
end of protein G are three Fc-binding domains (C1, C2 and C3) followed by a cell
membrane anchoring domain [47, 237]. In constructing the pG_EAK polypeptide, only
the Fc-binding track of sequence (C1-D1-C2-D2-C3) was included, with three GS linkers
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connecting to three repeats of AEAEAKAK at the C-terminal (Figure 4-1 (a)). The
rationale for the order is that the Fc-binding and amphiphilic domains are physically
connected yet operate independently. Removal of the albumin binding sites reduces the
extent of cellular internalization via opsonization [239]. The pG_EAK polypeptide was
expressed in E. Coli transformed with a plasmid encoding the amino acid sequence of the
truncated pG domains, the GS linker, and the EAK tract, as well as GST and His-tag for
purification. Composites of pG_EAK and EAK were characterized in vitro and in vivo
for stability and kinetics of association with IgG molecules. As with the dL5 gel system,
the purpose is to construct an antibody-delivery system for local or topical applications in
models of inflammatory diseases. The diagram for the proposed design is shown in
Figure 4-1 (b).

Figure 4-1 Diagrams showing (a): the construct of pG_EAK and (b) coassembled pG gel
displaying IgG molecules.
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Materials and Methods
Peptides and reagents
EAK16-II was custom synthesized by American Peptide Company (Sunnyvale,
CA) at greater than 95% purity with the N-terminus acetylated and C-terminus amidated.
The sequence was confirmed by mass spectrometry by the manufacturer. The peptide,
received lyophilized, was reconstituted in sterile deionized water (18.2 M at 25°C) as
needed and stored at -80°C until use.

Expression and purification of pG_EAK
Expression and purification of pG_EAK was performed after transforming
plasmid (pET21) engineered with the nucleotide sequences encoding both protein G and
EAK, together with 10X His GST HRV cleavage site into BL21(DE3) competent
Escherichia Coli (Invitrogen One Shot®). The diagram showing the complete procedure
is depicted in Figure 4-2. Full protein sequence of pG_EAK after HRV protease
cleavage is as follows:
GPSKLTYKLILNGKTLKGETTTEAVDAATAEKVFKQYANDNGVDGEWTYDDAT
KTFTVTEKPEVIDASELTPAVTTYKLVINGKTLKGETTTEAVDAATAEKVFKQYA
NDNGVDGEWTYDDATKTFTVTEKPEVIDASELTPAVTTYKLVINGKTLKGETTT
KAVDAETAEKAFKQYANDNGVDGVWTYDDATKTFTVTEGGRGGGGSGGGGS
GGGGSAEAEAKAKAEAEAKAKAEAEAKAK.

Specifically, the starter culture of transformed bacteria was grown in 5 ml of LB
media with 100 μg/ml ampicillin, then transferred to 500 mL of LB+ media (LB media

118

with 100 mM phosphate, 20 mM succinic acid and 0.4% gylcerol) and grown until its
optical density at 600 nm reached 0.6. The temperature was then changed to 20°C and
the culture was grown for another 1h before adding 500 μM IPTG and 0.4% glucose
(final concentration) to start induction for expression of pG_EAK. After overnight
culture at 20°C, cells were pelleted at 4°C, 6000 rcf for 20 min, resuspended in 30 ml of
buffer (50 mM Tris HCl, 750 mM NaCl, 50 mM imidazole, 0.1% TritonX-100 and
0.025% Tween 20) and frozen at -20ºC for at least 4 hours. Thawed cell pellet was lysed
by sonicating on ice for 15 min (level 3, 10s on, 5s off). Lysate was clarified by
centrifugation at 13000 rpm, 4°C for 30 min. Lysate was then added to 0.6 ml of NiNTA agarose (washed with 1X Ni-NTA bind buffer: 300 mM NaCl, 50 mM NaH2PO4,
10 mM imidazole, pH 8.0) and incubated on shaker in cold room for 2 hours. Bound
agarose was washed with 21 mL of 1X Ni-NTA wash buffer (300 mM NaCl, 50 mM
NaH2PO4, 20 mM imidazole, pH 8.0) and 14 ml of 1X HRV 3C cleavage buffer (150
mM NaCl, 50 mM Tris-HCl, pH7.5). The column was capped on bottom after which 120
µL of 2U/µL HRV 3C protease and 1.2 ml of 1X HRV 3C cleavage buffer were added to
the Ni-NTA agarose. The column was capped on top as well and incubated overnight on
shaker in cold room. Eluted proteins were collected the following day by adding 50 µL
of Ni-NTA agarose to bind potential excess HRV 3C protease, followed by incubation in
cold room for another 2 hours. Column was then uncapped and eluent was collected.
Additional 0.8 ml of 1X HRV 3C protease cleavage buffer was passed over the column
twice to collect any additional digested protein. Purified pG_EAK was quantified by 280
nm absorption measurements.
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Figure 4-2 Diagram showing the procedure flow for pG_EAK plasmid construction,
transformation, expression and purification.

MALDI-TOF mass spectrometry
Purified pG_EAK obtained from above procedure was diluted 10 times with a final
concentration of 5.46 µM. Combine 40 ul of this diluted solution with 10 µL of 0.5%
TFA in MilliQ-water and apply the protein directly to target of Applied Biosystems
Voyager DE-STR MALDI-TOF mass spectrometer.

Coassembly experiments
Coassembly of pG_EAK into EAK16-II fibrils was studied using gel
electrophoretic (SDS-PAGE), Congo red binding, and viscosity measurement which were
described separately below.
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Gel electrophoresis
Different amounts of EAK16-II (10 µL, 20 µL, 40 µL or 80 µL, at 5 mg/ml) were
added to 7.34 ul of pG_EAK (82.2 μM) to prepare mixtures of EAK16-II and pG_EAK at
different molar ratios (50:1, 100:1, 200:1 and 400:1) of the two components. Each
mixture was q.s to a total volume of 500 µL and incubated overnight at 37°C. The
samples were centrifuged at 16000 rfc for 6 min with 5 µL of the supernatant analyzed
using denaturing Novex SDS-PAGE gel electrophoresis (NuPAGE 4-12% Bis-Tris
Electrophoresis system). For sample preparation, 5 µL of the supernatant was mixed
with 5 µL of NuPAGE sample buffer and 10 µL of PBS. The mixtures were heated at
70°C for 10 min before loading while 5 µL of the molecule maker was mixed with 10 µL
of sample buffer and 25 µL of PBS without heating before loading. All samples were run
at 200 V for 35 min in NuPAGE MES SDS running buffer. Fast silver staining
procedure (SilverQuestTM staining kit) was used to visualize the protein bands. Gel
images was captured using Kodak 440 image station and band intensities were quantified
by Image J software. Percentage of pG_EAK incorporated into EAK coassemblies was
calculated by subtracting the intensity of the protein band in samples containing EAK16II from the control sample with only pG_EAK in solution.

Congo red binding
The stock solution of 0.005% Congo red was prepared by diluting 30 µL of 0.1%
of its aqueous solution using 570 µL of PBS. The absorbance spectra of Congo red were
scanned from 400 nm to 700nm with Tecan Infinite M1000 microplate reader after
adding 40 µL of the stock solution to each of the samples either containing 20 µL of
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EAK alone at the concentration of 5 mg/ml, 20.8 µL of pG_EAK alone at the
concentration of 7.2 μM or the mixture of the two components. For the sample
containing only one component before adding Congo red, either water was added to
substitute EAK or PBS was added to substitute pG_EAK. The molar ratio of EAK and
pG_EAK was at 400:1. Incubation was performed for 1 hour after adding Congo red and
before the absorbance scan. The absorption peak of each sample was registered for
comparison as an indication for fibril formation confirmation.

Viscosity measurement
Stock solutions of EAK and pG_EAK were prepared at 10 mg/ml in water and
9.26 μM in PBS respectively. Samples of EAK with or without pG_EAK were prepared
in PBS and drew into positive displacement pipettes (RheoSense Inc., San Ramon, CA).
The ratio of EAK to pG_EAK was prepared at 400:1 and the final concentrations were
1.5 mg/ml and 2.3 μM, respectively. Measurements were conducted using the μVISC
unit (RheoSense Inc) equipped with a temperature control module, which was set at
25°C. Samples were subjected to different shear rates (1200-4000 s-1) by changing the
flow rate through the capillaries (depth = 50 μm) in the sensor cartridge (HA01-01).
Controls including pG_EAK alone and distilled water alone were measured at the same
conditions.
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IgG binding experiments
Surface plasmon resonance
Biacore T200 was used to conduct experiments with a CM5 chip at 25°C. pG
(25.3 kDa, 0.92 mg/mL stock concentration) were used as ligand to immobilize onto the
CM5 sensor surface. Ab-1 (mouse monoclonal IgG, 150 kDa, 3.3 µM stock
concentration), Ab-2 (goat monoclonal IgG, 150 kDa, 6.7 µM stock concentration), and
Ab-3 (rabbit IgG monoclonal, 150 kDa, 3.3 µM stock concentration) were used as
analytes to flow over the ligand immobilized surface. Flow Cell (FC) 1 was used as
reference for FC2, and FC3 for FC4. pH scouting of ligand was done and pH 4.0 was
selected for pG as the immobilization pH value. pG was diluted (1:500 dilution, 1.84
µg/mL diluted concentration) in 10 mM sodium acetate buffer at pH 4.0 and immobilized
onto FC4 to a level of ~300 RU, using standard amine coupling chemistry. PBS-P (20
mM phosphate buffer pH 7.4, 2.7 mM KCl, 137 mM NaCl, 0.05 % (v/v) surfactant P20)
was used as the immobilization running buffer. Based on the captured ligand response
values, theoretical Rmax values were calculated. The Rmax values assumed 1:1
interaction mechanism. Overnight kinetics were performed for all analytes binding to the
ligands. The kinetics experiments were performed in the presence of PBS-P. The flow
rate of all analyte solutions was maintained at 50 µL/min. Association and dissociation
times used for all analytes were 60 s and 600 s, respectively. One 20s pulse of Glycine
pH 1.5 was used to regenerate the sensor surface. Injected compound concentrations
were 0 µM, 3.125 nM, 6.25 nM, 12.5 nM, 25 nM, 50 nM, and 100 nM. Sensorgrams
from the overnight kinetics were evaluated using 1:1 steady state affinity or 1:1 kinetics
model fitting.
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Loading of IgGFITC on pG hydrogel
The binding of IgG to pG bioaffinity hydrogel was measured by determining the
loading of IgG on the hydrogel. Fluorescein (FITC) labeled IgG (Invitrogen) was used as
the model IgG to provide the readout in the form of FITC fluorescence. 11.25 μg (75
pmol) of IgGFITC was added to gel formed with 20 µL of 5 mg/ml EAK (60 nmol) and
24.5 µL of 6.16 μM pG_EAK (150 pmol) (molar ratio of EAK : pG_EAK = 400 : 1).
After incubated for 15 min, the sample was brought up to 100 µL with PBS. The IgGFITC
loaded hydrogel was collected by centrifugation and washed with 1ml of fresh PBS five
times before re-suspended and transferred to black 96 well plate for FITC fluorescence
measurement. Control samples including IgGFITC loaded in hydrogel made of only EAK,
IgGFITC mixed with only pG_EAK, or only IgGFITC were also prepared by replacing EAK
with water and pG_EAK with PBS when either one is missing.

Paper chromatography
The binding of IgG to pG gel was examined using a thin layer chromatography
based on the trapping of IgG on the path way of its migration driven by capillary action
on a chromatography paper (WhatmanTM GE healthcare) and concentration gradient.
Rabbit IgG800s (NOVUS biologicals, 1 mg/ml) were spotted horizontally (numbered 1-3
from left to the right) near the bottom of the paper (leaving about 3 cm to the edge of the
bottom) with different samples including PBS, EAK (5 µL of 5 mg/ml), or EAK and
pG_EAK (5 µL of 5.46 μM) mixture spotted above the IgG spotting positions
corresponding to each IgG spot vertically. After the drying of the spots, the bottom of the
chromatography paper was immersed in a reagent reservoir filled with PBS. Allow the
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liquid to migrate upward through capillary action and take the paper out of the PBS when
the water front move up to the top of the paper. Let the paper dry completely before
imaging the migration of IgG800 in the path of convective flow using an Odyssey imager
(Li-Cor, Inc., Lincoln, Nebraska) set at low intensity (L2.0) and focus offset of 3.2mm.

Multi-IgGs loading on pG hydrogel
The loading of three different IgGs on the pG hydrogel was verified by detecting
the fluorescence spectra from three different dyes labeled to each of these three IgGs
respectively. Specifically, equal molar amount (25 pmol) of PerCP-Cy5.5 labeled rat
anti-mouse CD4 IgG (BD Pharmingen), PE labeled rat anti-mouse IgG (BD pharmingen)
and FITC labeled mouse IgG (Southern Biotech) were added to EAK and pG_EAK
coassemblies (20 µL of 5 mg/ml EAK mixed with 24.5 µL of 6.16 μM pG_EAK) and
EAK without pG_EAK as the control. After one hour of incubation for the binding to
reach equilibrium, the samples were washed five times with 1ml of fresh PBS and
transferred to black 96 well plate to get the emission spectra from (495 nm to 800 nm)
under the excitation of 488 nm. The combination of the three IgG solutions was also
included as the positive control to show the desirable peak locations as reference.

FITC-IgG self-quenching after loaded to pG hydrogel
The distribution of loaded IgG in pG hydrogel could be speculated by studying
the quenching effect of FITC dye labeled on the loaded IgG. Specifically, 22.5 µL of 0.5
mg/ml mouse FITC-IgG (Southern Biotech) was added to the pG_EAK and EAK
coassemblies (20 µL of 5 mg/ml EAK mixed with 24.5 µL of 6.16 μM pG_EAK)
established at the bottom of black 96-well plate. The fluorescence from FITC-IgG was
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scanned from 500nm-800nm after excitation at 494 nm and compared to the fluorescence
spectra from the same amount of FITC-IgG in aqueous solution or loaded in EAK gel.
The single point measurement at its emission peak (520 nm) was also scanned separately
for better comparison.

In vitro IgG release
The release kinetics of a fluorescein-labeled IgG (Pierce goat anti-human IgG)
from pG bioaffinity hydrogel were determined by monitoring the cumulative
fluorescence in release medium over 3 months. IgG-loaded hydrogels were established at
the bottom of MicroSert (inner diameter = 4.15 mm, maximum volume = 500 µL) by
instilling a mixture of EAK (60 nmol), pG_EAK (150 pmol) and IgGFITC (75 pmol). The
55 µL mixture was incubated overnight at 37°C before adding 400 µL of PBS containing
0.1% BSA, 0.024% NaN3 as the release medium. The insert was placed in its receptacle
vial and capped to prevent the medium evaporation. The vial was put under 37°C for
incubation. At various time points, 200 µL of the release medium were collected for
measurement using plate reader (Perkin Elmer 1420 Multilabel Counter VICTORTM,
excitation = 485 nm; emission = 535 nm). Aliquots of fresh release medium were added
to restore the system to its initial volume.

Mice and in vivo studies
Six to eight week old female BALB/c or C57BL/6 mice were purchased from
Hilltop Lab Animals (Scottdale, PA) and housed in the Duquesne University Animal
Care Facility certified by the USDA. Animals were handled in accordance with protocols
approved by Institutional Animal Care and Use Committee.
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Retention after foot pad injection (preliminary test, no replicates)
The injection mixture containing 60 nmol (in 20 µL) of EAK together with 150
pmol of pG_EAK and 75 pmol of Dylight 800 4X PEG conjugated goat anti-rabbit IgG
(Thermo Scientific) was drawn into 25G’ needled syringe and injected subcutaneously
into one foot pad of the mouse while free IgG800 control was injected into the other foot
pad of the same mouse when the mouse was anesthetized with isoflurane (induction 5%;
maintenance 3%). The mouse was sacrificed 2 days after the injection and foot pads
were excised and imaged using an Odyssey imager (Li-Cor, Inc., Lincoln, Nebraska).
The image captured from Odyssey was set at low intensity (L2.0) and focus offset of
3.2mm. This preliminary test was conducted to get a sense of the performance of pG gel
in retaining IgG in foot pad (as tested in dL5 gel) before moving forward to the
investigation of its performance in other subcutaneous location or inflammatory
conditions.

Stability after back injection
Inject onto the back of C57BL/6 mice IgG800 (45 μg in 1 mg/mL goat anti-rabbit
Dylight 800 4X PEG conjugate) or IgG800 displayed by pG hydrogel (80 µL of 10 mg/mL
EAK and 82.4 µL of 14.556 μM pG_EAK) (4 replicates each). The NIR signal at 800nm
on the back was monitored at the local injection site using Li-Cor Pearl live imager
before and over 2 days period after the injection. At the end of day 2, all the mice were
sacrificed for liver, spleen and lymph nodes scan using Odyssey imager at low intensity
(L2.0) and the same focus offset (3.2mm).
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Stability after undergraft injection
To demonstrate the stability of the bioaffinity hydrogel under inflammatory
conditions, we used a murine allogeneic skin transplantation model (donor: BALB/c;
recipient: C57BL/6) and tracked its undergraft stability over 6 days after injection. The
procedure has been approved by the University IACUC. Six- to eight-week old mice was
purchased as certified pathogen-free from Hilltop Lab Animals (Scottdale, PA). Mice
were quarantined for at least five days prior to use in experiments. Mice between the
ages of 8-12 weeks were randomized into three groups in the transplant experiments.
The procedure entailed harvesting skin grafts by euthanizing donor mice, making incision
at the base of the ear and splitting the dorsal side from the base. The dorsal layer was
rinsed with sterile saline prior to the transplantation to serve as the donor. Then a 0.5 cm
incision was made in the left flank of a C57BL/6 mouse for placement of donor skin.
Excess donor skin was trimmed so that transplant lies flatly within graft bed. The
recipient mouse was wrapped in sterile bandage and secured using a 7mm stainless steel
wound clip (Reflex 7). Recipient mice were recovered under heat lamp while waking up
from anesthesia before placement in a clean cage. Optical imaging of the mice was
scanned using a Pearl Impulse (Li-Cor) small animal imaging system. Pre-injection
images were taken by placing the animals in the instrument chamber. Post injection
images were taken at specified time intervals. To image in the near infrared range, the
mice were kept under anesthesia and exposed to a 700 nm laser, followed by an 800 nm
laser, and then a white light image was taken. Grafting of BALB/c skins onto C57BL/6
mice is a well-characterized model in studying acute rejection of allografts. The fullMHC (class I and II) mismatch renders consistent rejection in >90% of cases.

128

In this in vivo undergraft stability test, IgG800 (11.24 μg in 1 mg/mL goat antirabbit Dylight 800 4X PEG conjugate), IgG800 displayed by EAK hydrogel (20 µL of 10
mg/mL EAK) or IgG800 displayed by pG hydrogel (20 µL of 10 mg/mL EAK and 5.5 µL
of 54.577 μM pG_EAK) was injected subcutaneously underneath the skin graft (3
replicates each) two days after the transplantation surgery. Signals retained under the
skin graft was recorded in real time using a Li-cor Pearl Impulse Imager before, right
after and 2, 4, 6 days after the injection for each mouse. NIR fluorescence intensity at
different time points was quantified using Li-Cor Pearl imager software.

Dual delivery of Fc-CTLA-4 and Fc-TGF-β1 in skin transplantation
Skin transplantation surgery was performed in the same way as described in the
previous undergraft stability test. 33 μg of TGF-β1 Fc (Chimerigen laboratories, 1
mg/ml) and 33 μg of CTLA-4 (CD152) Fc non-lytic recombinant protein (ProSci, 1
mg/ml) displayed by pG gel (20 µL of 10 mg/ml of EAK mixed with 4.34 µL of 69.2 μM
of pG_EAK) or only the pG gel were injected underneath the skin graft two days after the
surgery. The same injection was repeated 3 days after the first injection. Four days after
the second injection, the mice were euthanized to collect the spleen. The splenocytes
were processed for in vitro re-stimulation with allogeneic antigen presenting cells from
BALB/c spleen and cultured for 3 days before flow cytometry analysis for Treg cell using
mouse regulatory T cell staining kit (eBioscience).
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Results
Confirmation of pG_EAK molecular mass
pG_EAK recovered from nickel resins were further purified using endotoxin
removal spin column (Pierce®, Thermo Scientific, 0.5ml). The final eluent was analyzed
using denaturing SDS-PAGE and mass spectrometry. Electrophoretic image indicated a
single band near the 35 kDa mark, and MALDI-TOF showed a singly-charged species
with Mr of 25.3 kDa (Figure 4-3), consistent with the theoretical Mr of pG_EAK
(predicted using ExPASy Bioinformatics Resource Portal). In conjunction with
functional studies that will be shown later in this chapter, it was concluded that the
predicted protein pG_EAK was expressed and purified.

Figure 4-3 MALDI-TOF mass spectroscopy of pG_EAK protein.
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Co-assembly
Gel electrophoresis was used to determine the fraction of pG_EAK incorporated
into excess EAK. The unincorporated portion of pG_EAK retained in the sup was
reflected in the pG_EAK band on the SDS-PAGE gel after intermixing EAK16-II with
pG_EAK at different ratios (Figure 4-4). The ratio of 400:1 for EAK and pG_EAK
resulted in 92% of the latter being incorporated into the final composite. Therefore,
except where stated otherwise, the experiments described in this chapter were conducted
using gels admixed at the 400:1 molar ratio.

The absorbance spectra for different components mixed with Congo red, the dye
found to have a shift in its absorbance peak after binding to fibrils formed by β-sheet
structure, were obtained. After Congo red was added to samples containing pG_EAK
alone, the samples exhibit the same absorbance peak as free Congo red at 486nm,
indicating that pG_EAK does not self-assemble to form fibril itself. In contrast, both
Congo red added to EAK or the mixture of EAK and pG_EAK at ratio of 400:1 exhibit a
red shift in absorbance peak, at 510nm and 506 nm respectively, indicating the fibril
formation in those two samples.
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Figure 4-4 Coassembly between EAK16-II with pG_EAK (a) SDS-PAGE analysis of
incorporation of pG_EAK into EAK16-II fibrils. The protein bands in image represent
the unincorporated, soluble fraction in the mixture of EAK : pG_EAK coassemblies at
different ratios of the two. (b) Congo red absorbance spectra after added to different
samples containing EAK, pG_EAK alone or the mixture of these two components at the
ratio of 400:1

Injectable composite
The viscosity of the composite materials was determined using a microfluidicbased measurement where the sample is injected at a constant flow rate through the flow
channel, a rectangular slit constructed of borosilicate glass, of a measuring cell or chip.
Samples of EAK, EAK intermixed with pG_EAK and pG_EAK alone were analyzed
using a VISC module where multiple pressure sensors were mounted within the base to
monitor the pressure drop from the inlet to the outlet of the channel. The viscosity was
calculated based on the shear rate and shear stress at the boundary wall which are
correlated with the pressure drop, geometry of the rectangular slit and the flow rate.

Solution dissolved with only pG_EAK exhibited baseline viscosity, at near that of
water (1 mPa·s), confirming our previous observation that pG_EAK do not self-assemble
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at the concentrations tested. At shear rate of 4,000 s-1, the viscosity values of EAK and
EAK mixed with pG_EAK registered 2.3 0.56 mPa·s and 2.5 0.24 mPa·s, respectively,
indicating that the materials lack shear resistance and can be injected using conventional
needled syringes. At the low shear rate of 1200 s-1, EAK mixed with pG_EAK deviated
from EAK, at 2.9  0.87 mPa·s and 4.4  0.32 mPa·s, respectively. Yet pG gel holds
sufficient mechanical strength to be suspended and adsorbed to a silica vessel and
remained suspended for at least 24 h (Figure 4-5b).

Figure 4-5 Viscosity profile of pG gel and its physical appearance visualized by Congo
red (a) Viscosity of EAK16-II mixed with pG_EAK (400:1) at different shear rates
compared with pG_EAK, EAK or deionized water alone. (b) pG gel stained with Congo
red at the bottom of silica vessel inverted for 24 hours.

Capture of IgG in pG gels in vitro
The affinity and kinetic constants of IgG for pG_EAK were measured using
surface plasmon resonance (Table 4-2). Sonograms indicate that the fusion polypeptide
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bound to IgG at high affinity. The association (kon = 9.435 x 105 M-1s-1) and dissociation
(koff = 21.81 x 10-3 s-1) constants were also found in the same magnitudes of documented
for the native proteins. The apparent binding constant (Ka) for mouse IgG has been
reported as strong (1.13 x 108 M-1), with association rate kon = 3.29 x 104 M-1s-1 and
dissociation rate koff = 2.90 x 10-4 s-1 [49]. The Kd (8.8 nM) is close to the Kd tested in
our measurement for mouse IgG (23.1 nM). The differential affinities across the species
documented in the literature were reproduced in that pG_EAK exhibited strong affinities
for goat and rabbit IgG, but relatively weak for mouse IgG1. These results show that
pG_EAK associated and dissociated with IgG through specific interactions.

Table 4-2 Binding and kinetic constants of pG_EAK
Kd (nM)

kon (1/Ms)

koff(1/s)

Goat IgG polyclonal

0.005

3.658 * 105

2.0 * 10-6

Rabbit IgG polyclonal

0.1

3.225 * 105

3.817 * 10-5

Human IgG polyclonal

4.1

1.273 * 105

5.265* 10-4

Mouse monoclonal IgG1

23.1

9.435 * 105

2.181 * 10-2

To investigate the extent to which pG_EAK gel could display solvent-accessible
Fc-binding sites, an in vitro pull-down assay was used to test capture of IgG molecules.
A 3-fold higher fluorescent intensity was observed in samples in which IgGFITC was
mixed with pG_EAK and EAK compared with EAK alone (Figure 4-6b). Mixing the
antibody with pG_EAK resulted in low amounts of fluorescent aggregates collected by
centrifugation, consistent with the Congo red and viscosity measurements showing that
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the lack of fibrillization of the polypeptide itself. In addition, association of IgG and pG
gel was examined in paper chromatograph under non-equilibrium conditions (Figure
4-6c). IgG800 accumulated at the pG_EAK/EAK spot in the pathway driven by capillary
action verified the specific association between IgG and protein G.

Figure 4-6 Capture of IgG in pG gels in vitro (a) Schematic depiction of the affinity
hydrogel for retention of IgG and assay procedure. (b) Loading of FITC-labeled antibody
on pG bioaffinity hydrogel compared with that on incomplete systems. (c) paper
chromatography showing IgG800 migration driven by capillary action in paper
chromatography with pG_EAK spot in path of convective flow
As expected, pG_EAK gel can be used to capture three different antibodies in the
same mixture simultaneously (Figure 4-7). The crystal structures of protein G indicate a
single α-helix stabilized by four β-strands. One of the β-strands in protein G appears to
interact with the β-strand in CH1 of IgG. It may be deduced that in pG_EAK a trivalent
(C1, C2 and C3) Fc-binding module displaying independent helix-β-strand structures.
The data indicate that at least one of the C1, C2 and C3 segments was solvent accessible
in the pG_EAK fibrillar gel network.
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Figure 4-7 Emission scan of three different dye labeled (FITC, PE and PerCP-Cy5.5)
IgGs on the pG hydrogel.
A self-quenching phenomenon was observed for FITC-IgG loaded on pG gel
(Figure 4-8). Fluorescence quenching is the phenomenon where the quantum yield of a
fluorophore is decreased, which is induced by the molecular interaction with quencher
molecules. Self-quenching takes place when the quencher molecule is the same
fluorophore. When the fluorophore molecules are in close proximity to each other, the
manifested fluorescence intensity would be decreased due to self-quenching. The
observation of lower fluorescence intensity in sample where FITC-IgG was loaded to pG
gel compared to the other two samples where the same amount of FITC-IgG was added
to either aqueous solution or EAK gel, indicates that FITC-IgGs were highly
concentrated by the IgG binding domain pG embedded in the gel matrix, causing the selfquenching effect of the dye molecules labeled to IgG. In contrast, free FITC-IgG
exhibited the highest fluorescence intensity while the fluorescence of FITC-IgG loaded to
non-specific EAK gel lies in between free FITC-IgG and FITC-IgG loaded in pG gel.
The specific binding between FITC-IgG and pG was thereby verified.
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Figure 4-8 Self quenching phenomenon of FITC-IgG loaded on pG gel (a) Emission
fluorescence scan for FITC-IgG established in black 96-well plate together with pG
hydrogel and compared that with free FITC-IgG or FITC-IgG nonspecifically trapped in
EAK gel. (b) Emission fluorescence intensity of FITC-IgG at its maximum emission
wavelength under the same setup as (a).

In vitro IgG release
To understand the microscopic properties of the bioaffinity interaction, release of
antibodies from pG_EAK gel were monitored in vitro over a three-month period (Figure
4-9). The experiment was initiated by mixing IgGFITC with pG_EAK and EAK in a
cylindrical vessel with defined dimensions. In control experiments in which gels were
made with only EAK, 85.2% ± 2.3% of the antibody loaded were released in the first 5
days (Figure 4-9a). In contrast, a slow rate of release was observed with pG gel; by day
5, 2.7% ± 0.5% were released. It was calculated that 82.7% of the IgG remained at the
end of the 12-week period. These data show that the pG_EAK module can be used to
delay the release of antibodies from EAK gels.
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Figure 4-9 In vitro release of IgG from the gel. (a) Cumulative release of IgGFITC from
pG gels (n = 3) or EAK gels (n = 3). Each time point represents measurement from
triplicate samples in gels setup in parallel. (b) initial release phase fitting to 1D unsteady
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The apparent diffusivity (Dapp) of IgG in pG gel was estimated by fitting the
initial release to the non-steady state Fickian equation, relating Mt/M∞ as a function of
t0.5. Dapp of IgG in pG gel was determined to be 5.6 x 10-15 m2 s-1, three orders of
magnitude lower than Dapp of IgG embedded in the EAK gel (Table 4-3). The analysis
shows that incorporating pG_EAK served to retain a large fraction of the IgG loaded in
the EAK matrix.
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Table 4-3 Calculated apparent diffusion coefficients for both IgG displayed by EAK gel
and pG gel and the IgG remaining in the gel at the end of release study.
Dapp (10-10 m2s-1)

R2

IgG remained in gel (%)

Control

0.0563

0.83

2.4

System

0.0000564

0.77

82.7

Mice and in vivo studies
pG_EAK gel extends IgG localization in vivo
The in vivo fate of antibodies co-injected with pG_EAK gel components into the
subcutaneous space on the back was tracked in C57BL/6 mice real-time (Figure 4-10a).
Superior local fluorescence was observed in mice injected with IgG800 mixed with
endotoxin removed pG_EAK and EAK (test), compared to mice injected with the
antibody in saline (9-fold on day one and 12-fold on day two) (Figure 4-10b). Systemic
distribution of the antibody was analyzed on day 2, based on fluorescent intensities in the
liver, spleen and lymph nodes recovered from euthanized mice and measured ex vivo.
IgG800 delivered in saline appeared in the liver, spleen, and brachial, inguinal and sciatic
lymph nodes, while the same antibody injected in pG gel was restricted to the immediate
draining branchial lymph nodes (Figure 4-10c). pG_EAK also conferred superior IgG
retention where the components were injected into mouse footpads (Figure 4-10d), which
is consistent with the effects observed in the torso. In addition, no immediate
inflammatory reactions were observed in mice injected with pG_EAK, and low levels of
IL-6 were detected incubating the peptide with freshly isolated mouse splenocytes in
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vitro (Figure 4-11). These results indicate pG gel impeded the draining and distribution
of IgG deposited at the injection site.

Figure 4-10 IgG retention in subcutaneous space after injection into the back of the mice.
(a) Real time images of C57BL/6 mice injected with free IgG800 (control) and IgG800
displayed by pG bioaffinity hydrogel (system) (n=4). (b) Quantification of the remaining
NIR signal on the back of the mice over 2 days. (c) NIR signal distribution in liver,
spleen and lymph nodes (axillary, inguinal and sciatic) at the end of day 2. (d) Image of
mouse foot pads 2 days after injection with control (free IgG800) and test (IgG800
displayed by pG hydrogel) hydrogel.
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Figure 4-11 Interleukin 6 production. “EAK” represents cells added with EAK16-II (100
µg/ml) alone. Different concentrations (200 ng/ml, 2 µg/ml and 20 µg/ml) of endotoxin
(LPS) were used as positive controls. Splenocytes were harvested from a naïve C57BL/6
mouse and cultured (106 cells/ml) for 24 h at 37°C in complete RPMI medium
supplemented with 10% fetal bovine serum, and the substances indicated. The BD
Mouse IL-6 ELISA set was used to determine the concentration.
Having established that the self-assembly and bioaffinity interactions took place
in vivo in normal subcutaneous tissues, the capacity of pG_EAK gel to concentrate IgG
in skin allografts was examined. IgG co-injected into skin allografts with pG gel were
retained locally in mice for at least 6 days (Figure 4-12), concentrating in the center of
the wound bed. This resulted in an average 2-fold higher exposure in terms of AUC
compared to IgG delivered in saline control, with 229.1 v.s. 131.6, respectively. The
higher graft retention coincided with reduced distribution to liver, lymph nodes, and
spleen (Figure 4-12c). Thus, the pG gel platform can be deployed in vivo for displaying
antibodies in inflammatory tissues.
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Figure 4-12 Retention of subcutaneously injected IgG800 under inflammatory condition
(skin transplantation). (a) Real time images of C57BL/6 mice injected underneath the
skin graft with free IgG800 (control 1), IgG in EAK gel (control 2) and IgG800 displayed
by pG bioaffinity hydrogel (system) (n = 3). (b) Quantification of the remaining NIR
signal under the skin graft of the mice over 6 days. (c) NIR signal distribution in liver,
spleen and lymph nodes (brachial, axillary and inguinal) at the end of day 6.

Dual delivery of Fc-CTLA-4 and Fc-TGF-β1 in skin transplantation
It has been shown that TGF-β1 and CTLA-4 mutually support
immunosuppression. The capacities of Tregs to regulate naïve CD4+ T cells and DCs are
primarily attributed to TGF-β1 and CTLA-4 [240]. These factors are best function in
concert, and tolerance is acquired only if Tregs accumulate in skin allografts [241]. TGFβ1, signature cytokine secreted by Tregs, convert naïve T cells to iTregs (induced Treg)
by inducing Foxp3 [242]. In combination with IL-10, TGF-β1 facilitate the generation of
tolerogenic DCs (tDCs) [243]. Host tDCs in turn secret IL-10, thereby driving cycles of
suppressive milieu, promoting tolerance in direct and indirect recognition of alloantigens
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[244]. Tregs constitutively express on the surface CTLA-4, which competes with CD28
for B7 (CD80/CD86) molecules on DCs [245]. CTLA-4 ligation of B7 downregulates
the costimulatory molecules, and suppresses production of IL-, TNFα and IL-6 in DCs
[246]. Mice lacking the CTLA-4 gene display phenotypes that resemble Foxp3-deficient
mice [247, 248]. We therefore postulate that sustained supply of CTLA-4 and TGF-β1 in
grafts will raise the thresholds of Th1 activation, disrupt Th17 differentiation, increase
Tregs, and generate tDCs [243, 244].

Here we seek to recapitulate Treg functions in a cell-free system by concentrating
Fc-tagged TGF-b and CTLA-4 in skin allografts shortly after transplantation during
which T cells and DCs are polarized [243, 244]. Non-lytic, mouse Fc fusion proteins of
TGF- (TGF-1/Fc, Mr=190 kDa), and CTLA-4 (CTLA-4/Fc, Mr=220) have been
validated functionally in mice [249-254] and are available at high purity with endotoxin
below 0.06 EU/µg (Chimerigen Laboratories, San Diego, CA). While infusing all factors
into patients would lead to detrimental immunosuppression, simply injecting Fc-proteins
into skin grafts will not result in retention, as we have shown [202]. The targeted,
localized approach proposed will increase the bioavailability of these factors at the
transplant site, thereby sparing patients from systemic toxicities. The clustered factors in
protein G gel is expected to engage signaling pathways more efficiently by cross-linking
cell surface receptors [255]. In this preliminary in vivo study for the demonstration of pG
gel application, Fc fused CTLA-4 and TGF-β1 was multiplexed on pG gel and
administered underneath the skin graft after the transplantation surgery. An upregulation
of regulatory T cells was observed in the flow cytometry analysis for the splenocytes
collected from treated mice and restimulated with allogeneic antigen-presenting cells
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(Figure 4-13). The increase in the Treg population suggests sustained signaling of
CTLA-4 and TGF-1 in the transplant microenvironment, most likely rendered by the
affinity capture mechanism of the pG gel. Additional experiments will be necessary to
confirm this preliminary finding.

Figure 4-13 representative flow cytometry plots of in vitro allogeneic re-stimulated
splenocytes from mice treated with pG gel displayed Fc-CTLA and Fc-TGF-β1 (exp) or
only pG gel (control) after allo skin transplantation surgery. (a) forward and side scatter
plots for the gating of lymphocyte population P1; (b) histogram for the gating of CD4
positive population M2; (c) dot plots showing Foxp3-A CD25 double positive cells gated
on P1 and M2 indicating induced Treg population.
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Discussion
The data presented in this chapter support the notion of generating antibody
depots in situ by intermixing IgG and pG_EAK with molar excess of EAK. The system
was designed around the concept of multivalent display of antibodies in vivo, employing
a direct, specific and reversible binding interaction between the materials and antibodies.
Derived from the partial sequence of Streptococcal protein G, consisting of the IgGbinding C and D domains, without the albumin binding A and B domains, pG_EAK has a
molecular weight of 25.3 kDa, a big reduction in molecular weight from dL5 complex
with dL5_EAK of 28.4 kDa and pAGMG of 51 kDa. The non-covalent interactions were
also reduced from two to one. This simplified system has the potential to increase the
translational prospect due to the reduction of potential immunogenicity concerns and
modeling complexity.

The platform can be armed with multiple therapeutic antibodies, thereby enabling
targeting distinct pathways simultaneously in pathogenic tissues and their draining lymph
nodes. In combination therapies, the prolonged concentration of antibodies in draining
lymph nodes would enhance the synergistic impacts on multiple cellular and molecular
entities driving pathogeneses. The novelty of the system rests on the extent to which an
antibody can be concentrated by varying the ratio of IgG and pG_EAK in the gels. The
simplified design facilitates the modeling of IgG release from the system by using
reaction-diffusion model proposed by Lin and Metters [17, 256]. Two release
mechanisms, the diffusion of the IgG from the hydrogel and the specific affinity
interaction between the IgG and protein G, are controlling the release rate of IgG from
the gel system. This is manifested by three important parameters: IgG diffusivity (D),
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IgG-pG dissociation constant (Kd) and IgG debinding rate constant (Koff). Specifically,
the release of free IgG from the bioaffinity pG gel is governed by Fick’s second law of
diffusion and binding affinity between pG and IgG. Kd determines the fraction of bound
and free IgG in the gel throughout the release process and Koff determines the debinding
rate. The following equation could be used to describe the change in the IgG
concentration within the hydrogel due to both diffusion and reversible binding to pG
where 𝑥 is the spatial coordinate in the gel perpendicular to the gel surface (assuming
one-dimensional release) and t is the time.

𝜕[𝐼𝑔𝐺]
𝜕 2 [𝐼𝑔𝐺]
=𝐷∗
− 𝑘𝑜𝑛 [𝐼𝑔𝐺][𝑝𝐺] + 𝑘𝑜𝑓𝑓 [𝐼𝑔𝐺 − 𝑝𝐺]
𝜕𝑡
𝜕𝑥 2
With specific values of these constants possibly obtained from SPR experiments
for different antibody species and subtypes (example evidenced in Table 4-2), a timedependent distribution of [IgG], [pG] and [IgG-pG] within the gel should be able to be
generated for a given IgG through numerical solution of the equation using finitedifference method when the initial and boundary conditions describing the concentration
changes of free IgG, unbound ligand and bound IgG-pG during the period of IgG release
from the gel matrix is provided.

The discordance between the in vitro release kinetics (Figure 4-9) and the in vivo
retention profiles of IgG (Figure 4-10 and Figure 4-12) in pG gel can be attributed to
several factors. The ambient movements of the animals can disrupt the integrity of the
localized soft gel, thereby increasing the rate of release. The lack of a strong buffering
system in the subcutaneous space may allow the pH to drift, perturbing the affinities of
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pG for IgG in inflammatory tissues acidified by lactate [257]. The ionic strength may be
depleted in vivo compared to the in vitro setting as the former may not be fully hydrated.
pG_EAK and EAK may be degraded through proteolysis in the extracellular space and in
intracellular organelles upon phagocytosis by macrophages, neutrophils and/or dendritic
cells. Multiple cleavage sites are embedded within the pG_EAK sequence for peptidasecleavage. The low viscosity of the gel is conducive to such cellular uptake. Eventually
the materials will disintegrate after approximately 21 days [21], most likely due to a
combination of proteolytic degradation and macrophage phagocytosis [228].

For macromolecules such as IgG, lymphatic uptake is the main route of
absorption from subcutaneous depots into the systemic circulation. Preclinical studies
indicate that diffusion of IgG through the extracellular matrix (ECM) is the rate-limiting
step, given the relatively rapid transport from the lymph network to blood circulation. In
the ECM IgG are degraded by proteolytic enzymes [68]. This elimination pathway is
compensated in part by endosomal recycling of IgG via neonatal Fc receptors (FcRn)
expressed by local phagocytes, in which a fraction of the administered IgG is protected
from proteases. This is evidenced in that high doses of IgG (e.g. 40 mg/kg), however,
can saturate FcRn in local tissues, thereby increasing the fraction vulnerable to
proteolysis [69]. Mager and coworkers have demonstrated this by monitoring
subcutaneous-administered rituximab in rats, in which they observed a reduction of
bioavailability from 31% to 18% corresponding to increasing the dose from 10 mg/kg to
40 mg/kg [258]. We postulate that the pG_EAK gel depot mimics the protective effects
of FcRn recycling in limiting the diffusion of IgG through the ECM. The system may be
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analogous to biomolecular condensates discovered in eukaryotic cells, phase-separated in
the cytoplasm, concentrating proteins and nucleic acids in a small finite volume [259].

Conclusion
The second generation bioaffinity hydrogel built on pG_EAK was demonstrated
to be a simpler IgG local delivery platform involving less binding interactions in the
design while retaining stable IgG binding capability to provide prolonged retention of
IgG at both normal and inflammatory subcutaneous space. The release rate could be
modulated by varying the ratio of IgG and pG in the formulation. The delivery of Fc
fused immunosuppressive cytokines by pG gel underneath transplanted allogeneic skin
graft has the potential to prolong the survival of the graft skin through upregulation of
immunosuppressive T cell populations—regulatory T cells, which generally
downregulate the induction and proliferation of effector T cells.
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Appendix:
Content for appendix includes 2 sections. The first section is the continuous
miniaturization of IgG binding domain in the bioaffinity hydrogel design and the
preliminary data generated regarding its application in neutrophil inhibition. The second
part is focused on the application of these bioaffinity hydrogels as three-dimensional cell
culture scaffold. The construction of thymus epithelium cells aggregates could be
facilitated by the gels to promote T cell development in immunomodulatory deficient
animals.

I. Miniaturization of IgG Binding Domain in the Bioaffinity Hydrogel Design
Z34c functionalized EAK gel
The design of bioaffinity hydrogels has undergone progressive miniaturization in
our lab, in using lower molecular weight Fc-binding domains, and reducing the number
of non-covalent interactions, in order to simplify the optimization and reduce the
potential immunogenicity. Toward this goal, the construction and characterization of
pG_EAK has been described in chapter 4. Built on top of this pG_EAK design was the
construction of another fusion protein Z34c_EAK for bioaffinity hydrogel formation
(Figure 5-1). Z34c_EAK consists of the B domain mimetic (4.18 kDa) of the
Staphylococcal protein A (MW = 42 kDa) [260]. Generated through phage display
randomization and point mutations from the earlier protein A mimetic Z38, Z34c is a
disulfide-linked cyclic peptide consisting of two helices, analogous to helix-1 and helix-2
of domain B in the native protein A [261]. The binding constants for IgG of Z34c and
native protein A are comparable, both at approximately 20 nM [260], yet Z34c is
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significantly smaller in size (4.18 kDa) compared to protein G domain (22 kDa) in
pG_EAK. Z34c_EAK was expressed in E.coli as well and Z34c is predicted to have low
immunogenicity, with few potential MHC-II ligands [92] compared with other Fc binding
domains (Table 5-1). Specifically, Z34c_EAK has only one predicted ligand with
smaller than 10th percentile while native protein A has 88 and pG_EAK has 62 predicted
ligands with smaller than 10th percentile and smaller percentile rank indicates higher
potential immunogenicity.

Figure 5-1 Diagrams showing (a): the construct of Z34c_EAK and (b) coassembled Z34c
gel displaying IgG molecules.
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Table 5-1 immunogenicity prediction for different IgG binding domains based on MHCII ligand scanning using immune epitope database (IEDB)

Allele

Predicted
ligands
10th
percentile

Peptide

Percentile
rank
(consensus
method)

Native
protein G

HLADRB1*0401

137

VSDYYKNLINNAKTV

0.41

Native
protein A

HLADRB1*0401

88

QNAFYQVLNMPNLNA

0.49

pG_EAK

HLADRB1*0401

62

GKTLKGETTTKAVDA

1.88

Z34c_EAK

HLADRB1*0401

1

QRRFYEALHDPNLINE

9.71

Intermixing Z34c_EAK with molar excess of EAK resulted in gels that bind IgG
antibodies which was reflected by the superior PE fluorescence signal from PE-IgG
loaded in Z34c gels compared to other incomplete systems as well as the colocalization
of IgG with the hydrogel fibril under fluorescence microscope by PE fluorescence from
IgG and ThT fluorescence stained with EAK fibrils (Figure 5-2).
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Figure 5-2 IgG loading on Z34c bioaffinity hydrogel and its colocalization with gel fibrils
(a) Loading of PE-labeled antibody on Z34c bioaffinity hydrogel compared with that on
incomplete systems. (b) florescence microscopy showing the colocalization of loaded
IgG and gel fibrils reflected by the overlapping signal from PE fluorescence from labeled
IgG and ThT fluorescence after binding to gel fibrils.
In addition, Z34c is effective in increasing retention of IgG at host-graft interface
in murine skin transplantation model after subcutaneous injection of IgG loaded on
Z34c_EAK/EAK composite underneath the skin graft. IgG displayed by Z34c gel
retained better than free IgG control which diffuses away from the injection site fast.
Relatively strong signal remained at the center of the graft for Z34c gel displayed IgG 2
days after the injection at the host-graft interface of BALB/c donor skin on C57BL/6
recipient mouse Figure 5-3. Thus, we stabilized the antibody on the graft bed through
Z34c gel.
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Figure 5-3 The fluorescence decay over 2 days after injection of IgG800 with (test) or
without (control) Z34c gel at the interface of host-skin graft.

Inhibition of neutrophil trafficking in skin transplant model using anti-neutrophil
surface marker IgGs displayed by Z34c gel
One possible application of Z34c gel is to inhibit neutrophil trafficking in skin
transplant model. Neutrophil trafficking inhibition at the host-graft interface in allograft
transplantation patients may play an important role in prolonging survival of skin
allografts. It could potentially limit fluid loss, prevent infection, decrease pain and
promote wound healing. We expect that neutrophil migration be impeded by antibodyinduced oligomerization of the cell-specific surface molecules Ly6G and CD11b. The
antibodies against those surface molecules (anti-Ly6G and anti-CD11b IgGs) can be
displayed by our Z34c gel. The 4.16 kDa mimetic of Staphylococcal protein A (Z34c), is
a disulfide-linked cyclic peptide consisting of two helices. It mimicks helix-1 and helix-2
of domain B in the native protein A and possesses comparable affinity toward IgG to
native protein A, but retains low immunogenicity and reduced steric hindrance during
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coassembly with EAK16-II due to its relatively low molecular weight after fused to EAK
(6.9 kDa). Therefore, by displaying anti-Ly6G and anti-CD11b IgGs on Z34c gel,
activated neutrophils can be intercepted locally and its infiltration to draining lymph
nodes will be reduced, thus suppressing the following immune response and prolonging
allograft survival (Figure 5-4).

Figure 5-4 Schematic diagram showing the design of anti-neutrophil Z34c gel delivered
at the interface of host-graft in skin transplant model
The infiltration of neutrophils at the graft site were verified both ex vivo and in
situ by detecting neutrophil elastase activity as the indicator, assuming more neutrophil
infiltration would cause higher production of neutrophil elastase at the graft site. For ex
vivo assay (Figure 5-5a), neutrophil elastase was extracted from transplanted skin graft
two days after transplantation and incubated with the fluorogenic elastase substrate
MeOSuc-AAPV-AMC. The fluorescence intensity generated after incubation was
compared to that generated from elastase extracted from naïve ear skin without
transplantation. Higher elastase activity was detected in skin graft recovered from a
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transplanted mouse compared to fresh ear skin reflected by higher fluorescence intensity
detected from the former at varying time points resulting in a higher slope of the line
fitting the data, which indicates a higher catalytic rate facilitated by more neutrophil
elastase. For in situ assay (Figure 5-5b), local administration of NE680, the agent which
contains an elastase substrate that relieves the quenching of two conjugated dye when
cleaved, was performed on the graft bed of transplanted mouse one day after the
transplantation surgery. The yielding fluorescence in the near infrared range on the graft
bed after removal of the skin graft was monitored for 2 days and compared to the control
fluorescence generated on the open wound on the same location without transplantation.
Higher elastase activity detected on allo-transplanted mouse compared to control open
wound is in agreement with the in situ assay.

Figure 5-5 verification of neutrophil infiltration after skin transplantation surgery at the
graft site (a) ex vivo assay determining the fluorescence intensity of the fluorogenic
neutrophil elastase substrate after incubation with transplanted skin graft or naïve ear skin
without transplantation. (b) in situ assay determining the near infrared signal after
delivering signal generating neutrophil elastase substrate NE680 to the transplantation
site and compared to open wounds without allo skin transplantation surgery.
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After the elevated neutrophil infiltration level at the graft site after skin
transplantation surgery was confirmed, the effect of anti-neutrophil antibody treatment
displayed by the Z34c bioaffinity module was tested in vivo by injecting neutrophil
specific, NIR fluorescent imaging agent cFLFLF-PEG-Cy7, which binds to formyl
peptide receptor on activated neutrophil, through tail vein the second day after
transplantation surgery and anti-neutrophil antibody treatment. The signal accumulation
at the graft site was compared to the control setup with the administration of only Z34c
gel. From the in vivo imaging scan, less neutrophil accumulation at transplantation site
was observed in treated mouse, suggesting that this treatment could effectively impede
continuous neutrophil infiltration after immobilizing first wave of neutrophil infiltration.

Figure 5-6 Graft homing-neutrophil impediment at host-graft interface (a) diagram
showing the treatment and injection regime after skin transplantation surgery. (b) NIR
signal tracking after injection of neutrophil specific, NIR fluorescent imaging agent
cFLFLF-PEG-Cy7.
Meanwhile, this strategy can be coupled with anti-neutrophil elastase particles to
counter tissue-destructive mechanism elicited by neutrophil elastase. Alvelestat (AZD
9668), a selective elastase inhibitor, can be loaded in PLGA particles and the particles
could be trapped into the EAK gel matrix to work synergistically with the displayed
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antibodies to constrain neutrophil effect. The EAK gel could trap the particles and
slowdown the release of the particles. Transplant necrosis is expected to be reduced
through this method. DiR dye loaded PLGA particles was used as the model particles to
demonstrate their entrapment effect in EAK gels. The NIR dye DiR (ex/em:
750nm/780nm) can provide a readout signal representative of the particle location. The
entrapment of DiR loaded PLGA particles in EAK was successfully verified by
comparing the NIR signal distribution in systems with or without EAK. A localized and
concentrated NIR signal can be observed in system incorporating EAK (Figure 5-7).

Figure 5-7 Odyssey scan (800nm channel) for particle distribution before and different
time points after the addition of release medium to the system. DiR particles were set up
at the bottom of the vials initially with (left) or without (right) EAK gels (first panel) and
200 ul of PBS was added to each sample before inversion of the vials (system
incorporating EAK gel shows on the right side for later time points)
This is the demonstration of potential combination of anti-neutrophil antibodies
treatment and anti-neutrophil elastase therapy facilitated by miniaturized bioaffinity
hydrogel and small molecule weight drug incorporated particles trapped in the gel
respectively. The experiments described in this section are mainly preliminary data, most
of which are still lack of replicates. Further verification of the results would be required
in the future by adding replicates. In addition, the proposed combination use of
bioaffinity hydrogel and particles is proof of concept where the entrapment of particles in
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the gel was realized by using dye loaded particles. The effectiveness of the
combinational therapy needs further investigation by using real drug loaded particles.
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II. Bioaffinity Hydrogels for Cell Therapeutics
3D cell culture facilitated by hydrogels
Another application of the functionalized EAK based hydrogels is to facilitate
three-dimensional (3D) cell culture for cell therapeutics in tissue engineering. 3D cell
culture facilitated by hydrogels is a commonly exploited strategy in tissue engineering
field to provide the cells with the mimetic microenvironment when they actually reside in
tissue. Hydrogel affords necessary geometry and provide similar environment to
extracellular matrix (ECM) to facilitate cell survival or proliferation, allowing the cells to
behave more reflective of their in vivo response [262]. In addition, the spatial
organization of the cell surface receptors involved in the interactions of neighboring cells
could be influenced and physical constraints will be exerted to the cells with the hydrogel
facilitated 3D cell culture. The potential application of the bioaffinity hydrogel was
explored in the generation of mini functional thymic units which is essentially 3D culture
of thymic epithelial cell (TEC) clusters. The TEC clusters lie in the stroma of the
thymus, the essential gland for adaptive immunity which is responsible for continuous
generation of new T-lymphocytes to effectively respond to evading pathogens, while
remaining unresponsive to self. The epithelial cells in thymus is unique in that their
functional and survival are relying on their 3D organization because TECs cultured in a
2D monolayer display altered patterns of expression of key genes for TEC function and
growth, thereby losing their ability to support T cell development [263].
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Construction of mini thymus unit through bioaffinity hydrogel assisted 3D
aggregates of thymus epithelium cells (TECs)
The construction of mini artificial thymic units to support the development of
mature T cells in immunomodulatory disorders can be achieved by 3D aggregation of
thymus epithelium cells (TECs). Formation of 3-D TEC clusters facilitated by antiEpCAM (TECs surface marker) IgG displayed EAK gel helps to retain the molecular
properties of those cells, thus generating a functional mini thymus and supporting
functional T cells development. Anti-EpCAM antibodies could be displayed by any Fcbinding domain functionalized EAK gel described previously including Z34c, protein G
(pG), or protein A/G (pAG) either attached to EAK sequence directly or with the help of
adaptor complex formation. Figure 5-8 shows an example of one design incorporating
coassembly of EAK16-II and its histidinylated analogue EAKIIH6, and the formation of
adaptor complexes (pA/G loaded with both anti-His and anti-EpCAM IgGs) [264].

Figure 5-8 Schematic drawing showing the strategies to generate the TECs mini thymus
unit. The tri-component adaptor complex was formed by mixing anti-EpCAM antibody
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(Ab), anti-His Ab and recombinant protein A/G at 3:3:1 ratio. Isolated thymic epithelial
cells (TECs) were stained with the adaptor complexes, and mixed with EAK16-II and
EAKIIH6 mixture in 10% sucrose. Gelation was initiated by adding complete RPMI-10
medium to the cell material mixture.
As a demonstration of bioaffinity hydrogel application in cell therapeutics,
primary medulla thymic epithelial cells were delivered in an anti-EpCAM antibodyarmed bioaffinity gel into nude mice. The cells are expected to congregate into
functional units in vivo, leading to emergence of CD4 positive and CD8 positive T cells
in the mice. Toward this goal, the 3D mini thymus unit was constructed in vitro by using
the bioaffinity hydrogels described in Figure 5-8 to provide geometrical organization of
the TECs in the 3D gel scaffold, thereby helping to establish proper TEC-TEC and TECthymocyte interaction for successful thymopoiesis.

In this design, the amphiphilic peptide EAK16-II co-assembles with its Cterminal histidinylated analogue EAKII-H6 (AEAEAKAKAEAEAKAKHHHHHH) to
generate the Histidine (His)-tags integrated, ionic strength responsive bioaffinity
hydrogel. This functionalized bioaffinity 3D scaffold provides a docking mechanism,
with antibodies of interest being anchored to the gel with the help of a linker complex
comprised of anti-His antibodies and the Fc-binding, recombinant protein A/G. It was
utilized to induce 3D aggregation of TECs for in vitro culture through the display of antiEpCAM IgGs which target the surface marker of TECs. This bioaffinity hydrogel design
based on EAKII-H6 was systemically characterized by previous member in our lab and is
out of the scope of this dissertation. However, its application in the cell therapeutics was
explored here since the same principle could be applied to all the bioaffinity hydrogel
designs described in this dissertation.

162

The high affinity interaction between the His-tag embedded in the bioaffinity
hydrogel matrix and the anti-His IgG served as a molecular bridge to anchor the EpCAM
expressing TECs on the EAK16II/EAKIIH6 structure through another high affinity
interaction between protein A/G and anti-EpCAM/anti-His IgGs. TECs formed clusters
of 20-30 cells in the hydrogel matrix as shown in Figure 5-9a, suggesting that the
EAK16-II and EAKIIH6 bioaffinity hydrogel system could induce the aggregation of
TECs. The viability of TECs embedded in the EAK16-II/EAKIIH6 bioaffinity hydrogel
was examined using calcein-AM and ethidium homodimer-1 (EthD-1) staining. The
presence of green calcein-AM signal indicates live cells with intracellular esterase
activity, whereas red-fluorescent EthD-1 is retained in dead cells with compromised
plasma membrane integrity. Most of the TECs remained alive after 3 days culture within
the gel as shown in Figure 5-9b. These image results, together with detection of
expression of genes specific to thymic epithelium (EpCAM) and different TEC subsets
(Krt5 and Krt14 for mTECs and Krt8 for cTECs) as well as transcriptions of TECspecific transcription factors (FoxN1 and Tbata) and expression of signaling molecules
(CCL25) important for lympho-stromal interaction through RT-PCR, suggest that TECs
embedded in the bioaffinity hydrogel as clusters not only can maintain their thymic
epithelium identity in vitro, but also be able to retain their functionalities to support T cell
development in vivo. The EAK16-II/EAKIIH6 based mini-thymus units were
transplanted underneath the kidney capsules of athymic B6.FoxN1-/- nude mice and flow
cytometry analyses revealed the presence of circulating CD45+CD3+ T cells 5 weeks post
operation. Both CD3+CD4+ and CD3+CD8+ T cells were found to be present in
secondary lymphoid organs. Those T cells are capable of reacting to alloantigens but not
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syngeneic antigens which was reflected by their proliferating response after mixed
leukocyte reaction (MLR) assay where drastic proliferation was observed for T cells
mixed with allogeneic antigen presenting cells while only limited, background levels of
proliferation were observed for T cells when syngeneic antigen presenting cells were
supplemented. Therefore, the functionality of the mature T cells in the thymus
reconstructed B6. Nude mice was confirmed to be similar to that of wild-type B6 mouse
while staying self-tolerant. The RT-PCR experiments in verifying the gene, transcription
factors and signaling molecules expression levels in vitro, and flow cytometry analyses
for in vivo T-lymphopoesis verification after transplantation of mini thymus units into
athymic mice, were conducted by our collaborators at Allegheny General Hospital and
documented in the paper published on clinical immunology. Details of those experiments
could be found in reference [264].

Figure 5-9 Generation of TECs mini thymus complex in vitro. (a) representative phase
contrast microscopic image (50X) of TEC aggregations (arrows) in EAK16-II/EAKH6
hydrogel. (b) representative fluorescent microscopic images of TEC aggregates in
EAK16-II/EAKH6 hydrogel cultured in vitro for 3 days. Live cells were discriminated
from the dead cells by their intracellular esterase activities to generate green fluorescen
calcein-AM (green) and their capabilities to exclude the red fluorescent ethidium
homodimer-1 (EthD-1, red) from entering the nucleus. Left panel, low magnification
image (100X) of the TEC aggregates (white arrows). Right panel, high magnification
image (400X) of the TEC aggregates.
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Taken together, it was demonstrated that TECs anchored to EAK16-II/EAKIIH6
bioaffinity hydrogel with anti-EpCAM IgG containing tri-component adaptor complex
could self-assemble into 3D aggregates. This 3D configuration could retain, to a certain
degree, the properties of the TECs in vitro, and enable them to function as mini thymus
units to support the development of mature T cells when engrafted into athymic nude
mice. The construction of mini thymus units, which is essentially TECs organized in the
3D configuration, mimicking TECs cultured in the thymus stroma, could be extended to
other bioaffinity hydrogel designs, including the ones described in chapter 3 and chapter
4.
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